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Abstract 
 
Glucagon-like peptide-2 (GLP-2) is a pleiotropic peptide secreted in the 
human intestine with known intestinotrophic properties beneficial in conditions 
like short bowel syndrome (SBS); a condition characterized by malabsorption 
of both fluid and nutrients. Left untreated, SBS can lead to dehydration, 
malnutrition, and weight loss. Teduglutide, a long acting analogue of GLP-2, 
has been used in multiple clinical studies to elucidate its trophic properties. 
Murine studies however have also shown that GLP-2 inhibits pro-inflammatory 
cytokines raising the possibility of an anti-inflammatory property and its 
potential use in intestinal inflammatory conditions; in particular inflammatory 
bowel disease (IBD).  Dendritic cells (DC) play a central role in the initiation 
and regulation of the immune system. They bridge the innate and adaptive 
immune systems and are unique in their ability to activate naïve T cells as 
well as dictate the type of T-cell immunity.  
 
We hypothesized that GLP-2 has an immunomodulatory role and exert this 
action via DC. Toxic effects of GLP-2 peptide on human DC in-vitro have not 
previously been experimented. Our experiments showed that GLP-2 did not 
have a toxic effect on DC at 1pM, 1nM and 1µM concentrations and hence we 
were subsequently able to look at the effects of GLP-2 on human DC 
phenotype and function. Using whole blood and intestinal biopsies from 
healthy volunteers, we obtained a population of enriched low density cells 
(LDC) which offered a novel and ‘physiological’ model for DC. These cells 
4 
 
were labelled with appropriate fluorochromes and assayed by a flow 
cytometer.  
 
We established that DC incubated overnight with GLP-2 had a reduced 
intensity ratio of HLA DR and an increased expression of CD14 in a dose 
dependent way compared with controls. The expression of co-stimulatory 
molecule CD86 was also higher in the treated DC. This phenotypic change 
suggests that GLP-2 modulated DC into an immature state although still able 
to stimulate T-cell proliferation. Ongoing cytokine production of IFN-γ and IL-
12 from healthy blood DC was inhibited by GLP-2 however only cytokine 
production of IFN-γ from intestinal lamina propria DC was inhibited. These 
findings suggest that GLP-2 may induce a ‘homeostatic’ or ‘immuno-tolerant’ 
state and block Th1 cytokines in DC.  
 
Functional experiments confirmed that GLP-2 modulated DC enhanced T cell 
proliferation although this occurred only with intestinal DC. GLP-2 conditioned 
DC also functionally affected the cytokine profile of T cells by reducing the 
cytokines IFN-γ in both human blood and intestinal DC and IL-12 in only the 
latter. Hence our human DC in-vitro findings mirror some of the results found 
in murine studies showing GLP-2 effects on blocking Th1 cytokines. The 
results suggest that GLP-2 has an immunoregulatory effect and that the 
mechanism of action may possibly involve direct effects on DC. GLP-2 
therefore is able to modulate DC characteristics and function leading to future 
application as an immunotherapy for inflammatory diseases.   
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Abbreviations 
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31 
 
IL  Interleukin 
IR  Intensity Ratio 
L.   Lactobacillus 
Lin Lineage cocktail of monoclonal antibody (CD3, CD14, CD16, 
CD19 and CD34) 
LDC  Low Density Cell(s) (enriched for blood DC) 
LP  Lamina Propria 
LPS  Lipopolysaccharide 
mDC  Myeloid Dendritic Cell  
min  Minute(s) 
M cell  Microfold cell 
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Introduction to GLP-2 and Dendritic cells 
 
Glucagon like peptide-2 (GLP-2), a potent intestinal peptide growth factor 
secreted from the human intestine has garnered significant interest in the last 
few decades amongst scientists and physicians. This is in light of its wide 
variety of potential biological functions in treatment of gastrointestinal (GI) – 
related disorder, such as short bowel syndrome (SBS), inflammatory bowel 
disease (IBD), chemotherapeutically induced GI mucositis and NSAID 
induced enteritis. This interest has generated recent drug development with 
therapeutic potentials. Teduglutide, a long acting analogue of GLP-2, has 
been used in multiple clinical studies to elucidate its trophic properties and is 
now the first orphan drug for the treatment of SBS. 
 
The main focus of this thesis is to investigate the possible immunological 
effects of GLP-2, primarily on dendritic cell (DC) function, which is thought to 
be fundamental in the inflammatory process. DC is distinct from other immune 
cell types because they possess unique abilities to initiate the primary 
immune response and determines whether an active or tolerogenic immune 
response occurs. Another property of DC is their ability to imprint homing 
properties on T cells (effector cells) that they stimulate, in order to localise 
immune responses to a specific tissue. Augmenting the phenotype and 
function of DC could be an important therapeutic target to modulate the 
inflammatory pathway.  
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Hence, apart from knowledge of GLP-2, an understanding of DC origin, 
identification, functionality as well as role in inflammatory bowel disease in 
relation to GLP-2 is essential and key in this thesis.  
 
1.1 Dendritic Cells  
 
Dendritic cells (DC) are professional antigen presenting cells (APC) that play 
an essential role in the initiation and regulation of the immunity. They originate 
from haematopoietic stem cells (HSC) in the bone marrow and are situated in 
all tissues particularly at sites of pathogen entry (skin, nose, lungs, stomach 
and intestines). DC are a complex, heterogenous population of cells and are 
widely distributed. Although they constitute a small proportion of the overall 
mononuclear cell population, they play a disproportionate role in orchestrating 
the immune response.  
 
DC are distinct from other professional APC (B-cells and macrophages) 
because they possess the unique ability to initiate the primary immune 
response, generating immunological memory. They act as immune sentinels 
or ‘gate-keepers’, constantly patrolling the peripheral tissues and responding 
to a spectrum of environmental cues. DC expresses microbial pattern 
recognition receptors (PRR) and once DC encounter an antigen, PRR 
activates DC, enabling them to migrate to secondary lymphoid organs and 
initiate the adaptive immune response. DC can determine whether an active 
or tolerogenic immune response occurs to a particular antigen hence whether 
an inflammatory (e.g., against invading pathogens) or tolerogenic (e.g., 
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against commensal bacterial antigens) immune response predominates 
(Banchereau and Steinman, 1998; Bell et al., 1999; Hart, 1997; Steinman, 
2012). This pivotal position at the interface between innate and adaptive 
immunity allows DC to shape the immune response to a vast range of 
antigenic challenges. 
The ‘gate-keeper’ role of DC is dependent on several intricate innate 
properties: 
 
1) Acquisition of antigen in the peripheral tissues, such as the lamina 
propria of the gut, through special mechanisms for antigen capture and 
processing e.g. endocytosis. DC recognise microbial antigens through 
PRR, such as Toll-like receptors (TLR), or respond to a spectrum of 
non-microbial stimuli including cytokines that indicate danger or tissue 
damage (e.g. TNFα) (Stagg et al., 2003). 
2) Capacity for rapid differentiation and maturation enabling DC to 
present antigen, expressing high levels of several molecules on the cell 
surface such as MHC class I and II molecules, accessory molecules 
CD40, CD80, CD86 and early activation markers such as CD83.  
3) Migration to local lymphoid tissues from specific tissue 
compartments e.g. lamina propria of the gut to mesenteric lymph nodes 
(MLN) and Peyer’s patches. 
4) Interaction of naïve effector T-cells to initiate and determine adaptive 
immune responses. The profile of DC-derived cytokines directs the 
polarization of T cell Th1/ Th17 and Th2 phenotypes. Production of IL-
12 and IL-23 by DC promote a Th1/Th17 response, which 
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predominates in inflammatory conditions like Crohn’s disease, whereas 
IL-4 and IL-10 contribute to a Th2 or T regulatory cell response 
(Steinman & Banchereau, 2007). 
 
1.1.1 Dendritic Cell Origin 
 
The first description of DC was in 1868 by the medical student Paul 
Langerhans. His ‘Langerhans cell’ was initially observed in gold-stained 
human skin epidermis and demonstrated dendritic-like projections in their 
cytoplasm (Langerhans, 1868). These cells were subsequently identified as a 
unique subset of DC containing specific cytoplasmic Birbeck’s granules 
(Birbeck et al., 1961). In 1973, Steinman and Cohn then discovered and 
characterised an unusual population of cells that were widely distributed in the 
lymphoid organs. In the murine spleen these large stellate cells had properties 
distinct from those of phagocytes, lymphocytes and granulocytes. This 
included large nuclei, a lack of features suggestive of active endocytosis and 
cytoplasm bearing ‘pseudopods’ or ‘dendrites’ of various forms, sizes and 
numbers; they were therefore named ‘Dendritic Cells’ (Steinman & Cohn, 
1973), although Brigid Balfour coined the term ‘veiled cells’, referring to their 
veil-like rather than dendritic morphology at electron microscopy (Figure 1.1).  
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a)      b) 
Figure 1.1 Dendritic Cell Morphology by Electron Microscopy.  
a) Scanning electron micrographs of ‘veiled’ human dendritic cells (work done 
by Brigid Balfour and Stella Knight). b) DC ‘veils’ interacting with lymphocytes 
(Tyndall, Knight et al., 1983). 
 
Steinman and Cohn subsequently showed that DC expressing major 
histocompatibility complex (MHC) class II molecules were required for antigen 
presentation and were major stimulants in the mixed lymphocyte response 
(MLR) (Steinman et al., 1983). It was later demonstrated that DC also existed 
in humans (Van Voorhis et al., 1982). Multiple DC subsets have now been 
identified in mice and humans that can be characterised by distinct 
phenotypes and functional activities (Ardavin, 2003; Shortman & Liu, 2002; 
Mann ER et al., 2013).  
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1.1.2. Dendritic Cell Lineages and Subsets in Humans 
 
DC constitute a relatively small proportion of immune cells in blood and 
peripheral tissues (0.5-1%). They do not express a single specific marker that 
identifies the cells as DC. Hence, DC can be difficult to identify. DC 
characterisation in humans is however possible through a process of 
exclusion. This procedure is done by elimination of cells expressing non-DC 
cell surface markers using flow cytometry. DC express MHC Class II (HLA-
DR), but this histocompatibility antigen is also expressed on other APC such 
as B-cells and macrophages. However, DC do not express a set of lineage 
markers such as CD3 (T cells), CD 14 (monocytes), CD16 (macrophages), 
CD19 (B-cells), or CD34 (progenitor/ stem cells) (Bell et al., 2001). Therefore 
DC can be classified as HLA-DR positive but lineage marker negative. 
Molecules involved in maturation, co-stimulation, antigen uptake, microbial 
recognition, migration and also cytokine production are all used to 
phenotypically distinguish DC subset. 
 
Identification of Subsets in Dendritic Cell populations 
 
DC are produced from haematopoietic stem cells within the bone marrow. 
Common lymphoid progenitors (CLP) or common myeloid progenitors (CMP) 
are derived from differentiation of these stem cells within the bone marrow. 
Progenitors of DC in bone marrow migrate via the blood stream and home to 
peripheral tissues where they encounter several essential growth factors such 
as GM-CSF, IL-4, IL-5, TNF-α, TGF-β, and IL-3 secreted by various cell types 
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including endothelial cells, keratinocytes and fibroblast in the 
microenvironment. Such growth factors determine the fate of the progenitors 
to differentiate into multiple subsets of DC described both in mice as well as 
human populations, e.g. immature Langerhans DC, intestinal DC or 
plasmacytoid DCs (pDC) (Ardavín, 2003; Shortman and Liu, 2002). These 
subsets are characterised by expression of cell surface markers such as 
CD11c, CD4, CD8α and CD11b to name a few (Shortman and Liu, 2002).  
 
The subsets of mature DC freshly isolated from tissue within humans are not 
as well studied as mouse DC. Human DC subtypes have previously been 
mainly defined using peripheral blood, although tissue data is also available 
primarily from immunohistological analysis of DC populations in human 
tissues. The ability to generate DC in-vitro, led to an expansion of research on 
DC but it is important to note that differences exist between ex-vivo and in-
vitro (Osugi, 2002; Mann ER et al., 2013).  
 
There are two distinct subsets of DC found in humans, conventional CD11c+ 
‘myeloid’ DC and the CD11c- ‘plasmacytoid’ or ‘lymphoid’ DC. These DC 
subsets recognize different microbial pathogens through specific receptors, 
which in turn induce different types of innate and adaptive immune response 
(Figure 1.2) (Shortman, 2002).   
 
42 
 
 
Figure 1.2. Dendritic cell lineage.  
Differentiation of CD34+ stem cells into epidermal (Langerhans) DC, dermal/ 
interstitial DC and ‘myeloid’ and ‘lymphoid’ DC. 
 
Myeloid DC CD 11c+ 
 
Myeloid DC (mDC) in humans are monocyte derived and require GM-CSF for 
their survival and maturation. Within the blood, there are low levels of co-
stimulatory markers (Sallusto, 1994) and these cells have a high phagocytic 
capacity suggesting that mDC are immature DC. mDC express CD11c+, 
which is a β2 integrin that can act to mediate adhesive leukocyte interactions 
with other cells (Córbi, 1997). mDC also express other myeloid markers such 
as CD11b, CD13, CD33, CD1c and CD141 as well as expressing high levels 
of GM-CSF receptors. CD45RO is also expressed, with little expression of 
CD45RA. They express low levels of IL-R3+ critical for development of pDC. 
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Final maturation to CD14-, CD83+, CD86+ DC expressing high levels of 
surface MHC class II is achieve by stimulation with proinflammatory cytokines 
such as tumour necrosis factor-α (TNFα) or microbial products such as 
lipopolysaccharide (LPS) (Han, 2009). Monocyte derived DC can be derived 
in-vitro from monocytes in the presence of GM-CSF and IL-4 (Sallusto, 1994). 
 
Plasmacytoid DC CD11c- 
 
Human pDC were initially recognised by their plasma cell-like morphology and 
unique surface phenotype (CD4+, IL-3R+, CD11c-). Originally called interferon-
producing cells due to production of type 1 interferons (IFNs), they are found 
in blood and many lymphoid tissues (Shortman and Liu, 2002). IFNs produced 
by pDC directly inhibit viral infections and also activate antiviral functions of 
other cells, such as mDC, natural killer (NK) cells and B-cells. Distinct factors 
regulate the survival and differentiation of CD11c- DC precursors; these cells 
are critically dependent on interleukin 3 (IL-3) and CD40L for maturation 
(Grouard et al, 1997). pDC do not express or express very low levels of 
CD11c and GM-CSF, but rather express high levels of other lymphoid 
markers such as CD123, CD303 and CD304 (Ardavín, 2001).  
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Functionality of DC subsets 
 
It has been proposed that different DC subsets direct specific immune 
responses, such as polarising a Th1/Th2 response or immunotolerance. For 
example, human myeloid DC derived from monocytes (MoDC) in the 
laboratory are associated with elevated IL-12 production and the generation of 
IFNγ stimulating proliferation of Th1 cells (Rissoan et al., 1999). pDC are 
functionally characterised by the production of large amounts of type-1 
interferons (IFN α/ β) in response to viral antigens, stimulating IFNγ producing 
T-cells and a Th1 type immune response, but are also capable of generating 
Th2 responses (Siegal et al., 1999; Cella et al.,2000).  
 
This outline of DC function is likely to present a gross oversimplification of DC 
capabilities since there appears to be a considerable degree of plasticity in 
their responses, which is dependent on several factors including local 
environmental factors such as DC lineage, maturation status and numbers; 
danger and inhibitory cytokine exposure and modulation by microbial factors 
or other environmental cues. Hence, DC are likely to display tissue specific 
specialisation that enables them to function appropriately in diverse settings.  
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1.1.3 Dendritic cell Maturation  
 
DC are able to evolve from immature, antigen-capturing cells to mature, 
antigen-presenting, T cell-priming cells. They are able to convert antigens into 
immunogens and express molecules such as cytokines, chemokines, co-
stimulatory molecules and proteases to initiate immune responses. The T-cell 
mediated immune responses can vary to include tolerogenic or inflammatory 
Th1, Th2 or Th17 responses, depending on the specific DC lineage and 
maturation stage, in addition to the activation signals received from the 
surrounding microenvironment.  
 
The ability of DC to regulate immunity is dependent on DC maturation. A 
variety of factors can induce maturation following antigen uptake and 
processing within DCs. These factors include bacterial-derived antigens such 
as LPS or whole bacteria, inflammatory cytokines, ligation of select cell 
surface receptors and viral products. The process of DC maturation involves a 
number of phenotypical and functional changes. These changes can 
commonly involve redistribution of major histocompatibility complex (MHC) 
molecules from intracellular compartments to the DC surface, down-regulation 
of antigen internalisation, an increase in the surface expression of co-
stimulatory molecules, morphological changes with formation of dendrites, 
cytoskeleton re-organization, secretion of chemokines, cytokines and 
proteases, and surface expression of adhesion molecules and chemokine 
receptors (Shin 2006).  
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Immature DC reside in peripheral tissues and in the absence of further 
stimulation remain in an immature state, with low expression of co-stimulatory 
molecules and cytokines (Mahnke, 2005) (Kubach, 2005). These cells 
possess high phagocytic activity and if they encounter tissue injury, captured 
antigens will become activated (Hart, 1997). It is this encounter with antigens 
that induces the maturation of immature DC to functional APC. With DC 
maturation there is less expression of the receptors involved in antigen uptake 
and higher expression of molecules required for T cell activation or priming 
such as MHC, CD40 and CD86; thus enabling T cell signalling via CD28 on T 
cells (Caux, 1994).  
 
The level of expression of the co-stimulatory molecules CD40 and CD86 are 
higher in activated DC. These DC surface molecules engage with their 
respective ligands on T-cells, in addition to MHC class II/ T cell receptor 
interaction. One of the major DC functions regulated by CD40 ligation is 
cytokine production leading to downstream production of IL-12p and IL-6. 
CD40 ligands are also expressed on B-cells and DC/B-cell interaction via 
CD40 ligand plays a role in B-cell proliferation as well as regulation of B cell 
homeostasis (Ma 2009). Similarly, CD86 upon DC-T-cell interaction is able to 
induce IL-2 production and T-cell proliferation (Freeman, 1993). 
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1.1.4 Dendritic Cell Migration and Recruitment 
 
DC migration is dependent upon the coordinate expression of distinct 
chemokine receptors that direct immature precursor cells into the peripheral 
tissues and translocation of mature DC in regional lymphoid follicles. In the 
absence of inflammation or infection, immature or ‘steady state’ DC within 
tissues are continuously on patrol and migrate to organised lymphoid tissues 
via the lymphatic channels; these immature cells present self-antigens for the 
induction and maintenance of self-tolerance (Steinman et al., 2000; Steinman 
et al., 2003). In contrast, when exposed to inflammatory signals or microbial 
products, DC mature and migrate at higher rates to secondary organised 
lymphoid tissue where stimulation of naïve T cells takes place. This pathway 
is mediated by the interaction between PRRs, such as TLR, nucleotide-
binding sites and leucine-rich repeat containing receptors (NLR), retinoic acid 
inducible gene-I (RIG)-like receptor on DC (Lavelle et al., 2010), and 
pathogen-associated molecular patterns (PAMPs) present on the surface of 
microorganisms (Kaisho and Akira, 2003). Some DC populations may enter 
lymph nodes directly from the circulation whereas others pass through non-
lymphoid tissues and in doing so may transport antigens from the periphery to 
lymph nodes. When migrating from the peripheral tissues to lymph nodes, DC 
mature by which they downregulate their antigen acquisition machinery and 
enhance ability to stimulate T cells (Banchereau and Steinman, 1998).  
 
Different chemokines receptors are important for the process of DC migration. 
CCR2 is involved in DC translocation into T cell rich areas of lymphoid tissues 
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during infection with Leishmania Major (Sato et al., 2000). In the intestine, 
CCR2 may be responsible for recruitment of DC to the lamina propria. CCR5 
is important in DC recruitment to inflammatory sites (Aliberti et al., 2000; 
Sallusto et al., 1998). CCR6 is essential for DC positioning at epithelial 
surfaces (Cook et al., 2000; Vanbervliet et al., 2002) and CCR7 drives the 
migration of lamina propria DC to mesenteric lymph nodes (MLN) (Dieu et al., 
1998; Forster et al., 1999; Jang et al., 2006; Sallusto et al.,1999). In the 
mouse, mucosal DC drive intestinal immune compartmentalisation by 
imprinting a4b7 integrin and CCR9 on T cells that they activate resulting in 
homing to the small intestine (Mora et al.,2003, Stagg et al., 2002). More on 
lymphocyte homing will be discussed later in this chapter. 
 
1.1.5 Stimulation of Adaptive Immunity 
 
DC can contribute to the expansion and differentiation of most classes of 
lymphocytes. Apart from T cells, they play a role in the differentiation of B 
cells, innate NK (Gerosa et al., 2002) and NKT cells (Vincent et al., 2002), 
although little is known about the mechanism for stimulating these other 
lymphocytes. Both the type of DC and its maturational status influence the 
subsequent T cell responses and their effects on adaptive immunity. In 
addition to driving the clonal expansion of proliferative T cells, DC can shape 
the functional differentiation of dividing T cells. CD4+ T cells known as T 
helper (Th) cells can be divided into two functional subsets based on their 
cytokine production (Mosmann et al., 1986). These two pathways of 
differentiation are known as Th1 and Th2. 
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Th1 cell differentiation  
 
The Th1-Th2 hypothesis was based on the observation that each subset of 
CD4+ Th cells produces different patterns of cytokines and induces different 
effector functions. Th1 differentiation has been characterised by the 
production of IL-2, GM-CSF, TNF-α and IFN-γ which are instrumental 
cytokines in cell-mediated immunity against intracellular virus, bacteria or 
protozoa and/or promotion of cytotoxicity in NK cells and CD8+ T cells 
(Mosmann et al., 1986). The production of IL-12 by DC drives a Th1 response 
(Macatonia et al., 1995). IL-12 is a heterodimeric cytokine composed of 2 
disulphide-linked subunits, p35 and p40. IL-12p40 expression is generally 
thought to be restricted to cells with phagocytic activity whereas IL-12p35 is 
expressed ubiquitously at low levels (Trinchieri, 2003). The p40 subunit’s 
production is regulated and induced by products of bacteria, parasites, viruses 
and fungi in DC as well as monocytes, neutrophils and macrophages. DC 
secrete IL-12 in large quantities once stimulated through their cell surface 
receptors and antigens. Ligands of Toll like receptors that induce IL-12 
release include lipopolysaccharide (LPS), lipoteichoic acid (LTA), 
peptidoglycan and bacterial (CpG) DNA. IL-12 then subsequently leads to 
release of IFN-γ after the induction of NK cells and T cells. This effect on NK 
and T cells is enhanced synergistically by IL-19 (Yashimoto et al., 1998). Also, 
the combination of IL-12 and IL-18 continue to stimulate IFN-γ and IL-12 
production from APCs. The cytokine combination of IL-12 and IFN-γ also 
serve to inhibit Th2 cell differentiation as well as inhibiting the production of 
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cytokines involved in Th2 pathway differentiation; IL-4, IL-5 and IL-13 (Agnello 
et al.,2003).  
 
Two other known IL-12 related cytokine members IL-23 and IL-27 have also 
been described. IL-23 is a heterodimer of p19 and p40 subunits and it induces 
proliferation of memory T cells (Oppmann et al., 2000). Like IL-12, IL-23 
induces IFN-γ production in both T cells and DC, and may promote the 
expansion of CD4+ T cells that produce IL-17 (Langrish et al., 2005). IL-27 
consists of p28 and EB13 subunits and it induces the proliferation of naïve T 
cells (Pflanz et al., 2002). Both IL-23 and IL-27 are produced by DC (Smits et 
al., 2004). 
 
Th2 cell differentiation 
 
Th2 cells drive humoral immunity directed towards clearing extracellular 
pathogens most notably parasitic infections as well as inflammatory allergic 
reactions. They stimulate B cells to produce immunoglobulin (IgG)-E and 
enhance the maturation of eosinophils and the degranulation of mast cells 
and basophils. The production of IL-4 after stimulation by antigens influences 
naïve T cells to differentiate through the Th2 pathway. Also involved in the 
initiation of Th2 differentiation is the thymic stromal lymphopoetin (TSLP). 
TSLP is an epithelial cell-derived cytokine implicated in promoting type 2 
inflammation through effects on both innate and adaptive immune cells and is 
also known to activate basophils. TSLP-activated DCs prime naïve T cells to 
produce IL-4 and other cytokines linked to the Th2 profile (Soumelis et al., 
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2002). TSLP also induces DCs to produce Th2-attracting chemokines such as 
CCL-17 and CCL-22 (Perros et al 2009).  
 
IL-4 acts to optimize the molecular requirements for Th2 cell differentiation via 
the IL-4/ STAT 6 pathway leading to an increased expression of the 
transcription factor GATA3. GATA3 is an important regulator of Th2 cell 
phenotype, stabilizing it by inhibiting IFN-γ production (Ferber et al.,1999) and 
downregulating IL-12Rβ2 expression in a manner independent of IL-4 
(Ouyang et al.,1998). GATA3 is expressed in small amounts by naïve T cells 
but this is markedly upregulated during Th2 cell differentiation. STAT6, 
additionally, controls the expression of IL-4 locus control region (Ansel et al., 
2006). In vitro studies have also identified the involvement of STAT5, which is 
activated early in the pathway after T cell receptor engagement induces IL-2 
production that then activates STAT5. This activation of STAT5 coupled with 
the early production of GATA3 seen after T cell receptor activation induces IL-
4 production. The IL-4 produced then affects the IL-4R/STAT6 pathway to 
upregulate GATA3 (Paul, 2010).  
 
Th17 cell differentiation 
 
The relatively recent discovery of a further Th cell lineage Th17 cells have 
shifted thinking away from the previously described Th1/Th2 paradigm. Their 
primary role in health appears to be clearance of pathogens not adequately 
handled by Th1 or Th2 cells (Korn et al., 2009). Pathogens as diverse as the 
Gram-positive Propionibacterium Acnes; the Gram-negative Citrobacter 
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Rodentium, Klebsiella Pneumoniae, Bacteroides and Borelia species; the 
acid-fast Mycobacterium Tuberculosis; and fungi-like Pneumocystis Carinii 
and Candida Albicans can all trigger strong Th17 response (Korn et al.,2009). 
This cell lineage develops from naïve T cells in the presence of TGF-β and IL-
6 and has contrastingly been described as both an immunoregulatory and 
pro-inflammatory cytokine respectively. The effects of the Th17 response 
have been viewed as pro-inflammatory given the secretion of cytokines 
including IL-17a, IL-17f, IL-21, IL-22, IL-6 and TNF-α and it’s regulation by IL-
10 (Yosef et al., 2013)(Olsen et al., 2011). There is also data supportive of 
anti-IL17a antibody therapies in psoriasis, rheumatoid arthritis and uveitis 
(Hueber et al., 2010).  
 
There is however suggestion that Th17 have some plasticity to their function, 
with an ability to stop production of IL-17a as well as express T-bet, which is a 
regulator in Th1 cell differentiation and IFN-γ (Symons et al., 2012). There 
also appears to be a variation in the function of Th17 signatory cytokine IL-
17a. A mouse transfer model of colitis has shown that IL17a -/- T cells induce 
a more aggressive disease phenotype compared with the wild type cell 
population, implying a protective effect of IL17a in this model (O’Connor et al., 
2009).  
 
The key transcription factor involved in the process is retinoic acid-related 
orphan receptor (RORγτ), with its importance being demonstrated in RORγτ 
negative mice (Ivanov et al., 2006). Similarly, there is markedly decreased IL-
17 expression in vitro in T cells that lack RORγτ (Ivanov et al., 2007). The 
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induction of RORγτ is dependent on STAT3, which in turn is activated by IL-6, 
IL-21 and IL-23 (Korn et al., 2009). STAT1 activation acts to inhibit the 
development of Th17 cells and is activated via IL-27 and IFN-γ pathway 
(Batten et al., 2006; Stumhofer et al., 2006). The important role of the STAT 
proteins in the differentiation and regulation of Th17 cells is further 
demonstrated by the inhibitory role that IL-2 dependent STAT5 expression 
has on these cells (Laurence et al., 2007). 
 
1.2 Intestinal Dendritic Cells and Immune Regulation 
 
The gastrointestinal (GI) tract is in constant contact with a diverse and 
dynamic luminal environment that contains large numbers of commensal 
bacteria and a variety of pathogens. In this highly antigenic environment, the 
ability to maintain immune tolerance to commensal bacteria or self-antigens 
and the ability to mount effector responses to invading pathogens is a key 
feature of the gut immune system. Mucosal DC located at the intersection 
between the innate and adaptive immune systems are likely to be central to 
this process. They constantly survey the microbial environment, coordinate 
immune responses to danger signals (Niess and Reinecker, 2005), and prime 
naïve T cells to control overwhelming infections or tissue inflammation 
(Nagler-Anderson, 2001; Steinman et al., 2003).  
 
There is a general consensus that DC in the gut are generally hyporesponsive 
(Coombes JL et al., 2008) maintaining immune tolerance in the gut by 
generation of tolerogenic T-cell responses towards food antigens and 
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commensal microbiota, preventing unnecessary inflammation and 
hypersensitivity. However, when this process is dysregulated, inflammation 
ensues and this is considered a probable pathway of which inflammatory 
bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis 
(UC) occurs (Strober et al., 2007). The decision between the induction of 
tolerance and active immunity depends on the subpopulation of DC and the 
surface receptors involved, and the tissue environment during DC activation 
and T cell priming (Chirdo et al., 2005; Hart et al., 2005). During the steady 
state, DC traffic through intestinal tissues with the turnover time of a few days 
(Pugh et al., 1983).  
 
Within the GI tract, DC are found in the organised lymphoid tissue. This 
include Peyer’s patches and mesenteric lymph nodes (MLN) (where the 
induction of T and B cell response occurs) and within generalised tissues 
interspersed with effector cells, which include the lamina propria and intestinal 
epithelium (Iwasaki and Kelsall, 2001; Maric et al., 1996). Recently, a 
previously unrecognised network of DC that respond to microbial stimuli and 
upregulated CD80 and CD86 in vivo have been identified within the muscular 
layer of the mouse intestine (Flores-Langarica et al., 2005).  
 
In the mouse, three subsets of CD11c+ DC have been described in the MLN 
and Peyer’s patches: CD11b+CD8α- DC in the subepithelial dome, CD11b-
CD8α+ in the interfollicular regions and CD11b-CD8α- (double negative) 
subsets in both areas (Iwasaki and Kelsall, 2000; Iwasaki and Kelsall, 2001). 
The murine spleen also contains three main CD11c+DC subsets which include 
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CD11b+CD4+, CD11b+CD4- and CD11b-CD8α+ cells. CD11b+ and CD11b- 
populations, but not CD8α+ DC, have been described within the murine small 
intestinal lamina propria. The former appears to be the predominant subset in 
the terminal ileum. Lamina propria DC that express the integrin CD103 have 
been identified in the mouse intestine (Annacker et al., 2005; Johansson-
Linbom et al., 2005). 
 
Similar to other tissues, intestinal DC is a heterogenous population. Although 
diverse DC lineages with distinct morphology have been recognised in the 
lamina propria and organised lymphoid tissues, their specific role in antigen 
sampling and presentation remains largely unknown. In the mouse intestine, 
the most extensive DC system populates the lamina propria of the small and 
large intestine. Many different cell types in the gut mucosa express CD11c 
and HLA-DR/ MHC Class II, which various groups use as a basis of DC 
characterization; however, other studies have indicated that most of these 
cells are not genuine DC (Persson EK et al., 2010, Varol C et al., 2010).  DC 
expressing CX3-chemomokine receptor 1 (CX3CR1), a molecule essential for 
ability of cells to extend transepithelial projections into the gut lumen (Niess et 
al., 2005), have been described in mice, but these cells expressed CD14 
(Rescigno et al., 2009, Varol C et al., 2009). Several laboratories exclude 
CD14+ cells in their criteria used to identify DC. Indeed, DC ‘exclusion ‘ or 
lineage cocktail comprises CD3, CD14, CD16, CD19, CD34 and CD56 and is 
used to identify DC by excluding T-cells, B-cells, monocytes, macrophages 
and stem cells, then selecting HLA-DR+ cells as putative DC.  
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In the human colon, lamina propria DC are characterised by their expression 
of CD83 and dendritic cell specific ICAM-3 grabbing non-integrin (DC-SIGN), 
and they have the phenotype of CD11c+Lin- with an immature state and low 
TLR-2 and -4 expression compared to their blood counterparts. These are 
largely CD11c+ myeloid cells with few identifiable pDC (CD11c-CD123+) (Bell 
et al., 2001; Hart et al., 2005).  
 
It has been thought that the main site of induction of mucosal immunity occurs 
in the Peyer’s patches due to their close proximity with the intestinal lumen 
and specialized M cells however recent evidence suggests that the Peyer’s 
patches may not be essential for the induction of oral tolerance or active 
immunity (Mowat, 2003). In the absence of the Peyer’s patches, MLN are 
critical for the tolerance induction (Guegemann et al., 1998; Spahn et al., 
2002). The tissue microenvironment, among other factors, influences DC 
responses to stimulation. In addition, the subsets, phenotype and functions of 
DC are likely to be influenced by tissue specific factors produced by 
intraepithelial lymphocytes and epithelial cells in response to signals from 
commensal or pathogenic microorganisms. 
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1.2.1 Sampling of Luminal Antigens by Intestinal Dendritic Cells 
 
DC are present as immature cells with high phagocytic activity within the 
peripheral tissues and discrete regions of organised secondary lymphoid 
organs. Immature DC act as sentinels of the immune system where they 
constantly sample foreign and self-antigens from the intestinal lumen (Liu and 
Macpherson, 1991).  
 
Within the GI tract, several pathways have been described by which DC can 
sample and process specific antigens or pathogens. The main route for 
microorganisms or macromolecules to gain access to the mucosal immune 
system is via specialized epithelial cells, known as M cells. These cells are 
scattered among conventional epithelial cells overlying the dome of the 
Peyer’s patches follicle and they shuttle luminal antigens to DC in the 
subepithelial dome regions (Kraehenbuhl and Neutra, 2000). In this regard, 
DC have been shown to phagocytose orally administered Salmonella 
Typhinurium into the tissue via the M cells (Hopkins et al., 2000; Hopkins and 
Kraehenbuhl, 1997). DC are also early cellular targets for Listeria 
Monocytogenes infections in rats, and are responsible for bacterial spread to 
the host (Pron et al., 2001). A population of CD11c+CD11b-CD8- DC residing 
in the subepithelial dome take up fluorescent polystyrene microparticles given 
orally and subsequently migrate to B cell follicles or T cell parafollicular zones 
following the ingestion of Cholera Toxin or live salmonella bacteria. 
Macrophages in close proximity were however not involved in this process. 
These data suggests that DC can migrate in response to enterotoxin 
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adjuvants and live bacteria that enter the mucosa via M cells (Shreedhar et al., 
2003). Antigen uptake by M cells can be enhanced by IgA (Neutra and 
Kraehenbuhl, 1993; Weltzin et al., 1989). The observation that DC express 
IgA receptors suggests that this interaction may help to increase antigen 
uptake (Geissman et al., 2001; Heystek et al., 2002). M cells covering the 
Peyer’s patches also express chemokines such as CCL20 and CXCL16 which 
may facilitate DC migration (Hase et al., 2006; Iwasaki and Kelsall, 2000). 
 
Secondly DC may acquire antigen indirectly via the internalisation of apoptotic 
epithelial cells (Huang et al., 2000). Alternatively they may take up antigen 
exosomes shed from epithelial cells (Karlsson et al., 2001; Van et al., 2001). 
In addition DC in the subepithelial follicles can sample antigens directly from 
apoptotic epithelial cells. For instance, in mice infected with type 1 Roevirus, 
CD11c+CD11b-CD8-CD4- DC in the Peyer’s patches have been described to 
capture viral antigens from infected apoptotic epithelial cells (Fleeton et al., 
2004).  
 
DC within the lamina propria can sample luminal contents directly by opening 
tight junctions between enterocytes and extending dendrites into the gut 
lumen, an observation that was first made in the 1970’s through electron-
microscopic (EM) studies of rat ileum (Collan, 1972; Rescigno et al., 2001b; 
Rescigno et al., 2001a). This process of sampling by DC has now been 
demonstrated in the terminal ileum of mice both in the steady state (Niess et 
al., 2005), as well as in studies of bacterial uptake in vivo by Salmonella 
Typhinurium and non-pathogenic Escherichia Coli (E Coli) (Rescigno et al., 
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2001b). The formation of transepithelial dendrites depends on CX3CR1. 
These lamina propria DC may include subsets that express IL-12p40 and 
IL12p19, suggesting that they may be producers of IL-23 (Becker et al., 2003). 
It is likely that antigen sampling is induced by signals from epithelial cells that 
have been in contact with luminal bacteria. Figure 1.3 shows an electron 
microscopy (EM) picture of a human lamina propria colonic DC sending 
processes into the intestinal lumen for sampling of antigen (APRG EM). 
 
Figure 1.3. Electron Microscopy (EM) of a human colonic DC sampling 
antigen.  
This EM picture shows antigen sampling by human lamina propria colonic DC 
from a control subject (Courtesy of Mr Nicolas English, APRG).  
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1.2.2. Induction of Tolerance and Active Immunity by Intestinal Dendritic 
Cells  
 
During the ‘steady state’ such as in the absence of inflammation, infection or 
vaccination with mucosal adjuvants, intestinal DC migrate constitutively from 
the lamina propria and/or Peyer’s patches to the MLN. This process of 
migration occurs at a faster rate when DC are activated. However, the nature 
of DC migration in the ‘steady state’ versus the ‘stimulated’ state remains 
unclear. It is likely that ‘steady state’ mucosal DC are involved in tolerance 
induction via the induction of regulatory T cells that produce TGF-β or IL-10, 
or via functional T cell anergy/deletion. In contrast, upon exposure to 
pathogens or cytokines such as IL-1 or TNFα, activated DC that migrate to 
secondary lymphoid tissues become inducers of effector cells (Cerovic et al., 
2009). DC which migrate from the intestine in the steady state, are 
paradoxically able to induce strong inflammatory responses from naïve T cells, 
despite their role in the maintenance of oral tolerance. Intestinal lymphatic DC 
from the thoracic ducts of rats stimulated strong proliferative responses, 
induced secretion of INF-γ and proliferation of FoxP3-positive lymphocytes 
(Milling et al., 2009; Hadis et al., 2011). 
 
Earlier studies have shown that enhanced tolerance to intestinal antigens is 
observed after expansion of DC following stimulation with Fit3-ligand (Viney et 
al., 1998). Various pathways have been described by which DC achieved 
tolerance. This process involves the interaction between commensal bacteria 
and distinct DC populations, both in the periphery and local mucosal tissue. 
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Several studies have demonstrated that DC tolerance can be achieved by the 
downregulation of CD80 and CD86 (Steinman et al., 2003), the interactions 
between DC and novel co-stimulatory molecules such as CD200 and CD200R 
(Gorczynski et al., 2005), and the signalling through novel receptor ligand 
interactions (Howne et al., 2000). In addition, induction of tolerance can be 
achieved by the control of T cell proliferation through release of 
immunosuppressive cytokines, IL-10, TGF-β and INF-γ (Levings et al., 2001; 
Levings et al., 2002; Yamagiwa et al., 2001, Saraiva et al., 2010), and the 
production of metabolites such as indoleamine 2,3 deoxygenase (IDO) 
(Grohmann et al., 2000; Matteoli et al., 2010).  
 
After oral administration, antigen is transported via afferent lymphatic by DC 
into the draining MLN, which is obligatory for the induction of oral tolerance 
(Worbs et al., 2006). The majority of DC entering the MLN largely originates 
from the lamina propria suggesting that these cells are likely to contribute to 
antigen presentation for oral tolerance induction (Bimczok et al., 2005; 
Turnbull et al., 2005).  
 
The same DC population derived from different tissues can exhibit different 
responses to the same stimuli. For example, in the mouse, mucosally-derived 
pDC induces differentiation of ‘T regs’ like cells that release IL-10 and IL-4 
after DC maturation with CpG (Bilsborough et al., 2003), whereas bone 
marrow and spleen derived pDC induce a Th1 T cell phenotype when 
stimulated by CpG (Boonstra et al., 2003). Moreover within the same mucosal 
tissue, different DC populations display distinct functional phenotypes under 
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the same stimulation conditions. In the Peyer’s patches CD11c+CD11b+DC 
produce IL-10 whereas CD11c+CD8α+ DC and CD11c+CD11b-CD8α- DC 
produce IL-12p70 following stimulation with CD40L (Iwasaki and Kelsall, 
2001; Kellermann and McEvoy, 2001). The data therefore suggests that the 
induction of tolerance versus active immunity may be complex and is 
dependent on the tissue microenvironment, the types of DC signalling events 
and response to microbial stimuli.  
 
It remains unclear whether the immune environment in the human gut is the 
same as animal models. Ways in which DC interact with microbes may be 
different in human and mice. Furthermore, it remains to be seen whether the 
functional distinct properties of intestinal DC have been predetermined by 
local microenvironment or whether they are functionally committed precursors 
that have been directed to return to the intestine.  
  
1.2.3. Intestinal Dendritic Cells and Microbial Interactions 
 
DC display significant plasticity in their ability to respond to microbial stimuli. 
The outcome of stimulation is dependent on the local interaction between DC 
populations and lymphocytes. The ability of DC to sample luminal bacteria 
suggests that they play a critical role in the surveillance of pathogens in the 
gut environment. Studies using oligonucleotide microarrays to compare gene 
expression of DC exposed to candida, influenza virus or E. Coli have 
demonstrated that DC are able to elicit tailored immune response to certain 
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bacteria. For instance, when monocyte derived DC were exposed to different 
pathogens, organism-specific responses occurred in addition to a temporal 
cascade of common core response to all tested antigens (Huang et al., 2001).  
 
Human CD4+ T cells from the lamina propria of healthy intestinal tissue 
exhibits reactivity to commensal bacteria (Enterobacter, E. Coli, Enterococcus 
species) as well as to the pathogen, Salmonella Typhimurium. Depletion 
studies suggested that bacteria-specific CD4+ T cell activation and 
proliferation were dependent on intestinal DC, which themselves exhibit a pro-
inflammatory cytokine profile upon bacterial stimulation (Howe et al., 2009).  
 
Activation and maturation of DC occurs when DC recognise PAMPs on the 
surface of bacteria by way of PRR on their surface. It is unclear how PRR 
monitoring and response distinguish between abundant normal microbiota 
and the rare pathogen. It is thought that the difference between pathogen and 
commensal can be due to the acquisition of a single plasmid. This has 
resulted in the current designation of PRR ligands as microbial associate 
molecular patterns (MAMPs) as opposed to the previous more limited term 
PAMP (Neish, 2008). 
 
The best characterised of all PRR are the TLRs. At least 11 members of the 
TLR family have been described and their respective microbial products 
reported (Akira et al., 2001). TLR-2 expressed by CD11c+ DC and its ligands 
is required for recognition of gram-positive cell wall components, including 
lipoproteins and peptidoglycans (Kadowaki et al., 2001). TLR-4 recognises 
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lipopolysaccharide (LPS) from E. Coli (Takeuchi et al., 1999); TLR-5 
recognises flagellin from gram-negative bacteria, and TLR-9 recognises 
bacterial DNA and it is expressed by pDC and B cells.  
 
It has also been recognised that there is receptor specific spatial distribution 
that helps to discriminate between pathogen and commensal bacteria. TLR-2 
and -4 are express on the surface of DC and macrophages; TLR-5 is found on 
the basolateral surface of epithelium; TLR-9 is restricted to the cytoplasmic 
vacuolar compartments whereas nucleotide-binding oligomerization domain 2, 
(NOD2), is detected intracellularly.  
 
In the mouse, pDC and CD4+ DC express TLR-7 but lack TLR-3 expression 
(Doxsee et al., 2003). In human, mDC express TLR-1 to -6 and TLR-8 (Liu, 
2005), whereas pDC exclusively express TLR-7 and TLR-9 (Krug et al., 
2001a; Stagg et al., 2003).  
 
DC express NOD1, which recognises muramul-tripeptides from gram negative 
bacteria, and NOD2, common to peptidoglycans of all bacteria species. 
Mutation in NOD2 has been associated with ileal Crohn’s disease (CD) 
(Hugot et al., 2001; Ogura et al., 2001) suggesting that the dysregulated 
recognition of intestinal microbiota bacteria results in inflammatory disease in 
genetically predisposed subjects. NOD2 is a key cytoplasmic sensor of 
intracellular bacterial peptidoglycan and a mediator of innate immunity. 
Enteric pathogens can alter intestinal DC function. For example, 
Heligmosomoides Polygyrus infection induces DC activation and IL-10 
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expression, which impair host protection against Citrobacter Rodentium 
infection, resulting in an enhanced bacterial infection and the more severe 
colonic inflammation (Chen et al., 2006). It is likely that exposure to microbial 
products alone is insufficient to activate intestinal DC and there may be a 
need for inflammatory signals from cytokines to indicate local tissue damage.  
 
Bacteria (Lactobacillus Reuteri and Lactobacillus Casei) and its cell surface 
compounds can bind to DC-SIGN, and lead to the induction of regulatory T 
cells. DC-SIGN is implicated to play a role in the induction of various 
responses mediated by DC. It is a c-type lectin expressed mainly on DC and 
recognizes mannose- and fructose- containing glycans that are present on 
endogenous and on microbial or viral surface. Konstantinov et al. have shown 
that the major S layer protein, SlpA, of L. Acidophilus NCFM is the first 
probiotic bacterial DC-SIGN ligand identified that is functionally involved in the 
modulation of DC and T cells functions (Konstantinove et al., 2008).  
 
In ileal tissues from patients with CD, enhanced infiltrates of DC-SIGN+ and 
CD83+ DC have been found in the subepithelial dome. CD83+ cells in the 
Crohn’s tissues showed reduced expression of the lymph node migratory 
receptor, CCR7, possibly contributing to their retention within the epithelium. 
These cells express TLR-4 and produce TNF-α. When exposed to E Coli, 
CD83+ DC co-localized with translocated bacteria. Thus non-migrating DC in 
the subepithelial dome can internalize non-pathogenic bacteria that may be 
important for the onset and perpetuation of intestinal inflammation in CD 
(Salim et al., 2009).  
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1.2.4 Regulation of Lymphocyte Homing by Intestinal Dendritic Cells 
 
Lymphocytes continuously migrate around the body and meet with antigens 
via APC. T cells trafficking to lymphoid and extralymphoid tissues involves a 
multistep process and multiple signals that is regulated by the coordinated 
interaction between cell surface molecules on T cells with their respective 
ligands on the surface of vascular endothelial cells. In the intestine, 
lymphocytes primed in MLN draining intestinal sites have the propensity to 
home back to the intestine. Two homing molecules promote specific homing 
to the gut: α4B7 which is attracted to its ligand, mucosal addressin cell 
adhesion molecule (MAdCAM-1), expressed on high endothelial venules, 
Peyer’s patches and MLN in the intestine (Butcher et al., 1999) and the 
chemokine receptor CCR9 attracted to its ligand CCL-25 (TECK). The latter 
plays an important role in the recruitment of effector T cells to the small 
intestine (Zabel et al., 1999). In a recent murine study, a subset of CCR9+ 
pDC from small intestine suppressed development of intestinal inflammation 
in mice (Mizuno et al., 2010), linking CCR9 expression with immune tolerance. 
The study showed that CCRlo DC were potent stimulators of naïve T-cells and 
it hypothesised that this DC fraction may have a more pathogenic nature 
compared with its CCRhi counterpart.  
 
Specific homing pathways also exist for other organs. For example, 
cutaneous leukocyte antigen (CLA, a carbohydrate selectin ligand), CCR4, 
CCR8 and CCR10 have been implicated in homing to the skin (Campbell et 
al., 1999; Campbell et al., 2007: Ohmori et al., 2006; Schaerli et al., 2004). 
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Retinoic acid (RA) is required for the induction of α4B7 and CCR9 by mucosal 
lymphocytes. RA binds to intracellular retinoic receptors, which activates the 
transcription of genes encoding α4B7 and CCR9 (Figure 1.4).  
 
 
Figure 1.4. Control of lymphocyte homing by dendritic cells.  
DC in gut-related lymphoid organs imprint T cells with gut-homing specificity 
by providing retinoic acid during antigen presentation. MLN-DC and PP-DC 
produce retinoic acid from retinol (vitamin A), and imprint gut-homing 
specificity on T cells upon activation. The imprinted T cells express both α4B7 
and CCR9, which binds to MAdCAM-1 and CCL-25, respectively, and migrate 
into the small intestinal tissue (left panel). Conversely, DC in the skin-draining 
LN imprint CLA, CCR4 or CCR10 on T cells, which subsequently migrate to 
the skin (right panel).  
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DC not only activate and imprint antigen specificity by presenting antigen to 
lymphocytes, but they also direct lymphocytes to the site where the antigen is 
most likely to be encountered by imprinting tissue specificity. Several groups 
have shown that DC imprint the expression of homing molecules on T cells 
that they activate (Stagg et al., 2003; Johansson-Linborn et al., 2003; Mora et 
al., 2003). Work from our laboratory has demonstrated that in mice DC from 
MLN, but not from peripheral lymph nodes, induce α4B7 on T cells, thus 
targeting T cells back to intestinal tissue in vivo (Stagg et al., 2002). Murine 
intestinal DC from Peyer’s patches, MLN and the lamina propria induce α4B7 
and CCR9 expression on T cells (Johannson-Lindbom et al., 2003; 
Johannson-Lindbom et al., 2005). In contrast, T cells activated by DC from 
skin-draining nodes express ligands for skin homing molecules, P- and E- 
selectins and lack expression of gut homing markers (Mora et al., 2003).  
 
In addition to their key role in regulating tolerogenic and immunogenic 
responses, DC have a critical role in the generation of tissue trophic effector T 
cell subsets. In the mouse, the ability to generate CCR9+ α4B7+ gut homing T 
cells appear to be confined to a functionally distinct subset of MLN DC that 
express the integrin α chain CD103, and DC derived from this sites are more 
potent at generating gut trophic effector T cells than MLN DC. Hence, this 
implies that DC are imprinted with the ability to generate gut trophic T cells 
before entering MLN. In contrast to this, CD103- MLN DC are incapable of 
generating gut trophic T cells. CD103 (αE) is the α chain of the integrin β7; it 
is expressed on the majority of human and mouse intestinal lymphocytes and 
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CD103 mediates adhesion of lymphocytes to intestinal epithelial cells via 
interactions with E-cadherin (Cepek et al., 1994).  
 
Commensal bacteria can also directly influence the gut-homing capacity of 
leucocytes (Kunii et al., 2011). Work from our laboratory, recently identified a 
peptide secreted by Lactobacillus Plantarum, called STp due to the 
abundance of serine and theonine residues within its sequence. This peptide 
was present in the healthy human colon but missing from the gut in UC 
patients. It induced regulatory properties on human gut DC in vitro as well as 
had enhanced ability to imprint skin-homing properties on stimulated T-cells 
(Bernardo et al., 2012). It was hypothesised that STp has a role in gut 
homeostasis that is missing in UC, one potential mechanism being enhancing 
DC ability drive effector T-cell responses away from intestinal sites. 
 
The mechanism and specific signals involved in DC imprinting appear to be 
dependent on vitamin A. The vitamin A metabolite, retinoic acid (RA) can be 
endogenously produced, or converted from retinal by retinal dehydrogenase 
(RALDHs). RA induces gut homing markers on mouse T cells together with 
concomitant suppression of the skin-homing molecules E- and P-selectin 
(Iwata et al. 2004).  
 
T cells with regulatory properties ‘T reg’ play a central role in the maintenance 
of immunological haemostasis and tolerance in the gut. Most studies of these 
include naturally occurring population of CD4+CD25+Foxp3+ T reg cells that 
develop in the thymus. Similar to conventional T cells, ‘T reg’ have homing 
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receptors allowing migration into specific tissues and DC are thought to play 
an important role in the generation of ‘T reg’ cell responses. In particular α4B7 
is induced by ‘T reg’ when exposed to DC from MLN but not from peripheral 
lymph nodes, and RA appears to be central to this induction of α4B7 and 
homing to the intestine (Annacker et al., 2005). As with conventional T cells, 
the DC subset, CD103+ DC, is equipped for converting antigen-specific T cells 
into ‘T reg’ cells (Coombes et al., 2007; Sun et al., 2007). The CD103+ DC 
population displays an enhanced ability to generate ‘T reg’ compared with 
their CD103- counterparts in vitro, and this ability is inhibited by RA receptor 
(RAR) antagonist (Benson et al., 2007). 
 
Eckburg et al. found that CD103+ DC induced Th17 T cell differentiation in 
vitro can be inhibited by addition of an RAR antagonist to the culture medium 
(Eckburg et al., 2005). Moreover, the addition of high concentrations of RA 
inhibited Th17 cell differentiation, whereas addition of low doses of RA 
inhibited Th17 promoted Th17 cell differentiation. Thus, DC-derived RA can 
act as a co-factor for the generation of FoxP3+ regulatory cells and, 
dependent upon the prevailing cytokine milieu and levels of RA signalling, 
influence the balance between generation of regulatory cells and effector 
Th17 cells.  
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1.2.5 Differences in DC phenotype and function throughout the gut 
(differences between small bowel and colon).  
 
The GI tract is in constant contact with numerous commensal microbiota and 
food antigens hence it is necessary to have different mechanisms at play to 
generate an immune tolerance to prevent constant inflammation in a healthy 
gut. The colon and ileum have different functions as mentioned earlier, with 
the colon having the main function of water and salt extraction and the ileum 
being one of absorption of nutrients and minerals in food. Also, the load of 
bacteria in the ileum ranges from 104 to 108 CFU/mL; however, the colon is 
much more heavily colonised with a bacterial load of 1011 to 1012 CFU/mL 
(Simon GL et al., 1986, Quigley EM et al., 2006). Despite these differences 
both in function and bacterial colonisation, there are few studies that 
distinguish between properties of immune cells in these compartments. 
 
Recent data from our laboratory have shown that there are specific functional 
differences between gut DC derived from colon compared to ileum (Mann EM 
et al., 2015). Regulatory properties of gut DC and their ability to imprint 
specific homing profiles on T-cells are dependent on their anatomical location 
within the gut. There is a lower proportion of DC producing pro-inflammatory 
cytokines (TNF-α and IL-β) in the human colon compared with the ileum and 
colonic DC exhibit an enhanced ability to generate CD4+FoxP3+IL-10+ T cells 
(T-reg). Also, a greater proportion of colonic DC express the lymph-node-
homing marker CCR7 along side enhanced endocytic capacity for bacterial 
sampling; this difference was most striking in CD103+Sirpα+ DC. 
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Colonic DC also appear to be more tolerogenic compared to ileal DC with 
enhanced expression of inhibitory receptor ILT3 (although this expression was 
mainly restricted to CD103-) DC. There is also a difference between colonic 
and ileal DC abilities to imprint homing properties on stimulated T cells (CCR 
9 for small bowel homing and CCR 4 for skin homing). Ileal DC had an 
enhanced ability to generate CCR9+ (β7+) T cells compared with colonic DC 
which had an enhanced ability to imprint CCR4 on T cells. This differences in 
ileal and colonic DC imprinting may have implications in IBD with tissue 
compartmentalisation and also have bearing on how GLP-2 modulates DC 
inflammation within each of the compartments.  
 
1.3. Role of Dendritic Cells in Inflammatory Bowel Disease 
 
Microbial colonisation has an effect on the instruction and regulations of the 
gut immune system (Guarner et al., 2006). Abnormal interactions between the 
gut microbiota and the mucosal immune system are key in the development of 
chronic intestinal inflammation (Asquith et al., 2010). Crohn’s disease (CD) 
and ulcerative colitis (UC), collectively termed inflammatory bowel disease 
(IBD), results likely from a dysregulated response of the mucosal immune 
system to components of the luminal microbiota in individuals who are 
genetically predisposed to the disease (Bamias and Commeli, 2007; 
Baumgart and Carding, 2007; Sartor, 2006).  
 
In IBD, DC are likely to be of fundamental importance. Animal models of 
colitis have provided strong evidence that the interaction between intestinal 
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microbiota and mucosal immune system plays an important role in the 
pathogenesis of IBD (Karlis et al., 2004). In murine models of colitis, DC 
accumulate throughout the entire lamina propria and MLN (Leach et al., 1996; 
Strober et al., 2002). Approximately half of the colonic DC are CD11b+ whilst 
the remaining half were CD11b-B220+ pDC. In human IBD studies, activated 
DC has been shown to accumulate at sites of intestinal inflammation (Bell et 
al., 2001; Silva MA, 2009), comprising phenotypically heterogenous 
populations of DC (Verstage et al., 2008).  
 
One of the best characterise animal models involves the transfer of 
CD45RBhigh CD4+ T cells into SCID (severe combined immunodeficiency) 
mice which results in chronic intestinal lesions as those seen in human IBD 
(Malstrom et al., 2001). In such a model, colitis was associated with increase 
CD11c+ DC in the MLN and up to one third of the DC expressed high levels of 
activation marker OX40L (CD134L). Co-transfer of CD45RBlow CD4+ T cells 
inhibit the accumulation of CD134L+ DC suggesting that regulatory T cells 
may function, in part, to prevent DC activation. Moreover, blocking CD132-
CD134L interactions ameliorated the colitis, reduced T cell proliferation and 
the numbers of α4B7+ T cells in the MLN. 
 
DC are crucial for the activation and expansion of CD25+CD4+ T cells in both 
draining lymph nodes and at sites of inflammation to suppress functions of 
effector T cells. Using the CD45RBhigh CD4+ T cell transfer model of colitis, 
Mottet et al. showed that the transfer of CD25+CD4+ T cells into mice with 
colitis resulted in resolution of the lamina propria infiltrate (Mottet et al., 2003). 
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CD25+CD4+ T cells have been found to proliferate between clusters of 
CD11c+ DC in the MLN and inflamed colon. These results suggest that DC 
are important in driving T cell responses during inflammation (Krajina et al., 
2003).  
 
DC are also involved in the early events of intestinal inflammation 
demonstrated in a slightly different model in which total CD4+ T cells were 
transferred to RAG1 -/- mice resulting in colitis. Transplanted T cells formed 
aggregates with CD11c+ DC in the lamina propria, and subsequently 
underwent proliferation, approximately 8 to 11 days post transfer before the 
manifestation of colitis. The degree of expansion within the DC clusters was 
proportional to the severity of intestinal inflammation supporting the role of DC 
in the initiation, and possibly the maintenance of inflammation. It is most likely 
that pathogenic T cell responses inducing IBD are primed or re-stimulated in 
junctional CD4+ T cell/ DC aggregates (Leithauser et al., 2001). 
 
There are also studies showing the up-regulation of co-stimulatory molecules 
CD40, CD80 and CD86 together with the expansion of colonic lamina propria 
DC in murine models of colitis. In addition, lamina propria DC from inflamed 
tissue produce higher levels of IL-12p40, IL-23p19 and IL-10 (Becker et al., 
2003). 
 
IL-23 is a heterodimer that shares the p40 subunit with IL-12. IL-23 consists of 
IL-23p19 and IL12p40 whereas IL-12 comprises IL-12p35 and IL-12p40. Both 
cytokines, produced by activated macrophages and DC are potent regulators 
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of the adaptive immune responses. IL-12 is required for antimicrobial 
responses to intracellular pathogens, whereas IL-23 is likely to be important 
for the recruitment and activation of a range of inflammatory cells required for 
the induction of chronic inflammation and granuloma formation.  
 
Qualls et al. demonstrated that resident DC can suppress the severity of 
acute DSS colitis and that regulation of IL-6 production may contribute to DC-
mediated control of intestinal inflammation (Qualls et al., 2009).  
 
Similar to findings in murine models of colitis, studies of DC in human IBD 
have shown a role of activated DC at sites of intestinal inflammation (Bell et 
al., 2001), suggesting that they are likely to contribute to the generation of IBD 
in humans. Early studies have focussed on the comparison of cells in 
inflamed and normal colonic lamina propria.  
 
Several investigations have shown an increase in the number and maturation 
of DC within inflamed IBD tissue (Kaser et al., 2004), whilst others have 
suggested enhanced recruitment of immature DC into inflamed tissue (te 
Velde et al., 2003). In CD, there is an increase in CD83+ and DC-SIGN+ 
lamina propria DC, which may produce IL-12 and IL-18 during intestinal 
inflammation (Velde et al., 2003). Infiltration of CD83+CCR7- DC have been 
reported in the subepithelial dome; these cells internalize translocated E. Coli 
HB101 in the Peyer’s patches of ileal CD, and may be important in the onset 
and perpetuation of mucosal inflammation (Salim et al., 2009). In addition, 
MDC8+ monocytes, which are possible precursors of DC, have been identified 
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as a potential source of TNF-α. There are increase TNF-α producing cells in 
the ileal and colonic lamina propria of patients with CD than controls. 
Furthermore, abundant numbers of Langerin+ immature DC have been found 
in the subepithelial space of IBD tissue and are associated with enhanced 
expression of CCL20 in the intestinal epithelium. Thus CCL20 might regulate 
the attraction of T lymphocytes and DC in IBD (Kaser et al., 2004).  
 
Vuckovic et al. have also reported increased number of CD40+CD86+lin- DC in 
the peripheral blood and lamina propria of patients with UC and CD implying 
the presence of activated DC in the blood and tissue (Vuckovic et al., 2001), 
whereas Baumgart et al. have demonstrated that patients with active IBD lack 
immature blood plasmacytoid and myeloid DC, suggesting recruitment of 
these cells to the tissue (Baumgart et al., 2005). 
 
The expression of TLR-2 and -4, and the activation of CD40, is enhanced on 
lamina propria DC of patients with CD and UC. In CD, more colonic DC 
produce pro-inflammatory cytokines, IL-6 and IL-12p40, than controls. In 
addition, treatment of patients with CD with anti-TNF therapy resulted in a 
reduced expression of CD40 by lamina propria DC (Hart et al., 2005).  
 
One study in UC has identified an increase number of CD83+ and CD86+ 
lamina propria cells, most likely DC, which produce macrophage inhibitory 
factor (MIF). MIF can then induce the production of IL-1 and IL-8 by DC and 
monocytes, which may enhance neutrophil recruitment and activation 
(Murakami et al., 2002). In addition colonic lamina propria in UC contains 
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numerous basal aggregates consisting of lymphocytes and CD80+ 
dendritiform cells that most likely represent activated DC (Yeung et al., 2000). 
DC generated in vitro from peripheral blood monocytes show increase 
immuno-stimulatory capacity, and produce more nitric oxide in patients with 
UC (Ikeda et al., 2001).  
 
Lastly, DC can be the source of cytokine production. IL-12 related cytokine, 
IL-27, are increased in lamina propria of UC patients (Christ et al., 1998). UC 
is also associated with an atypical Th2 response mediated by non-classical 
NKT cells producing IL-12 suggesting that DC may regulate NKT cell activity 
through IL-27 in UC (Fuss et al., 2004). 
 
Unlike mouse models, studies of human DC in IBD have previously been 
hampered by the lack of adequate tissue, inconsistent phenotype or function 
of specific DC populations with the human intestine. Nonetheless, emerging 
evidence now supports the role of DC as important players in the regulation of 
human intestinal immunity.  
 
1.4 Glucagon Like-Peptide 2. 
 
Glucagon like peptide-2 (GLP-2), a potent intestinal peptide growth factor has 
specific trophic properties in the gut and is pivotal in the regulation of mucosal 
morphology, function and integrity. Daniel J. Drucker first described these 
properties in 1996 and since, the body of research investigating GLP-2 has 
grown exponentially, giving light to its central role in intestinal physiology in 
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both health and disease (Drucker DJ et al., 1996). In the last decade, it has 
become evident that GLP-2 has a therapeutic role in the treatment of short 
bowel syndrome (SBS) with a good safety profile (Wallis K et al., 2009; 
Yazbeck R et al., 2010).  
 
SBS is a malabsorption disorder that occurs when part of the small intestine is 
missing (congenital short bowel) or has been surgically removed due to 
pathology. Complications from nutritional malabsorption occur and cause 
significant comorbidities. Main causes of SBS include Crohn’s disease, 
volvulus, ischemia, injury from trauma, tumours, necrotizing enterocolitis 
(premature newborn), bypass surgery to treat obesity and surgical resection 
of disease or damaged small bowel. 
 
The effects of GLP-2 resulting in higher absorptive capacity of the intestine 
allowed patients with SBS less dependence on parenteral nutrition, therefore 
improving nutritional status and quality of life. This would be a ‘first in class’ 
treatment for patients with SBS (Hornby PJ et al, 2011).  
 
Recently, through a number of murine studies, GLP-2 has shown promise in 
reducing mucosal inflammation and maintaining mucosal integrity, leading to 
the concept that it may have therapeutic applications in conditions like IBD, 
chemo and radiation-induced mucositis as well as NSAID-induced enteritis. 
More studies, both murine and in humans are needed to see if these findings 
will translate into clinical practice. Through this thesis, we therefore wish to 
explore the possible immunomodulatory properties of GLP-2 at a cellular level 
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and explore the possible mechanisms by which GLP-2 could potentially do 
this.  
 
1.4.1 Synthesis, Secretion and Degradation 
 
Synthesis 
 
Glucagon like peptide-2 is a 33 amino acid peptide with an estimated 
molecular mass of 3766.16 (Hartmann B et al., 2000). GLP-2 is co-encoded 
within the proglucagon gene along with glucagon like peptide -1 (GLP-1), 
which in mammals, gives rise to a single mRNA transcript that is expressed in 
the alpha (α) cells of the endocrine pancreas, in the enteroendocrine L cells of 
the intestine and in the hypothalamus and brainstem of the central venous 
system (CNS) (Baggio LL et al., 2004; Drucker DJ et al., 1988; Drucker DJ et 
al., 1989). Proglucagon mRNA is translated into a single 160 amino acid 
precursor protein, producing several biologically active proglucagon-derived 
peptides via tissue-specific post-translational processing. In the pancreatic α 
cells, proglucagon is cleaved by prohormone convertase (PC)-2 to form 
glucagon, the major glucagon fragment and intervening peptide (IP)-1. In the 
GI tract and in the brain, the processing of proglucagon, which is operated by 
PC1/3, results in GLP-1, GLP-2, IP-2, oxytomodulin and glicentin formation 
(Figure 1.5). 
 
Much of the understanding of GLP-2 biology and function has been 
discovered in tandem with Glucagon like peptide-1 (GLP-1). GLP-1 is 
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synthesised in the same manner as GLP-2 but has mainly an incretin effect 
and this has led to development of its analogues being directed towards 
treatment of endocrine abnormalities and type 2 diabetes.  
 
 
Figure 1.5 Structure of proglucagon and glucagon-like peptide 2.  
The proglucagon-derived peptides, derived from post-translational processing 
of proglucagon, in both pancreas and intestine are indicated. 
Abbreviations: GLP-1, glucagon-like peptide 1; GRPP, glicentin-related 
pancreatic polypeptide; IP-1 and -2, intervening peptides 1 and 2; MPGF, 
major proglucagon-derived fragment. 
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Secretion  
 
Biologically active GLP-21-33 is secreted by enteroendocrine L cells, most of 
which are located in the distal ileum and colon. The chief stimulus for 
intestinal secretion of GLP-2 is the ingestion of nutrients, including glucose, 
fatty acids and dietary fibre (Brubaker PL et al., 1986). Protein has no effects. 
GLP-2 is secreted in a biphasic pattern, with an early peak followed by a 
longer second phase after ingestion of nutrients. It is likely that the early 
phase of GLP-2 secretion is due to the stimulation of the L cells by various 
neural and endocrine factors, in contrast with the second or late phase, which 
is caused by direct stimulation of intestinal L cells by digested nutrients (Xiao 
Q et al., 1999). After ingestion of nutrients, plasma levels of GLP-2 increase 
2- to 5-fold, depending on the size and nutrient composition of the meal. The 
peptide diffuses across the subepithelial lamina propria to activate afferent 
nerves and/or enter the circulation; thus they may act as paracrine agents as 
well as endocrine hormones (Figure 1.6). 
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Figure 1.6. Direct and indirect effects of nutrients on secretion of GLP-2. 
Entry of nutrients into the proximal small intestines initiates an early peak of 
secretion mediated through the vagus nerve. The afferent component of this 
neural loop is activated by ingested nutrients either directly or through release 
of an enteroendocrine hormone, such as GIP from the K cells. Vagal efferent 
fibres then stimulate the distal L cells through a pathway that likely involves 
both ACh and GRP within the enteric nervous system. Further aboral 
movement of the nutrients down the lumen of the small intestine stimulates a 
second, later peak of GLP-2 secretion through direct effects on L cells. 
Abbreviations: Ach, acetylcholine; CNS, central nervous system; GIP, 
glucose-dependent insulinotropic polypeptide; GLP-1, glucagon-like peptide 1; 
GLP-2, glucagon-like peptide 2; GRP, gastrin releasing peptide. (Reprinted 
with permission – Katharina Wallis PhD Thesis 2009) 
83 
 
The mechanisms by which nutrients induce the release of peptides from the 
enteroendocrine cells have not been fully elucidated. Currently little is known 
about the cellular/secretion mechanism responsible for GLP-2 but is felt to be 
analogues to that of GLP-1. One mechanism that has been described 
involves enteroendocrine cell activation to release these peptides and is 
mediated by cellular uptake and intracellular metabolism of glucose. This 
triggers peptide exocytosis via ATP-sensitive potassium-channel closure, 
depolarisation and calcium channel activation, similar to insulin secretion 
(Reimann F et al., 2002).  
 
Another suggested mechanism involves downstream mediating effects of 
GLP-2 (Dubé  PE et al., 2007) (Figure 1.7). For example, vascular endothelial 
growth factor [VEGF] and transforming growth factor-ß (TGF- ß) have been 
linked to GLP-2 induced wound repair (Bulut K et al., 2008), insulin-like 
growth factor-1 (IGF-1) appears to be essential for GLP-2 induced intestinal 
epithelial proliferation and nitric oxide [NO] might be a key mediator in GLP-2 
induced up-regulation of intestinal blood flow (Guan X et al., 2006) Also, the 
release of vasoactive intestinal peptide (VIP) from enteric neurons mediates 
the anti-inflammatory effects of GLP-2 (Sigalet DL et al., 2007). 
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Figure 1.7. Proposed model for the indirect mechanisms of glucagon-
like peptide-2 (GLP-2) action in the intestine.  
Expression of the GLP-2R in intestinal endocrine cells (A), intestinal SEMFs, 
(B) and enteric neurons (C) suggests that GLP-2 acts indirectly to produce its 
diverse actions in the intestine. IGF-I is critical for the ability of GLP-2 to 
induce intestinal growth and activate crypt cell proliferation. GLP-2-mediated 
enteric neuronal signaling enhances intestinal blood flow through a 
mechanism involving NO production and has anti-inflammatory actions 
through VIP [16]. (Reprinted with permission – Katharina Wallis PhD Thesis 
2009). Abbreviation: GLP-2R, Glucagon-like peptide-2 receptor; SEMFs, 
subepithelial myofibroblasts; IGF-I, insulin-like growth factor-1; NO, nitric 
oxide; VIP, vasointestinal polypeptide.  
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Degradation  
 
GLP-2 is degraded quickly through cleavage of N-terminal histidine and 
alanine by the ubiquitously expressed proteolytic enzyme dipeptidyl 
peptidase-IV (DDP-IV), resulting in the generation of biologically inactive GLP-
23-33 (Figure 1.8) The importance of DDP-IV in the regulation of GLP-21-33 has 
been demonstrated in vitro and in vivo using animal models (Meier JJ et al., 
2006). Bioactive GLP-21-33 has an apparent half-life of 7 min in humans 
(Hartmann B et al., 2000). Once in the plasma, the kidney provides the major 
route of clearance for GLP-2.  
 
 
Figure 1.8. The amino acid sequence of human GLP-2 (amino acids 1-33) 
and its site of cleavage by the peptidase dipeptidyl peptidase 4 (DPP-IV) 
(arrow) to GLP-2 (amino acid 3-33) are shown (Drucker D et al., 1999). 
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Prolongation of half-life  
 
To date, there are two different successful strategies in mitigating the issue 
with the short half-life of GLP-2. The first is to use the mimetics of GLP-2 that 
are resistant to inactivation by DPP-IV, thus prolonging and enhancing the 
effect of the hormone. Teduglutide (GATTEX; NPS Pharmaceuticals, 
Bedminster, NJ, USA) was developed by replacing alanine with glycine in 
position 2 of GLP-2, providing a molecule with a half-life of 3-4 h. 
 
The second strategy involves inhibition of DPP-IV therefore prolonging the 
effect of endogenously secreted glucagon like peptides (GLP-1 and GLP-2). 
Drugs like vidagliptin (Galvus; Novartis Pharmaceuticals, East Hanover, NJ, 
USA) and sitagliptin (Januvia; Merck & Co., Whitehouse Station, NJ, USA) 
that are specific DPP-IV inhibitor for GLP-1 are currently used for treatment of 
non-insullin dependent diabetes.  
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1.4.2 Role of GLP receptors 
 
Like glucagon, the action of GLP-2 and GLP-1 are mediated through class 2 
G-protein-coupled receptors. These receptors are distinct and specific for 
either GLP-2 or GLP-1, despite sharing the conserved properties of their class.  
 
GLP-2 receptor (GLP-2R) has been cloned from the stomach, small bowel 
and hypothalamus cDNA libraries (Munroe DG et al., 1999). GLP-2R 
expression is restricted to the GI tract and the CNS, with limited expression in 
the lung, cervix and vagal afferents, although cardiac expression in rats has 
been reported recently (Angelone T et al., 2012).  
 
The exact cellular localization of the GLP-2R in the gut in early studies has 
been a source of controversy. GLP-2R has been reported in enteroendocrine 
cells, enteric neurons and subepithelial myofibroblast. However, in the murine 
GI tract, the GLP-2R is expressed exclusively in neurons and myofibroblasts 
and is not present at the mucosal level (Bjerknes M et al., 2001). It is now 
generally accepted that the above three cell types express GLP-2R in the 
intestine.  
 
The relatively high prevalence of the GLP-2R in the gut might explain why, to 
date, GLP-2 mediated effects have been observed almost exclusively in the 
GI tract (Sinclair EM et al., 2005). Because the GLP-2R is expressed in the 
subepithelial myofibroblasts and in the enteric nervous system as well as 
human enteroendocrine cells, and not on the crypt cells or enterocytes 
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themselves, it has been proposed that GLP-2 exerts its actions on the 
mucosa via intermediate effectors derived from GLP-2R-expresing cells 
(Yusta B et al., 2000) as mentioned earlier. 
 
Determining how GLP-2 produces its biological effects, which mediators are 
involved and how these mediators interact is an area of intense research.  
 
1.4.3 Physiological effects of GLP-2 
 
GLP-2 was first discovered as an intestinotrophic factor in 1996; today, it is 
recognised as a hormone that influences multiple functions specifically in the 
GI tract. The main biological effects of GLP-2 are related to the regulation of 
energy absorption and maintenance of mucosal morphology, function and 
integrity of the intestine (Drucker DJ et al., 1996). However, in considering the 
actions of GLP-2, it is important to note that this peptide has been found to 
exhibit different actions in different species (i.e. rodents, pigs and humans). 
As mentioned earlier, over the last decade, it has become evident that GLP-2 
(and it’s analogues) play a growing has a therapeutic role in the treatment of 
short bowel syndrome (SBS) with a good safety profile based on its spefific 
effects on fluid absorption.  (Wallis K et al., 2009; Yazbeck R et al., 2010). The 
role of GLP-2 on absorption of fluid will be discussed in more depth at the end 
of the chapter.  
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Intestinotrophic Effects 
 
A key beneficial effect of GLP-2 on the gut is its ability to increase intestinal 
growth owing to the enhancement of crypt cell proliferation and inhibition of 
apoptosis, resulting in expansion of villus height (Figure 1.9). GLP-2 appears 
to act through intestinal IGF-1 to induce intestinal growth and crypt cell 
proliferation (Figure 1.10).  
 
 
 
 
Figure 1.9: Effect of GLP-2 on murine small intestine.  
Histological appearance of small intestine epithelium from control (a) and 
GLP-2-injected (10 days) (b) mice. (Reprinted with permission – Katharina 
Wallis PhD Thesis 2009) 
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Figure 1.10. Schematic representation of interactions between GLP-2 
and IGF-1 in the regulation of intestinal growth.  
After secretion by the intestinal L cell into the circulation, GLP-2 activates the 
G protein coupled GLP- 2 receptor in the subepithelial myofibroblast cells, 
which subtend the epithelium as a syncytium. This leads to release of IGF-1, 
which then acts in a paracrine fashion on the tyrosine kinase IGF-1R 
expressed in the proliferative compartment of the crypt (Dube PE et al., 2008). 
 
However, the mechanisms through which GLP-2 affects the epithelium in an 
IGF-1 dependent manner have not been fully explained. Studies in murine 
intestinal subepithelial myofibroblasts suggest that the phosphatidylinositol 3 
kinase/ Akt pathway may be implicated in the stimulatory effects of GLP-2 
(Leen JL et al., 2011). These findings provide further evidence that IGF-1 
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produced by intestinal subepithelial myofibroblast cells play a key role in the 
intestinotrophic effects of GLP-2.  
 
A number of studies have demonstrated that exogenously administered GLP-
2 is trophic for the small intestine and, to a lesser extent, the colon. 
Administration of exogenous GLP-2 to rats during and after massive bowel 
resection augmented adaptive growth in the residual small intestine without 
compromising endogenous GLP-2 production and secretion (Koopman MC et 
al., 2008). Sustained administration of GLP-2 is necessary for intestinal 
adaptation, and benefits are lost when exogenous GLP-2 is discontinued. 
Similar trophic and functional responses to exogenous GLP-2 administration 
are seen in adult patients in whom the terminal ileum and colon have been 
resected (Jeppesen PB et al., 2001; Jeppesen PB et al., 2005). Adaptive 
responses are impaired in these individuals, who have limited meal-stimulated 
GLP-2 secretion due to removal of GLP-2 secreting L cells. Treatment with 
GLP-2 improved intestinal function and nutritional status in these patients. 
 
The association between GLP-2 and intestinal growth/adaptation is most 
evident in a variety of pathological conditions, including post-resection 
intestinal adaptation, coeliac disease, parenteral nutrition-induced intestinal 
atrophy and IBD.  
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Mucosal Integrity 
 
GLP-2 maintains mucosal integrity by enhancing intestinal barrier function and 
decreasing transcellular and paracellular epithelial permeability (Benjamin MA 
et al., 2000). GLP-2 enhances barrier function within the setting of 
experimental food allergy, stress or diabetes, reducing the uptake of antigen, 
the secretory response and the number of inflammatory cells (Cameron HL et 
al., 2005; Cameron HL et al., 2003; Hadjiyanni I et al., 2009). The effects of 
GLP-2 in increasing barrier function have been confirmed in non-obese 
diabetic and ob/ob obese murine models. Administration of prebiotic to ob/ob 
mice induces GLP-2-dependent upregulation of tight junction proteins zonulin-
1 and occludin (Cani PD et al., 2009).  
 
Mucosal Immunity 
 
The protective and reparative effects of GLP-2 have also been studied in the 
context of IBD. Circulating concentration of bioactive GLP-2 were elevated in 
patients with IBD with active disease compared to healthy controls (Xiao Q et 
al., 2000) indicating an innate adaptive mechanism to the intestinal injury 
associated with IBD. Animal investigations have shown that mucosal GLP-2 
concentrations are decreased in areas of colonic inflammation (Schmidt PT et 
al., 2000). 
 
Evidence of GLP-2 potential anti-inflammatory properties surfaced when 
Sigalet et al looked at the use of GLP-2 in rats with trinitrobenzene sulfonic 
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acid (TNBS) - induced ileitis or dextran sulphate sodium (DSS) - induced 
colitis (Sigalet DL et al., 2007). GLP-2 treatment resulted in significant 
reduction in inflammatory cytokines such as IL-1ß, INF-γ and TNF-α along 
with reduction in neutrophil activity. This effect has been demonstrated in rat 
models of ileitis and colitis. GLP-2 treatment, given either immediately or after 
inflammation, significantly reduced body weight loss, mucosal inflammation 
indices, inflammatory cytokine levels and inducible NO synthase expression. 
These effects may be mediated by activity of VIP, which is produced by the 
enteric nervous system and known to act as an anti-inflammatory agent, 
because co-administration of selective antagonist for VIP blocked the actions 
of GLP-2. Notably, the anti-inflammatory activity of GLP-2 was not associated 
with an increase in the rate of crypt cell proliferation. Instead, crypt cell 
proliferation and apoptosis within crypts in inflamed tissues were reduced. 
These findings support a potential additional neural mechanism of action for 
GLP-2, with therapeutic implications distinct from its role in promoting crypt 
cell proliferation.  
 
Subsequently, Ivory et al confirmed the anti-inflammatory actions of GLP-2 via 
use of IL-10 knockout (IL-10-/-) mouse model and established that this 
immunomodulatory effect was IL-10 independent (Ivory CPA et al., 2008). 
GLP-2 altered the mucosal response of inflamed intestinal epithelial cells and 
macrophages by activation of the SOCS-3 pathway, which antagonizes the IL-
6 mediated increase in STAT 3 signalling. The study also confirmed that the 
anti-inflammatory actions of GLP-2 were IL-10 independent.  
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ZP1848 and ZP1846 are GLP-2 mimetics recently developed by Zealand 
Pharma to enhance intestinal repair and attenuate inflammation. More 
specifically, ZP 1848 is a GLP-2R agonist that is currently in clinical 
development for the treatment of Crohn’s disease (Skarbaliene J et al., 2011). 
ZP1846 is a GLP-2 peptide analogue that consistently stimulated growth of 
small intestinal mucosa in mice and decreased the incidence and severity of 
chemotherapy-induced diarrhoea in rats (Petersen YM et al., 2006). 
 
Energy Absorption 
 
GLP-2 exerts numerous other actions within the GI tract to promote energy 
absorption. It increases the uptake of luminal nutrients, including sugars and 
lipids, by augmenting the activity and the expression of nutrient transporters 
(Hsieh J et al., 2006) and by enhancing the expression of different enzymes 
involved in digestion. The major clinical benefit shown to date in adult patients 
is an increase in fluid and electrolyte absorption. In clinical studies, 
administration of GLP-2 or the degradation-resistant analogue teduglutide has 
been shown to slightly improve intestinal absorption, as indicated by 
increases in faecal wet weight (i.e. the measure of fluids and faeces excreted 
in bowel or ostomy output) and other indices of nutritional status (i.e. 
absorption of energy, macronutrients and electrolytes) in patients with SBS, 
even though differences were small and many did not achieve statistical 
significance (Jeppesen PB et al., 2001).  
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GLP-2 also increases mesenteric blood flow, thus providing another 
mechanism to facilitate digestion and absorption of nutrients (Bremholm L et 
al., 2009). GLP-2 has also been shown to inhibit gastric acid hypersecretion 
(Wodjdemann M et al., 1999) and intestinal chloride secretion (Baldassano S 
et al., 2009).  
 
Gastric motility 
 
The effects of GLP-2 and GI motility remain controversial. In animal models, 
GLP-2 has been demonstrated to reduce antral motility in pigs and decrease 
fundic tone in mice, leading to an increase of stomach capacity (Amato A et 
al., 2009). Results regarding the ability of GLP-2 to suppress gastric motility in 
humans are conflicting, with GLP-2 either having no influence or slowing 
gastric emptying (Jeppesen PB et al., 2001; Nagell CF et al., 2004). The 
discrepancies in results may be due to the differences in methodologies used 
to assess emptying or due to the type of test meal administered (low-calorie 
liquid meal vs high-calorie solid meal). The effects of GLP-2 on gastric 
emptying and fundus tone indicate that GLP-2 could influence feeding 
behavior. However, it is noted that the satiety effect is much more potent with 
GLP-1.  
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1.4.4 Clinical use of GLP-2 
 
Short bowel syndrome (SBS) is defined by a combination of symptoms and 
signs that occur after extensive surgical resection of the intestine. This highly 
disabling condition is characterized by malabsorption of both fluid and 
nutrients and, left untreated, can lead to dehydration, malnutrition, and weight 
loss. The term intestinal failure (IF) applies when an adequate balance of 
nutrients and water cannot be maintained without dietary support. IF often 
remains a short-term problem in the postoperative period. However, a small 
number of patients will require long-term parenteral nutrition (PN) or, in 
selected cases, intestinal transplantation. Such patients will typically have less 
than 100 cm of small bowel leading to an end-stoma or less than 50 cm 
connected to a functioning colon. Although PN has revolutionized IF treatment, 
it has a significant impact on quality of life and carries considerable risks, 
mainly hepatic failure, central vein thrombosis, and recurrent sepsis, all of 
which will reduce life expectancy. Survival following intestinal transplantation 
is still inferior to that of long-term PN due to the high incidence of graft 
rejection and other postoperative complications (Pironi L et al., 2008). 
 
To date, the management of SBS or other types of intestinal failure focuses 
primarily on supplementation of nutrients, fluid and electrolytes via long-term 
PN and supportive medical management via use of agents that reduce 
secretion (H2 receptor blockers, proton pump inhibitors, and octreotide) and 
motility (codeine, opium, lomotil, and loperamide)(Nightingale J et al., 2006). 
Hence, a major unmet need exists for treating patients with intestinal failure. 
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There has been much interest in GLP-2 as a target for SBS-associated 
intestinal failure. Preclinical studies in animal models of SBS have shown 
beneficial effects of GLP-2, consisting of increased body weight, restored 
absorptive capacity of the bowel, improved adaptive growth of the residual 
bowel, increased villus and mucosal height and improved mucosal antioxidant 
capacity (Liu X et al., 2006; Scott RB et al., 1998; Washizawa N et al., 2004) 
(Figure 1.11). Administration of GLP-2 improved nutrient absorption and 
nutritional status in SBS patients with colectomy, who have normal GLP-2 
fasting levels but do not show a post-prandial physiologic increase of the 
peptide. However, the limiting factor in clinical use of GLP-2 as mentioned 
previously is the short half-life in circulation (6-7 min); consequently, several 
DPP-IV resistant GLP-2 analogues have been develop, of which teduglutide 
has obtained FDA approval.  
 
 
Figure 1.11. The secretion, regulation and biological activity of GLP-2.  
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Moreover, exogenous GLP-2 analogues may be beneficial in treating other 
gut-related diseases, such as mucosal damage resulting from radiation, 
chemotherapy and non-steroidal anti-inflammatory drugs (NSAIDS) usage 
(Booth C et al., 2004; Boushey RP et al., 1999; Boushey RP et al., 2001). 
Although teduglutide may have therapeutic benefits at different stages of 
intestinal disease, the greatest therapeutic efficacy has been observed when 
the peptide is given before induction of gut injury. In mice with radiation-
induced mucositis, for example, teduglutide increased intestinal weight, crypt 
size, villus height and crypt stem-cell survival when given before irradiation. 
However, in experimental murine NSAID-induced enteritis, teduglutide 
improved histological evidence of the disease with a decrease in neutrophil 
infiltration, whether administered before, concomitant with, or after 
indomethacin. Consistent with the general mucosal cytoprotective actions of 
the peptide, findings from a pilot study suggested the potential effectiveness 
of teduglutide for inducing remission and mucosal healing in patients with 
active moderate to severe Crohn’s disease (Buchman AL et al., 2010)  
 
Teduglutide [h(Gly2) GLP-2, ALX-0600] substitutes glycine in place of alanine 
in the key second position of the peptide, resulting in resistance to DPP-IV 
degradation and a longer biological half-life. Teduglutide is expected to be the 
first orphan drug for the treatment of SBS. In an open-label 21-day study in 16 
patients with SBS, teduglutide doses ranging between 0.03 and 0.15mg/kg/d 
subcutaneous (SC) decreased faecal wet weight and faecal energy excretion 
and increased wet weight absorption, urine weight and urinary sodium 
excretion (Jeppesen et al., 2005). These effects were reversed over a 3-week 
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post-treatment follow-up period. The changes in excretion and absorption 
were associated with increased villus height, crypt depth and mitotic index in 
the jejunum, and no changes in these mucosal proliferation indices in the 
colon.  
 
In the pivotal phase III study (004 study), 83 SBS patients received placebo, 
teduglutide 0.05mg/kg/d or teduglutide 0.1mg/kg/d SC for 24 weeks and it 
was shown that the 0.05mg/kg/d group was superior to placebo in achieving a 
>20% reduction in parenteral fluid volume need and in obtaining a graded 
response score (a response evaluation taking into account magnitude and 
duration of reductions in parental fluid need) (Jeppesen PB et al., 2011). 
Response of similar magnitude of the 0.1mg/kg/d group did not reach 
statistical significance, probably because of higher baseline values in this 
group. Oral fluid intake was significantly decreased in the 0.1mg/kg/d group 
and statistically significant increases in body weight occurred in the two 
teduglutide dose groups compared with placebo. Sixty-five patients opted to 
enter an open-label, 28 week extension study (O’Keefe et al., 2013) which 
showed that patients who received 1 year continuous teduglutide treatment, 
the mean reduction of weekly parenteral support volume was 4.9L/week 
equivalent to a 52% reduction from baseline levels.  
 
A second phase III study (020 study) with similar design elements (Figure 
1.12) – 24 weeks prospective, randomized, double blind, placebo-controlled, 
parallel-group, multi-national and multicenter study was conducted in the US, 
Canada and Europe (Jeppesen et al., 2012). Adults with SBS (>18 years of 
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age) due to diverse causes (e.g. Crohn’s disease, vascular disease, volvulus, 
injury and other) who were dependent on parenteral support for at least 12 
months and at least three times per week were recruited. After an optimization 
and stabilization period of 16 weeks to achieve a urine output of 1-2L per day, 
43 patients were randomized to a 0.05mg/kg/day dose of teduglutide and 43 
patients received placebo. The proportion of teduglutide-treated patients 
achieving a 20-100% reduction of parenteral support at week 20 and 24 was 
statistically significantly higher compared to placebo (27 out of 43 patients, 
62.8% versus 13 out of 43 patients, 30.2%; p=0.002). At week 24, teduglutide 
treatment resulted in a 4.4L/week (32%) reduction in parenteral support 
volume from a pretreatment baseline of 12.9L/week while maintaining oral 
fluid intake, urine production and body weight constant throughout the study. 
Placebo-treated patients had average parenteral support reductions of 2.3 ± 
2.7L/week (21%) at week 24, but they significantly increased their oral fluid 
intake by 1.6 ± 3.6L/week (p<0/009) in order to maintain urine production 
constantly. In patients completing the study, 21 patients treated with 
teduglutide (54%) versus nine on placebo (23%) achieved at least 1-day 
reduction in parenteral support administration (p=0.005).  
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Figure 1.12. Design of the phase 3 placebo-controlled trials of 
teduglutide in adult patients with SBS-IF.  
SBS-IF, short bowel syndrome-associated intestinal failure. 
 
Following the 020 study, a long-term 30-month 021 extension study was 
carried out where teduglutide was showed to result in addition, clinical 
meaningful reductions in parenteral support volume from 12.9 L/week at 
baseline to 4.9L/week after 30 months of treatment. Independence from 
parenteral support was achieved in 13 patients included in the 020 and 021 
studies. In general, teduglutide was well tolerated with the distribution of 
discontinuation of treatment due to adverse events being similar between 
patients given teduglutide and placebo. The adverse event profile was 
generally consistent with the underlying disease condition and the known 
mechanism of action of teduglutide: the most frequently reported adverse 
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were gastrointestinal-related (Table 1.1) (NPS Pharmaceuticals). In the 020 
study, the overall parenteral support reductions were associated with 
increases in QoL. Teduglutide significantly improved the scores of 9 of 17 
individual items of SBS-QoL scale from baseline at week 24. Effects were not 
significant compared to placebo (Jeppesen PB et al., 2013). 
 
 
Table 1. Adverse reactions in at least 5% of teduglutide-treated SBS 
patients and more frequent than placebo in studies 004 and 020. 
 aPercentage based on 53 patients with a stoma (n 1⁄4 22 placebo, and n 1⁄4 
31 teduglutide 0.05 mg/kg/day). 
 
Teduglutide (Gattex) is now approved for use in treatment of patients with 
short bowel syndrome-associated intestinal failure by the US Food and Drug 
Administration (FDA) and the European Medicines Agency (EMA).  
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1.4.5 Safety and tolerability of GLP-2 
 
In human studies, GLP-2 and GLP-2 analogues and agonist have been 
generally well-tolerated, with the incidence of adverse effects similar to that of 
placebo-treated subjects. Because GLP-2Rs are found predominantly in the 
GI tract, to date GLP-2 associated GI adverse effects have been observed in 
clinical trials. In a 2-year open-label study with teduglutide in 76 SBS patients 
with intestinal failure, treatment was well tolerated, with the major adverse 
events being gastrointestinal (22% mainly abdominal pain, distension, nausea 
and vomiting) (Schwatrz LK et al., 2011). No neutralizing antibodies have 
been reported in published clinical trials.  
 
The potential for carcinogenesis or promoting the growth of subclinical 
malignancies is a concern with use of GLP-2 or its analogues. The 
proliferative actions of GLP-2 in the GI tract have been demonstrated to occur 
in a regulated manner in normal tissue. Findings that GLP-2R mRNA is 
present in human intestinal carcinoid tumours suggest that GLP-2 has the 
potential to stimulate the proliferation of neoplastic tissue. However, there has 
been no evidence of dysplasia or malignancy reported with the use of GLP-2 
in humans. Indeed, a recent report suggests that human colon cancer has 
less expression of GLP-2R protein than the surrounding noncancerous tissue 
(Bengi G et al., 2011). However, in preclinical models in which a known 
carcinogen was first used to induce a malignancy, GLP-2 may promote 
tumourigenesis (Thulesen J et al., 2004). In studies in which a known GI 
carcinogen was given first to stimulate malignant changes, GLP-2 enhanced 
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the growth of polyps and tumours; administration of a long acting GLP-2 
analogue (Teduglutide) or GLP-2 itself promoted the growth of 
dimethylhydrazine-induced colonic polyps – tubular adenomas confined to the 
colonic mucosa- in mice. Although the neoplasms were not cancerous, 
malignant transformation may occur in time. A recent report documented an 
increase in dysplasia with GLP-2 in two novel models of inflammation-
associated colon cancer. In rats fed the carcinogen 2-Amino-1-methyl-6-
phenylimidazo [4,5-b] pyridine and a high-fat diet, 2 of 9 (22%) rats receiving 
hGly2- GLP-2 developed intestinal cancer compared with 0 of 7 (0%) control 
rats. In the other set of experiments, mice with chronic dextran sodium-
sulphate induced colitis were administered azoxymethane to promote 
development of colon cancer. Among mice that received control injections, 
56% exhibit high-grade dysplasia or colon cancer compared with 64% of mice 
that received hGly2- GLP-2 and 46% of mice that received a GLP-2 antagonist 
(Trivedi S et al., 2012).  
 
Although there have been no safety signals of malignancy in the clinical trials 
for teduglutide, it remains unclear what impact such analogues will have in the 
long term.  
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Summary 
 
Given the trophic and immunological effects of native GLP-2 and teduglutide, 
and the preferential location of GLP-2 receptors within areas of the intestine 
often affected in patients with IBD, more studies looking into the 
immunomodulatory actions of GLP-2 would contribute to future translation 
studies ‘from bench to bedside’.  
 
1.5 Hypothesis 
 
We hypothesise that GLP-2 exerts its immunomodulatory actions via dendritic 
cells that are central in orchestrating the intestinal inflammatory process. 
 
1.6 Aims 
 
To test the above hypothesis, the specific aims of the project were: 
 
1. To assess the cellular toxicity of GLP-2 in culture, in preparation for in 
vitro experiments with human DC.  
 
2. To determine the effects of GLP-2 in vitro on the maturation and co-
stimulatory phenotype of human DC. 
 
3. To determine the effects of GLP-2 in vitro on the endocytosis of human 
DC.  
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4. To determine the effects of GLP-2 in vitro on the cytokine profile on 
human DC. 
 
5. To determine the effects of GLP-2 in vitro on the functional phenotype, 
stimulatory potency for allogeneic T cells on human blood DC and 
intestinal DC and T cell cytokine profile. 
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Chapter 2 
General Materials and Methods 
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2.1 General Materials 
 
2.1.1 Ethical Approval 
 
Ethics Committee and Competent Authority Approvals  
 
The study protocols and associated laboratory investigations of dendritic cell 
immune regulation in human blood and intestinal biopsy material was secured 
to investigate ‘’The Effects of GLP-2 on the immune system’’ and “Dendritic 
Cell Immune Regulation” using human blood and intestinal biopsy material 
(Brompton, Harefield & NHLI Research Ethics Committee, Ref. 09/H0708/78 
and Brent and Harrow Research Ethics Committee, Ref. 05/Q0405/71). 
Written informed consent was obtained from all participants, patients and 
healthy volunteers. 
 
Local NHS Research and Development approval and sponsorship to conduct 
the study was secured from Imperial Healthcare NHS Trust and North West 
London Hospital NHS Trust. 
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2.1.2 Materials 
 
Human Blood Samples 
 
Venesection was performed on participants, patients and healthy volunteers 
according to the study protocol. Informed consent (EC No.09/H0708/78 and 
05/Q0405/71) was obtained prior to peripheral blood sampling. Blood samples 
for in vitro laboratory investigations were collected in 10ml lithium heparin 
vacutainer tubes (BD Biosciences) and processed within 1 hour of 
venesection in the Antigen Presentation Research Group (APRG) laboratory.  
 
2.1.2 Human Intestinal Samples 
 
Colonic biopsies were obtained from healthy controls at routine colonoscopy 
from healthy patients. These patients had macroscopically and histologically 
normal intestines, and had been referred with symptoms of rectal bleeding or 
change in bowel habit. Exclusion criteria included inflammatory bowel disease 
or other inflammatory conditions (e.g. sarcoidosis, tuberculosis, diverticulitis), 
any current cancer of any type, previous bowel cancer or polyposis 
syndromes.  
 
Written informed consent was obtained from all patients before the procedure 
(EC numbers as above). Between eight to ten mucosal biopsies (40- 60 mg of 
tissue) were taken per patient from the ileum & colon. All patients had 
received either full bowel preparation with magnesium citrate and senna or 
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macrogol (Klean-Prep). The biopsies were collected in complete medium and 
transported immediately to the laboratory on ice for processing. All 
experimental procedures were started within an hour of taking the mucosal 
biopsies. 
 
2.1.3 Culture Media 
 
Culture Medium 
 
For the culture of both peripheral blood mononuclear cells (PBMCs) and low 
density cells (LDCs), cells were suspended in RPMI 1640 Dutch modification 
(Sigma Aldrick Co. Ltd, Irvine, UK) supplemented with 2mM L-glutamine, 
100ug/ml streptomycin, and 100units/ml penicillin. 
 
Complete Medium  
 
During prolonged processing or culture of intestinal biopsy and resection 
specimens, cells were suspended in RPMI-1640 Dutch Modification medium 
supplemented with 10% foetal calf serum (FCS, Harlan Laboratories), 2mM L-
glutamine, 100ug/ml streptomycin, 100 units/ml penicillin (Sigma, Poole, 
England). For culture of intestinal biopsy samples an additional 25ug/ml 
gentamicin (Sigma) was added. 
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2.1.4 Glucagon Like Peptide-2 (GLP-2) 
 
Human GLP-2 (1-33) trifluroacetate salt with a molecular formula of 
C165H254N44O55S (estimated 3766.16g molecular mass; 1mg) (BACHEM AG; 
Hauptstrasse 144, Switzerland H-5662) was diluted in 5uL (35%) ammonia 
and divided into aliquots of 10mM. Calculated concentrations of 10-12M (1pM), 
10-9M (1nM) and 10-6M (1µM) were obtained by dilution in sterile water within 
each experiment. 
 
2.1.5 Buffers 
 
FACS buffer 
 
Cells prepared for flow cytometry were washed and re-suspended in FACS 
buffer. This buffer was prepared from phosphate buffered saline (PBS) with 
added FCS (2%), sodium azide (0.02%) (Sigma, UK) and EDTA (1mM) 
(Sigma, UK).  
 
MiniMACS buffer 
 
MiniMACs Buffer contains PBS 500ml, 0.37g EDTA (2mM) and 2.5g (0.5%) 
Bovine Serum Albumin (BSA, Sigma, Germany). This was used for washing 
and labelling cells in the MiniMACSTM magnetic cell separation system 
(Miltenyi Biotec, Germany). 
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10x Binding Buffer 
 
10x Binding Buffer (Abcam, UK) was supplied pre-formulated and consisted of 
0.1 M Hepes, pH 7.4, 1.4 M NaCl 25 mM CaCl2 was diluted with distilled 
water to a working concentration of 1x Binding Buffer. This binding buffer 
contains an optimal concentration of calcium required during cell labelling for 
calcium-dependent binding of Annexin V to externalised phosphotidylserine 
(PS) on cell surfaces. 
 
2.1.6 Reagents 
 
5-carboxyfluorescein-diacetate-succinimidyl ester (CFSE) 
 
CFSE (Invitrogen Ltd., UK) is a fluorescent cell staining dye and was used to 
fluorescently label human T-cells prior to co-culture with allogeneic DC. CFSE 
is incorporated into cells upon CFSE-labelling. CFSE was used to identify 
lymphocyte proliferation due to the progressive halving of CFSE fluorescence 
within daughter cells following each cell division.  
 
Dithiothreitol (DTT) 
 
DTT (Sigma-Aldrich) is a strong reducing agent and was added to calcium- 
and magnesium- free HBSS to remove mucus, faeces and debris from human 
colonic biopsies. 
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Ethylenediaminetetraacetic acid (EDTA) 
 
EDTA (Sigma, Dorset) is a chelating agent; it chelates metal ions to prevent 
cell clustering. It was added to calcium- and magnesium-free HBSS to remove 
epithelial cells from human colonic biopsies.  
 
Leucoperm A and B 
 
Leucoperm A (Serotec, UK, 100µl per 50µl whole blood/ per tissue) was used 
as a fixative and contains paraformaldehyde. Leucoperm B (Serotec, UK, 
100µl per 50µl whole blood/ per tissue) was used to permeabilise cells and is 
detergent based. 
 
Ficoll- Paque 
 
Ficoll-PaqueTMPlus (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) is a 
polysaccharide dissolved in an aqueous solution and creates a density 
gradient at centrifugation for separation of peripheral blood mononuclear cells 
(PBMC) from whole blood. 
FITC-Dextran 
 
FITC-Dextran (Sigma) was used to determine phagocytic capacity of cultured 
DC by addition to culture at a concentration of 1mg/ml followed by 
demonstration of fluorescence upon cellular internalisation using Flow 
Cytometry. 
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Flow Count Beads 
 
Flow-countTM fluorospheres (Coulter Immunotech, High Wycombe, UK) were 
used as a reference population during flow cytometry analysis of human cells 
for the calculation of absolute cell numbers.  
 
Foetal calf serum (FCS) 
 
FCS (TCS cellworks, Buckingham, UK) was added to cell culture media to 
provide growth factors for cells. FCS also blocks non-specific binding during 
monoclonal antibody labelling. Stored in aliquots at -80°C. 
 
Hanks’ balanced salt solution (HBSS) 
 
Calcium- and magnesium-free HBSS (Gibco BRL, Paisley, Scotland) was 
used to wash tissue suspension from human colonic biopsies. 
 
Monensin 
 
Monensin (Sigma, UK) was prepared in ethanol at a stock concentration of 
3mM and stored at -70°C. Monensin was further diluted and added to cell 
cultures to give a final concentration of 3µM. This concentration inhibits 
intracellular protein transport and causes newly synthesized cytokine to be 
trapped within the Golgi apparatus of cells. 
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Nycoprep 
 
NycoPrepTM1.068 (PROGEN Biotecknik GmbH, Germany) was used to 
isolate low-density cells (LDC) enriched for DC from cell culture suspensions 
by creating a centrifugal density gradient to separate LDC from the non-
adherent fraction of PBMC or colonic “walkout” cells following overnight 
culture. LDC were used as a source of DC for mixed leucocyte reactions 
(MLR) with allogeneic T-cells. This was an alternative to a metrizamide 
density gradient, exposure to which can inadvertently decrease the 
expression of CD14 by monocytes through stimulation and alter the properties 
of antigen presenting cells (Kabel et al.,1989). 
 
Paraformaldehyde (PFA) 
 
Paraformaldehyde (BDH chemicals, Poole, UK) was used as a fixative by 
addition (100-400mL) to cells post antibody-labelling. Labelled cell 
suspensions could then be stored at 4°C in the dark until flow cytometry 
acquisition within 48 hours. A stock solution of 1% PFA was created by 
dissolving in saline (0.85%) with slow heating to 60°C at pH 7.0 – 7.4 and was 
stored at 4°C. 
 
Propidium Iodide  (PI) 
 
Propidium Iodide (Sigma, Poole) is a fluorescent compound that penetrates 
necrotic and late apoptotic cells. Live cells, or cells with intact cell membranes 
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do not allow passage of this fluorescent compound and hence it is excluded. 
Stock solution of 1mg ml-1 was diluted 1:20 in PBS to create a 50µg/ml 
working stock concentration in the Annexin V apoptosis assay. PI was stored, 
protected from light, at 4°C. 
 
Sodium azide  
 
Sodium azide (Sigma, MO, USA) is an inorganic compound that prevents 
capping and shedding of monoclonal antibodies used for flow cytometric 
analysis of cells. Sodium azide (0.02%) is one of the constituents of FACS 
buffer. 
 
Trypan blue   
 
Trypan blue (Sigma, Poole) is a diazo dye used to selectively colour dead 
cells and tissue. Live cells, or cells with intact cell membranes are not 
coloured; hence the dye exclusion method was used to count live cells. 
Trypan blue was used at a working concentration of 0.4%.  
 
2.1.7 Antibodies 
Conjugated antibodies  
 
The following monoclonal antibodies (mAb) and their isotype-matched 
controls were obtained from the same manufacturer (Table 2) 
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Table 2. Flurochrome-conjugated antibodies 
 
Abs 
Specificity 
 
Clone 
 
Conjugated 
Flurochrome 
 
Isotype 
Control 
 
Manufacturer 
 
Annexin V 
  
FITC 
 
N/A 
 
BD Bioscience 
B7 integrin FIB504 FITC/PE rIgG2a BD Pharmigen 
CCR 4 205410 PE mIgG2b R&D Systems 
CCR10 314315 APC rIgG2a R&D Systems 
CD3 UCHT1 FITC/PE mIgG1 BD Biosciences 
CD8 SK1 FITC/APC mIgG1 BD Biosciences 
CD11c KB90 FITC/PE mIgG1 Dako Cytomation 
CD14 RM052 FITC/PE mIgG2b Beckman Coulter 
CD40 LOB7/6 FITC/PE mIg2a Serotec 
CD86 24F FITC/PE mIgG1 BD Biosciences 
CLA HECA-452 FITC rIgM BD Biosciences 
DC-Sign 120507 PE mIgG2b R&D System 
HLA-DR G46-6 FITC/APC mIgG2a BD Pharmigen 
IFN-γ D9D10 PE mIgG1 Serotec 
IL10 JES3-19F1 APC rIgG1 BD Bioscience 
IL12 Ber-ACT8 APC mIgG1 BD Bioscience 
IL17a 41802 PE mIgG1 R&D Systems 
TLR 2 TLR2.3 FITC/PE mIg2a Serotec 
TLR 4 HTA 125 FITC/PE  mIg2a Serotec 
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mIgG1 X40 FITC/PE n/a BD Biosciences 
mIgG1 679.1Mc7 PECy5 n/a Beckman Coulter 
mIgG2a X39 FITC/APC n/a BD Biosciences 
mIgG2a G155-178 PE/PeCy5 n/a BD Pharmigen 
rIgG2a LODNP-16 PE/PeCy5 n/a Beckman Coulter 
rIgG2a 54447 APC n/a R&D systems 
mIgG2b 133303 PE/APC n/a R&D systems 
mIgG2b 27-35 PECy5/APC n/a BD Pharmigen 
rIgM R4-22 FITC/Biotin n/a BD Biosciences 
 
Dendritic Cell Lineage exclusion cocktail 
 
DC lineage cocktail is an optimised, pre-formulated cocktail of PE Cy-5 
conjugated anti-CD3, anti-CD14, anti-CD16, anti-CD19, anti-CD34 and anti-
CD56 used to exclude non-DC cell lineage at multi-colour flow cytometry. 
Lineage exclusion is important as there is some cross-reactivity with 
monocytes and B-cells when staining with CD11c+ / BDCA1+ alone (Personal 
communication: H.Omar, APRG). 
 
Immunomagnetic beads and cell separation columns 
 
Immunomagnetic beads (Miltenyi Biotec, Germany) conjugated to monoclonal 
antibodies (MAbs) specific for cell surface antigens (e.g. CD14, HLA-DR, CD3, 
CD19) were utilised in conjunction with LD magnetic columns to separate 
cells expressing these markers from a cell suspension using the MiniMACS 
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apparatus (Miltenyi) system. In a specially designed magnetic field, the 
immunomagnetically targeted cell is acted upon by well defined magnetic 
force, while the non-targeted cells are acted upon by a weak diamagnetic 
force operating in the opposite direction. As a result of this magnetic force, the 
cells can either be directed in a specific direction or retained in the magnetic 
field (positive cell fraction), thus facilitating the separation of the targeted from 
non targeted cells (negative cell fraction). To separate the targeted cell 
population from cell mixture, there are two main approaches in 
immunomagnetic separation: positive selection and negative depletion. In 
positive selection, the target cell population is magnetically labeled and 
collected in the positive fraction (either collected in an outlet flow or removed 
after being retained by the device) after running through the separation 
system. In negative depletion, the desired cells are not immunomagnetically 
labeled; in contrast the undesired ones are magnetically labeled and 
subsequently removed. The choice of the approaches depends on a range of 
factors including the concentrations of the desired cells, the final purity 
desired, and the commercial availability of magnetic reagents as well as the 
operation convenience. 
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2.3 Methods 
 
2.3.1 Separation of Peripheral Blood Mononuclear Cells from Whole 
Blood 
 
Peripheral blood mononuclear cells (PBMC) were isolated from whole blood 
over a Ficoll- Paque density gradient. Whole blood was diluted 1:1 in RPMI-
1640 Dutch Modification medium and layered onto the meniscus of 10ml 
Ficoll-Paque in 50ml plastic tubes (BD Falcon), taking care not to break the 
interface. This was centrifuged (2000rpm (550g) / 30 minutes / 20°C) without 
application of the centrifuge brake. PBMC were harvested from the Ficoll- cell 
interface (Buffy coat layer) with a Pasteur pipette. 
 
PBMC were washed in complete medium (for subsequent culture) or FACS 
buffer (for immediate antibody labelling), centrifuged (1800rpm / 10min / 
20°C), decanted of supernatant and re-suspended as appropriate. This 
washing step was repeated again (centrifuged at 1500rpm / 5 minutes / 20°C). 
Ficoll gradient separation yielded approximately 2-4 x106 PBMC per ml of 
whole blood obtained. The total number of mononuclear cells in suspension 
was calculated by the Trypan blue exclusion viability count. 
 
2.3.2 Viable cell Counting 
 
The Trypan blue dye exclusion method was used to count cells following 
density gradient separation for addition to culture or the Mixed Leucocyte 
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Reaction in appropriate numbers. Viable cells exclude the blue dye from their 
cytoplasm and are recognisable at light microscopy. A known volume of cell 
suspension (usually 50mL) was diluted (1:5) in culture medium containing 
Trypan blue (1:5) and dye-excluding cells counted using an improved 
Neubauer haemocytometer. 
 
The Neubauer Haemocytometer is commonly used to determine cell density 
(concentration) when in suspension. This glass slide consists of a rectangular 
indentation that creates a chamber of known volume. This chamber is 
engraved with a laser-etched perpendicular lines creating a grid of a known 
area. The raised edges of the haemocytometer hold the glass coverslip 0.1 
mm off the marked grid. This gives each square in the grid a defined volume 
(i.e. 1mm2 = 100nL). Cell suspension is placed on the chamber under the 
coverslip, and resultant capillary action completely fills the chamber with the 
sample. The number of cells in the chamber can be determined by counting 
cells under a light microscope. The total number of cells per ml can be 
discovered by simply multiplying the total number viable cells found in a 1mm2 
haemocytometer grid by 104. 
 
2.3.3 Isolation of Low-Density Cells from PBMC 
 
Low density cells enriched for DC were isolated by culturing PBMC for 24-
hours at 4 x 106 cells per ml (5ml) in T25 (25cm2) plastic flasks (Falcon) 
containing complete medium (37°C in a humidified atmosphere of 5% CO2). 
Non-adherent cells were removed by gentle agitation and aspiration of the 
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suspending media. Low-density cells (LDC) were then separated from the 
non-adherent cell suspension by density gradient centrifugation over 
NycoPrep 1.068 at 1700rpm for 15 minutes. LDC were harvested from the 
NycoPrep interface which was enriched for DC at 30-80%. 
 
2.3.4 Preparation and Processing of Intestinal Tissue 
 
Human intestinal biopsies were obtained at routine colonoscopy. Biopsies 
were collected in complete medium [RPMI 1640 Dutch modification (Sigma-
Aldrich, Dorset, UK) supplemented with 100U/ml penicillin/streptomycin, 
25µg/ml L-glutamine and 10% foetal calf serum] with gentamicin (25 mg/l) on 
ice.  
 
Our laboratory has optimized the walk out technique from mucosal tissue 
samples in which cells such as DC spontaneously migrate from the tissue 
sample into the culture media, thereby avoiding destructive and prolonged 
tissue digestion with collagenase (Bell et al., 2001). The “walkout” technique 
offered the ability to extract adequate cell numbers for phenotyping and has 
been favoured over tissue digestion for several reasons: 1) There were 
concerns over the adverse effects of collagenase on cells during prolonged 
tissue biopsy digestion (Personal communication Dr Hafid Omar, APRG); and 
2) LDC could be pre-conditioned in complete media containing GLP-2 whilst 
in situ within the biopsy tissue during the walkout process, likely with a limited 
degree of continued exposure to the gut tissue microenvironment.  
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Overnight “walkout” cultures were incubated overnight in a humidified 
incubator at 37°C, gassed at 5% CO2, in 24-well flat-bottomed plates (Falcon, 
Becton Dickinson, USA) containing 1mL complete medium with and without 
GLP-2 at various concentrations. Walkout cells from the individual wells of 
each GLP-2 conditioning were pooled after separation from the culture 
medium and remnant biopsy material removed using a cell filter (Beckton 
Dickinson). Walkout cells were then either labelled with directly conjugated 
antibodies for phenotypic analysis of gut DC or, following isolation of low-
density cells over a NycoPrep gradient, used to stimulate T-cells in the MLR. 
 
2.3.5 Preparing and Culturing MoDC 
 
MoDC were differentiated in culture from CD14+ monocytes isolated by 
positive selection from PBMC using the following protocol.  
 
PBMCs were prepared from peripheral whole blood (50ml) of healthy adult 
donors over a Ficoll gradient. PBMC were washed twice by suspension in ice 
cold Mini-MACS buffer and centrifuged (1500rpm / 5 minutes / 40C). 
Supernatant was decanted, leaving about 300 ml of cell suspension in the 
residual buffer. Thirty microlitres (30mL) of CD14+ immunomagnetic 
microbeads (MiltenyiBiotec, Germany) were added to the re-suspended cells 
and incubated on ice for 30 minutes. Afterwards, the cells were again washed 
twice in mini-MACS buffer as above. Following decanting of the supernatant, 
cells were again re-suspended in the residual volume of cell buffer. CD14+ 
cells were then separated from the PBMC suspension by positive selection 
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separation on Mini-MACS columns using the VarioMACSTM Separation 
System (MiltenyiBiotec, Germany). 
 
The Mini-MACS column, magnet was pre-cooled to 4°C and assembled. The 
mini-MACS column was flushed through with 2ml of cold mini-MACS and 
elutent discarded. PBMCs in residual buffer were then added to the column 
followed by 0.5ml of cold mini- MACS buffer. This eluent contained cell 
suspension depleted of CD14+ cells and was discarded. CD14+ cells 
adherent to the column were washed out by removing the column from the 
magnetic field and adding mini-Macs buffer (1ml). This was forced through the 
column using the plunger provided. This elutent contained the purified CD14+ 
cells (monocytes) and was retained. 
 
The CD14+ cell suspension was washed with mini-MACS buffer as above and 
centrifuged at 1400rpm / 5 minutes / 40C. After removing the supernatant, the 
cells were re-suspended in 4mls of complete medium and centrifuged at 
1500rpm / 5 minutes / 20°C. This was in order to wash out EDTA from the 
cells before the cell culture. After removing the supernatant, the cells were re-
suspended in complete medium (1 ml) and a cell count taken in a Neubauer’s 
chamber. 
 
The CD14+ cells were diluted in complete medium and cultured in wells of a 
24-well plate at a density of 500,000 cells per ml per well. The final culture 
medium contained complete medium supplemented with 0.1µg/ml 
Granulocyte macrophage colony stimulating factor (GM-CSF, Promega) and 
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50U/ml IL-4 (Promega). On day 4 of the cell culture, 0.5 ml of medium was 
removed from the top portion of each well (cells are adherent and lay at the 
bottom of the wells) and replaced with 0.5ml of complete fresh medium 
containing twice the concentrations of GM-CSF and IL-4. Therefore, after 
mixing the medium in each well, the final cytokine concentration was 
replenished (GM-CSF: 0.1mg/ml/well, IL-4: 50 U/ml/well). On day 5, the cells 
(now monocyte-derived dendritic cells, MoDC) were gently re-suspended in 
the culture medium using a Pasteur pipette.  
 
The cell culture was assayed using flow cytometry on day 6 to confirm 
differentiation of monocytes into MoDC, demonstrating loss of surface CD14 
expression but positivity for HLA-DR. MoDC were then simply identified 
according to the FSC:SSC scatterplots (Figure 2.1). 
 
For stimulation experiments, MoDC were cultured for an additional 24 hours 
at a concentration of 200,000 cells/ml, either in basal culture (internal control 
for each experiment) or after supplementation with GLP-2 at final 
concentrations of 10-6M, 10-9M and 10-12M. Each condition was assayed in at 
least 3 independent experiments (triplicate). 
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Figure 2.1 Identification of MoDC flow cytometry.  
A) Viable cell FSC:SSC plot (Gated); B) Gating on viable cell population 
(Gated) reveals cells are MoDC (negative for DC-exclusion cocktail 
expression CD14 expression). 
 
2.3.6 DC Endocytosis Assay 
 
FITC-dextran (1mg/ml) was added to each culture condition for the final two 
hours of culture. Immediately after the addition of FITC-Dextran, half of the 
labelled cell suspension volume (500ml) was transferred into a new tube and 
incubated at 4°C for two hours, while a parallel tube was incubated at 37°C. 
Therefore, at physiological temperature DC were able to phagocytose the 
FITC-labelled dextran after differential conditioning in the presence of GLP-2 
or basal medium. In contrast, cell metabolism was arrested in those cells 
incubated at 4°C; hence these cells were used as an internal negative control 
of the assay during flow cytometry. DC were cultured for 24 hours at a 
concentration of 200,000 cells/ml, either in basal culture (internal control of 
each experiment) or after supplementation with GLP-2 at final concentrations 
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of 10-6M, 10-9M and 10-12M. Each condition was assayed in at least 3 
independent experiments (each in triplicate). 
 
2.3.7 Cytokine Labelling 
 
For intracellular cytokine labelling, paired cultures of gut DC, one incubated 
with monensin to maintain cytokine within the golgi apparatus of cells and the 
other incubated without monensin, were cultured for 4 hours at 37°C in a 
humidified atmosphere of 5% CO2 in air. Cells were labelled for surface 
markers for 20 minutes on ice, fixed with 50µL leucoperm A and 
permeabilized with100µL leucoperm B 5 µL of anti-cytokine antibody (IL-10-
APC, IL-12-APC, IL-17-PE, IFN-γ-PE) were added for 20 minutes on ice. The 
cells were then washed twice in FACs buffer and fixed in 1% 
paraformaldehyde (500 µL of 0.5%). Samples were stored at 4°C until 
acquisition within 24 hours. 
  
2.3.8 Mixed Leucocyte Reaction 
 
Preparation of T-cells for Mixed Leucocyte Reaction  
 
PBMC were isolated from healthy donor blood (50ml) and suspended in 5ml 
complete medium before counting. Approximately 2 x 106 PBMC were 
removed and kept on ice. The remaining PBMC were washed twice by 
suspension in MiniMACs buffer with centrifugation (1400rpm / 5 minutes / 
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4°C). Supernatant was discarded and PBMC were re- suspended in the 
residual buffer (~200mL). 
 
T-cells were then separated from the PBMC suspension using negative 
selection to deplete CD19, CD14 and HLA-DR cells (including monocytes, B-
lymphoctyes and antigen-presenting cells such as macrophages and dendritic 
cells). Anti-CD19, anti-CD14 and anti-HLA-DR microbeads (30uL each) were 
added to the cell suspension and incubated on ice for 20 minutes. In the 
meantime, the magnetic cell sorting system (VarioMACSTM Separation 
System - Miltenyi Biotec) was set-up and columns washed through with 
MiniMACS buffer. 
 
PBMCs incubated with the microbeads were added directly to the column and 
allowed to run through, followed by 4 ml of cold mini-MACS buffer. This eluent 
contained T-cells depleted of CD19, CD14 and HLA-DR cells which were 
retained. In order to increase T-cell purity, a new depletion column was set-up 
and the T-cell eluent run through again, before washing twice in cold PBS with 
centrifugation (1200rpm / 5 minutes / 4°C). Supernatant was decanted and 
the T-cell pellet re-suspended in 3ml PBS. 
 
Five microlitres of stock CFSE (100uL) was suspended in 10ml PBS (CFSE1). 
Three millilitres (3ml) of this solution was then diluted in a further 3ml PBS 
(CFSE2). This was added to the T-cell suspension, mixed and left for 1 
minute 30 seconds. Immediately after this time period, the T-cell / CFSE 
suspension was vigorously mixed by shaking and left for a further 1 minute 30 
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seconds. Foetal calf serum (6ml) was then added to quench free CFSE. The 
CFSE- labelled T-cells were then washed twice by adding complete media 
and centrifugation (1200rpm, 5min). Supernatant was decanted and the T-cell 
pellet re-suspended in 1ml of complete medium. A Trypan blue cell count was 
then performed to determine T-cell concentration. 
 
Mixed Leucocyte Reaction (MLR) 
 
DC-rich low density cells from intestinal biopsies or blood were pre-
conditioned by culture for 24-hours in 5ml polystyrene round-bottom (FACS) 
tubes (BD FalconTM) containing 500,000 cells in 1ml complete medium with or 
without GLP-2 (10-6M, 10-9M and 10-12M). Cells were pooled into respective 
control and GLP-2 groups and washed in complete medium by centrifugation 
twice (1400 rpm for 5 minutes). 
 
Graded numbers of pre-conditioned LDC were added at concentrations 
equating to 0%, 1%, 2% and 3 % of the T-cell population (4 x 104 T-cells /well) 
to stimulate CFSE-labelled allogeneic T-cells in 96-well round-bottom plates 
made up to 200uL complete medium per well and incubated at 37°C in a 
humidified atmosphere of 5% CO2 for 5 days. 
 
Proliferation of T-cells leads to reduced CFSE-fluorescence in dividing cells 
compared to the original non-divided CFSE-labelled T-cell population. 
Consequently, homing marker expression by a specific proliferating T-cell 
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population, in response to stimulation by pre- conditioned LDC, could be 
determined. 
 
2.3.9 Annexin Apoptosis Assay 
 
Cells undergoing the early phases of apoptosis express phospholipid 
phosphatidylserine (PS) on outer layer of their cell membranes. Annexin V is 
a Ca2+ dependent phospholipid-binding protein that has a high affinity for PS. 
Annexin can be conjugated with a flurochrome (FITC). Cells in late apoptosis 
cannot exclude the dye propidium iodide (PI). These properties enable the 
identification of cells undergoing early and late apoptosis (Vermes et al.,1995). 
PBMC were diluted in complete medium at 1x106ml. PBMC or LDC were then 
incubated with complete medium or complete medium containing GLP-2 at 
several concentrations (10-6M, 10-9M and 10-12M) for time periods 4, 24 and 
48 hours. 
 
Upon completion of culture, cells were washed twice in cold PBS with 
centrifugation (1700rpm / 5minutes / 4°C). Following decanting of supernatant, 
the cell pellet was re- suspended in 1x Binding buffer. One hundred 
microlitres (100ml) of each cell suspension were removed to a series of 5ml 
polystyrene round-bottomed tubes (BD Falcon TM). Cells were labelled with 
5ml Annexin V– FITC and 10ml Propidium Iodide per tube as appropriate and 
incubated for 15 minutes at room temperature in the dark. After incubation, 
400uL of 1x binding buffer was added per tube. Samples were then 
immediately acquired by flow cytometry without online compensation. 
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2.3.10 Identification of Cell Populations and Phenotype 
 
Conjugated Antibody Labelling 
 
Cell suspensions were washed into FACS buffer before labelling in 5ml 
polystyrene round- bottom tubes (BD FalconTM) and placed on ice in the dark 
for 20 minutes. To reduce non- specific antibody binding, 15 mL FCS was 
added to each labelled tube prior to labelling. Cells were then washed twice 
into FACS buffer (1400 rpm for 5 minutes at 4°C). For labelling with directly 
conjugated antibodies, cells were fixed at this point with 1% PFA. In the 
absence of a directly conjugated antibody, for example there is no APC-
labelled CLA conjugate, an addition step was required prior to fixation. For 
indirect labelling, the cells were first incubated with the required biotinylated 
antibody (CLA-biotin), washed and then re- incubated with Strepavidin 
conjugated to the appropriate flurochrome dye (e.g. Streptovidin-APC). 
Unoccupied binding sites were blocked with the addition of 15 mL FCS before 
adding antibody at each labelling step. Cells were then washed twice into 
FACS buffer and then fixed in 1% PFA. Fixed cells were stored at 4°C prior to 
acquisition on the flow cytometer, within 48 hours. 
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Flow cytometry and Data Analysis 
 
Flow cytometry acquisition 
 
Flow cytometry allows simultaneous multiparametric analysis of the physical 
characteristics of thousands of cells per second, as they pass through a one 
or more focused laser beams whilst in suspension. As the cells pass through 
the beams, they disrupt and scatter light in two different planes; the degree of 
scatter in each plane is characteristic of the cells’ size (forward scatter/FSC) 
and granularity (side scatter/SSC). Monoclonal antibodies conjugated to 
fluorescent dyes and attached to cells can be detected by colour specific 
detectors (channels) of the flow cytometer. The machine registers the 
fluorescence generated as cells pass through it, enabling analysis of 
phenotypic properties of the cells. 
 
Cell data were acquired using a 4-colour FACSCalibur flow cytometer 
(Becton-Dickinson Biosciences) capable of detecting the flurochrome dyes 
FITC, PE, PECy5 and APC which correspond to 4 detector channels for 
specific wavelengths (FL1, FL2, FL3 and FL4 respectively). CellQuest 
software (Becton-Dickinson) was used for partial online compensation prior to 
cell acquisition, and generation of listmode data files. Total compensation and 
analysis of flow cytometry listmode data was carried out offline using 
WinListTM software (Verity Software House, Maine). 
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Partial online compensation required the use of 5 compensation tubes 
containing PBMC either unlabelled or single-labelled with flurochrome-
conjugated mAb to CD3+ or CD8+ (1 tube for each flurochrome: FITC, PE, 
PECy5 and APC). The compensation tube containing unlabelled PBMC cell 
suspension was initially used to set the amperes and voltages on the machine, 
based on the cells’ background or auto-fluorescence. First the FSC:SSC plot 
was adjusted using the FSC gain and range and SSC voltage to place the cell 
population of interest in the centre of FSC vs SSC dot plot and to eliminate 
most of the fine subcellular debris. 
 
Data was acquired partially compensated online during flow cytometer 
acquisition. For partial online compensation, a region was drawn around the 
lymphocyte region on the FSC versus SSC plot and the cell suspensions 
labelled with each flurochrome conjugated CD3+ or CD8+ mAb were analysed. 
Compensation involved adjusting on the flow cytometer so that 
autofluorescence of the unlabelled cells runs in the middle of the first decade 
on the four decade log scale (between 100 and 101). This was repeated for all 
fluorescence parameters (FL1, FL2, FL3). Samples were then acquired and 
saved as listmode data files. 
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Figure 2.2 CellQuest screenshots of FSC:SSC plot during Data 
Acquisition Plot set-up.  
A) Correctly set scatter plot showing lymphocyte region (arrow), B) SSC too 
low and C) FSC too low. CellQuest screen shots during partial compensation 
of FL1 using FITC- CD8+  labelled lymphocytes prior to data acquisition: D) 
Correctly compensated,showing background autofluorescence (white arrow) 
and fluorescence due to FITC antibody labelling, E) Under Compensated and 
F) Over Compensated. 
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WinListTM Analysis 
 
Completion of compensation 
 
Compensation was completed offline using compensation toolbox on the 
WinListTM software program, using lymphocyte populations labelled with 
mAbs specific for T-cells. Each individual experiment had specific 
compensation settings, saved as compensation files. 
 
Additional offline compensation of acquired data was necessary to remove 
artefact arising as a result of background cellular fluorescence and “spill-over” 
of fluorochrome fluorescence in the 2nd log across the different channel 
wavelengths, particularly between neighbouring fluorochrome channels i.e. 
PE(FL2) needed to be compensated from FITC(FL1) and PE-Cy5(FL3). 
 
 
Figure 2.3. Compensation involved drawing a region around the 
recognised lymphocyte population of the FSC versus SSC histogram 
plot.  
Single-colour cell samples labelled only with either anti- CD8 or anti-CD3 
were evaluated for each colour channel (FL1 - 4). 
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Figure 2.4 Winlist offline compensation. 
PE fluorescence in channel FL2: PE- CD8+ mAb labelled lymphocytes show 
the PE signal fluoresces a) mostly in the FL2 channel, but bleeds over into the 
2nd log decade (>101) of the FL3 channel, b) Correction of compensation 
parameter and c) Correct and complete compensation with minimal spill over. 
 
Gating and Subtraction of Isotype Control 
 
Region Method of Subtraction (RMS) 
 
The percentage of cells expressing a given surface marker was measured by 
determining the proportion of flurochrome-conjugated mAb stained cells 
demonstrating increased fluorescence beyond that due to staining with an 
isotype matched control antibody. Measurement of this difference in 
fluorescence can be achieved by 2 distinct methods during Winlist analysis: 1) 
Region gating and 2) Enhanced normalised subtraction. 
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A region is drawn that excludes irrelevant, isotype matched control mAb or 
non specific staining (Figure 2.5a). All cell events that fall within this region 
exceed isotype control staining fluorescent intensity and are regarded as 
positively labelled cells. Hence, in the cell sample labelled with the mAb of 
interest, any fluorescence detected within this region (beyond the distribution 
of the isotype staining) is a positively labelled cell (Figure 2.5b). The WinListTM 
software calculates the proportion of cells in any given region relative to that 
of the cell population on which it is gated. In this manner, regions can be 
drawn on single parameter histograms representing positive and negative cell 
populations, e.g. CD11c+ and CD11c- DC, for putative mDC and pDC 
populations respectively. When using the region gating method, the level of 
staining was quantified as the mean fluorescence intensity (MFI). 
 
This method discounts all events that fall within the distribution of the control 
histogram, more accurately delineates cell subpopulations based on surface 
antigen expression and reduces impact of differences in fluorochrome 
(antibody binding and free fluorochrome variation between batches of 
antibody).  
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Figure 2.5: Cell surface labelling by region gating.  
A region in drawn that excludes non-specific staining or isotype matched 
control monoclonal antibody staining. The same region is applied to the 
phenotype staining histogram (B). All events that fall within this region and 
exceed isotype control staining was calculated by WinList and regarded as 
positively labelled cells. This method was used in the generation of all 
percentage positive cells data for phenotypic analysis as it accurately 
delineates subpopulations based upon high surface antigen expression. 
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Figure 2.6: Positive Intensity Ratio.  
(A) is the isotype control which represents the level of non specific staining 
with an irrelevant isotype matched control monoclonal antibody whereas (B) is 
the staining of the surface marker CD40; this represents specific labelling for 
CD40 combined with an element of non specific staining. Using Enhanced 
Normalised Subtraction (ENS), WinList software generates positive intensity 
ratio (PI Ratio) after subtracting the non specific binding component from the 
phenotype labelling histogram. The median channel of fluorescence and 
distribution of each histogram is compared and the proportion of positive 
events calculated (B-shaded area). This is the ratio of linearised fluorescence 
median of only the positive events after subtraction to the linearised control 
median. The PI ratio compared the relative intensities of positive events in a 
test sample (B) compared with all events in control distributions (A). 
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Figure 2.7: Intracellular cytokine production by gut DC measured with 
Enhanced Normalised Subtraction (ENS).  
Detection of low amounts of ongoing intracellular cytokine production in DC & 
T-cells were measured by Enhanced Normalised Subtraction (ENS). This 
figure shows one-parameter histograms for the intracellular staining of IL-
12p40 in CD11c+ DC in the absence (B - No Monensin), and presence (A + 
Monensin) of monensin. Using Super- enhanced Normalised Subtraction from 
Winlist software, cytokine production was determined by the subtraction of 
staining in the sample with monensin from staining in sample without 
monensin. The shaded area (C) on the right panel represents the proportion 
of cells staining positive for IL-12p40 after subtraction. The IL12 in the sample 
without monensin acted as a reference sample so that when more “positive 
events” in this control histogram were detected compared with the monensin 
histogram, subtraction was reversed indicating loss cytokine. 
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Enhanced Normalised Subtraction 
 
Enhance Normalised Subtraction (WinList software) was used to measure (1) 
the level of staining for cell surface marker and; (2) the percentage of 
cytokine-positive cells. 
 
The level of staining for surface markers, expressed as an intensity ratio (IR) 
representing the ratio of median value of positive events in the test histogram 
to median value of staining with an isotype-matched control antibody was 
measured using Enhanced Normalised Subtraction (ENS) on WinList software 
(Verity Software House, Maine) (Panoskaltsis et al., 2003) (Figure 2.7).  
 
The percentage of cytokine-positive cells was determined by superenhanced 
Dmax (SED) normalized subtraction. Normalized cumulative histograms of 
staining of cells cultured without monensin (control) were subtracted from 
histograms of the staining in the presence of monensin (test histogram), 
allowing the build-up of trapped synthesized protein to be detected in a 4 hour 
window (Holden et al., 2008); staining cells from control and test histogram in 
the same way ensured minimal difference in non-specific binding between test 
and control samples. The result is representative of ongoing cytokine 
production in the absence of exogenous stimulation. The subtraction 
technique allows a more accurate calculation of the proportion positively 
labelled cells especially when events are low or when the test and controls 
histograms overlap. Conventional methods of analysis (region gating) 
disregard any portion of the test histogram that falls within the distribution of 
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the control histogram. In addition, a region drawn to exclude the control 
histogram removes “low positive” cells from the analysis and may 
underestimate the true proportion of positively labelled cells. The use of the 
same antibody to label cells from both the monensin- treated and untreated 
cultures gives this technique a high level of sensitivity for detecting small 
changes in antibody binding. An example is shown in Figure 2.6. 
 
The level of staining (IR) for cytokine positivity was determined using ENS, as 
a ratio of median value of positive events in test histograms to median value 
of control histograms (Gupta et al., 2007). 
 
Absolute cell numbers 
 
Absolute cell counts were obtained by simultaneous acquisition of Flow-
countTM fluorospheres. Fluorescent counting beads were identified using the 
WinListTM software and enumerated on a FL1 versus SCC plot. Absolute 
numbers of cells expressing a marker of interested or simply of types of cells 
themself were then calculated by:  
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2.3.11 Statistical Analysis 
 
The student t-test was frequently used in statistical analysis. The unpaired t-
test was used to compare 2 different groups. A paired, two-tailed t-test was 
used to determine statistical significance when analysing samples from the 
same subject exposed to different experimental conditions. For example, LDC 
derived from the same donor sample and exposed to control or GLP-2 
conditions in culture were compared using the 2-tailed T-test.  
 
Other statistical analysis were performed as appropriate, including the 2-way 
analysis of variance (ANOVA) with Bonferroni correction (corrects for a 
potential type 1 error based on n-number) when comparing more than a 2 
groups of data. The Pearson correlation was used for correlative data. P<0.05 
was considered statistically significant (data marked *) whilst p<0.001 was 
highly significant (data marked***). Software programmes utilised included 
Microsoft ExcelTM and Prism GraphPadTM (Graphpad Software Inc. San Diago, 
US). 
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Chapter 3 
Cytotoxicity of GLP-2 on Human Dendritic Cell in vitro 
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Abstract 
 
Background 
 
The interpretation of a cell phenotype and function in response to 
experimental interventions in cell culture can be potentially influenced by 
selective cell death or toxicity when compared to control populations. To this 
end, it was important to determine the potential of GLP-2 to induce cellular 
toxicity that may result in apoptosis or necrosis, prior to conducting in vitro 
culture experiments.  
 
Aims 
To investigate cellular toxicity of GLP-2 in vitro by determining apoptosis or 
necrosis of PBMC and LDC in culture. 
 
Methods 
 
PBMC from healthy volunteers were cultured in complete medium containing 
GLP-2 at several concentrations (1pM, 1nM and 1µM) over multiple time 
periods (0, 4, 24 and 48 hours). Cell viability from PBMC was demonstrated 
with Trypan Blue exclusion test. Multi-colour flow cytometry to determine 
external cell membrane expression of phosphatidylserine (PS), by surface 
staining with fluorochrome-labelled Annexin V and exclusion of Propidium 
iodide (PI) from the cytoplasm was used to assess cell viability, apoptosis and 
necrosis from LDC. 
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Results 
 
Trypan blue exclusion testing did not indicate significant differences in PBMC 
viability in response to culture with GLP-2. The Annexin V-PI assay revealed 
LDC conditioned in culture with GLP-2 did not exhibit significantly different 
proportions of cells in early & late apoptosis (Annexin+PI- & Annexin+PI+), late 
apoptosis (Annexin+PI+) or necrosis (Annexin-PI+) when compared to control 
cultures. 
 
Conclusion 
 
GLP-2 did not influence rates of PBMC and LDC viability, apoptosis or 
necrosis. This data provides a degree of confidence when interpreting any 
future observations of the effects of GLP-2 on cell phenotype and function in 
culture, which are not likely to represent disproportionate rates of cell 
apoptosis or death. 
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3. Introduction 
 
3.1 Effects of GLP-2 on Dendritic Cell viability, apoptosis or necrosis 
 
The interpretation of data representing an experimental intervention in cell 
culture can be influenced by associated direct or indirect toxicity. This may 
lead to damage or death to select cell populations resulting in 
misinterpretation of apparent changes in phenotype and function accredited to 
the intervention in question. In order to measure toxicity of a substrate in 
culture, demonstration of cell viability and lack of necrosis or cell death is 
required. The Trypan blue exclusion test is commonly used to identify viable 
cells; however, cells in the early stages of apoptosis that have compromised 
viability and function, may still be able to exclude Trypan Blue from their 
cytoplasm. Therefore a more accurate, alternative method to determine cell 
culture viability and necrosis involves the Annexin V – propidium iodide 
fluorocytometric assay which has the potential to identify cell viability and 
necrosis as well as indicate if cells are undergoing early or late apoptosis. 
 
3.1.1 Trypan blue exclusion tests 
 
Determining the number of viable cells in culture is important to standardize 
culture conditions and perform accurate quantitation experiments. The Trypan 
blue exclusion test is the commonest and simplest used method of 
determining cell viability in cultured cell populations. Trypan blue is an organic 
toluidine-based dye, so-called because it can kill trypanosomes, the parasites 
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that cause trypanosomiasis (African sleeping sickness). The Trypan blue 
exclusion test is based on the principle that live (viable) cells possess a cell 
membrane with the functional integrity to actively exclude certain dyes from 
their cytoplasm. Determination of cell viability requires a haemocytometer, a 
thick glass slide with a central area designed as a counting chamber, to which 
a known volume of cell suspension can be applied to a defined area and 
hence, cells can be counted such that cell density can be calculated. Live 
cells demonstrate an unstained cytoplasm, whilst in contrast dead cells 
cannot exclude Trypan blue and appear stained (blue) under the light 
microscope. Using this method however does not take into account that cells 
with compromised viability with transient intact cell membranes in the early 
stages of apoptosis are still able to exclude the dye. Furthermore, fluorometric 
assays of viability in culture may have less ambiguity in the identification of 
stained, non-viable cells in comparison to the haemocytometer-based ‘degree 
of blueness’ Trypan blue dye exclusion cell quantitation and viability assays 
(Altman et al. 1993). 
 
3.1.2 Phosphatidylserine expression, Annexin and Apoptosis 
 
The Annexin V – Propidium Iodide (PI) assay provides a simple and effective 
method to detect apoptosis at an early stage. This assay takes advantage of 
the fact that the phospholipid phosphatidylserine (PS) is translocated from the 
inner (cytoplasmic) leaflet of the plasma membrane to the outer (cell surface) 
leaflet soon after the induction of apoptosis, becoming available to bind 
fluorochrome-labelled Annexin V which has a strong, specific affinity for PS. 
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Fluorocytometric determination of surface binding of fluorochrome-conjugated 
Annexin V can be simultaneously correlated with the ability of cells to exclude 
the fluorescent dye PI, enabling identification of viable, early apoptotic, late 
apoptotic and necrotic cells. Necrotic cells or cells in the late stages of 
apoptosis can be identified using PI, an intercalating agent for double-
stranded DNA which produces a highly fluorescent adduct that can be 
detected during flow cytometry. PI is not excluded by necrotic cells or cells in 
late apoptosis and after entering the cell, intercalates with DNA. Viable and 
early apoptotic cells, which still have a functionally intact membrane capable 
of excluding PI, are not stained (Darzynkiewicz et al., 2000).  
 
However, the Annexin V – Propidium Iodide (PI) assay does have potential 
flaws. Firstly, PS externalization is not uniquely associated with apoptosis. For 
example, the majority of mature B-cells exposed PS on their surface, a 
feature that is not specifically associated with apoptosis (Dillon et al., 2001). 
Macrophages also appear to constitutively exhibit a degree of PS expression. 
In contrast, viable precursor monocytes do not express external PS and 
cannot bind Annexin V. 
 
Secondly, PS expression is required not just on the target cell surface, but 
also on the macrophage that engulfs the apoptotic cells (Callahan et al., 2000). 
Indeed, the blockade of PS by pre-treatment with Annexin V inhibits the 
phagocytic activity of macrophages. However, if both apoptotic cells and 
some types of viable cells can externalize their PS, this may create confusing 
signals for macrophages committed to recognizing and eliminating only dead 
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or dying cells. Consequently, the amount of externalized PS may be critical for 
macrophage discrimination between apoptotic and non-apoptotic cells 
(Callahan et al., 2003). The most common assays of PS externalization are 
based on fluorescent labelling with an Annexin-fluorescein isothiocyanate 
conjugate (Annexin V – FITC) and subsequent analysis by flow cytometry. 
These assays only assess the proportion of apparently apoptotic cells with 
external PS rather than determining the actual amounts express; by arbitrarily 
assigning ‘low’ levels of FITC fluorescence to viable cells with negligible PS 
externalization; and ‘high levels’ of FITC fluorescence (with sufficiently high 
PS externalization) to apoptotic cells (Borisenko et al., 2003). Hence, the 
investigator needs to be aware that there is potential for inaccurate 
discrimination between early apoptotic cells and viable cells constitutively 
expressing PS.  
 
3.2. Low Density Cells enriched for Dendritic Cells 
 
In view of the complexities inherent when assessing cell cultures of PBMC 
using Annexin V- PI assay, which contain multiple cell types some of which 
constitutively express PS, we decided to determine baseline and subsequent 
PS expression in cultures of isolated LDC. The degree of constitutive 
expression of PS by DC is not clearly documented in the literature, although 
the phosphatidylserine receptor required for interaction with PS is expressed 
by immature DC (Henson et al., 2001).   
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Using NycoPrep TM 1.068 we are able to obtained LDC. Despite monocytes 
having a lower average density than lymphocytes, it is difficult to achieve 
reproducible separation based on density differences alone. This is because 
the densities of the two cell types overlap. However, since lymphocytes are 
more sensitive than monocytes to the slightly hyperosmolar NycoPrep, upon 
contact lymphocytes undergo more significant loss of water from the cytosol 
and shrink, becoming more dense. This density difference between the two 
types of cells can be enhanced leading to a better separation of monocytes 
from lymphocytes upon centrifugation (Bøyum 1963, 1983; McLellan et 
al.,1995). 
 
The properties of Nycoprep are useful for enrichment of both DCs (which 
demonstrate monocytoid morphology) and monocytes in the process of 
becoming DCs. However, a period of in vitro culture is crucial to achieve 
separation of DCs from peripheral blood mononuclear cells (PBMC), since 
Nycoprep gradient centrifugation of fresh T-lymphocyte depleted PBMC do 
not result in the enrichment of allostimulatory cells. This is explained by 
recognizing that fresh human DCs are smaller (less mature) and resemble 
lymphoid cells (O’Doherty et al.,1993; Egner et al.,1993; Thomas et al.,1993), 
only acquiring increased density buoyancy (Van Voorhis et al.,1982; Young & 
Steinman 1988) and monocytoid morphology following a period of in vitro 
culture. The necessity to pre-culture blood DCs before DC-enrichment 
provides an additional opportunity to deplete lymphocytes and macrophages. 
DCs from human peripheral blood adhere transiently and later become more 
non-adherent within 16 hr, allowing depletion of non-adherent monocytes/ 
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macrophages whilst containing a greater proportion of lymphocytes and DCs 
(van Voorhis et al.,1982). 
 
There appears to be significant heterogeneity amongst monocytes with 
respect to culture-induced buoyancy. The vast majority of CD14+ monocytes 
along with the majority of lymphocytes (including B cells) are depleted from 
the interface. This results in marked enrichment of low density cells (LDC) at 
the interface expressing HLA-class II molecules. Although a significant 
proportion of monocytes constitute the LDC interface, these tend to be veiled 
(dendritic processes) suggestive of early DC morphology. However, only the 
CD3, CD14, CD16, CD19 negative LDC (putative DC) demonstrate a strong 
allo-stimulatory potential. In comparison, the pellet fraction demonstrates little 
residual allostimulatory activity. This suggests that almost all DC are retained 
at the Nycoprep-Media interface. 
 
Cell analysis has previously shown that the isolated population is highly 
enriched for DC with high surface expression of HLA-DR, CD11c, CD83 and 
CD86 (Knight et al., 1986). The LDC population (despite only up to 80% 
purified cells having DC phenotype and morphology) offered a novel and 
“physiological” model for blood DC responses to GLP-2. 
 
153 
 
 
 
Figure 3.1. Low Density Cells enriched for Dendritic Cell isolated from 
peripheral blood.  
a) Transmission Electron Microscopy + b) Scanning Electron Microscopy 
demonstrating typical veiled DC morphology at electron microscopy (from 
Tyndall, Knight et al.,1983) 
 
3.3 Methods 
 
For the Trypan blue exclusion experiments, PBMC were prepared from 
healthy donors over a Ficoll-Paque density gradient described in Chapter 2: 
Methods and Materials. PBMC were incubated in FACS tubes (2x106 cells in 
1ml) containing complete media at several concentrations of GLP-2 1pM, 1nM 
and 1µM in paired cultures (37oC, 5% CO2 in a humidified incubator) for 0, 2, 
4 and 24 hours. The GLP-2 concentration selected was based on pilot dose 
ranging experiments demonstrating optimal maturation and phenotypic 
changes (done as part of experiments in Chapter 4) without reducing total 
number of cells (pilot study results not shown). 
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Upon completion of each cell culture period, cells were washed twice in cold 
PBS and centrifuged (1700rpm, 4oC, 5 mins) before re-suspension in 1x 
binding buffer at a cell density of 1-2x106 ml-1. A Trypan blue exclusion test 
cell count was performed at this stage using a 50µL sample of each cell 
suspension in a Neubauer Haemocytometer (Figure 3.2) 
 
 
Figure 3.2. The Neubauer haemocytometer.  
A typical haemocytometer showing the counting chamber and counting grid. 
Each large square measures 0.1mm2. 
 
For the Annexin V-PI assay test, peripheral blood LDC enriched for DC were 
isolated on a NycoPrep gradient from non-adherent cells after overnight 
PBMC culture (Chapter 2 – Methods).  
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A Nycoprep density gradient was used to enrich dendritic cells from all tissue 
types. All DC underwent the same culture time, which is important as DC 
spontaneously mature upon in vitro culture. Our previous laboratory 
experiments demonstrated that the enriched DC populations isolated by this 
method were 98 - 100% HLA-DR+, with around 30% with unambiguous 
phenotypic identification as DC. Many cells maintained some macrophage 
markers but had morphological features of DC both at optical and electron 
microscopy with a veiled DC morphology (Knight et al., 1986; Holden et 
al.,2008). The population was useful for examining the effects of treatments 
on not only the DC but also on the maturing monocytes within the low density 
population. Enriching DC via Nycoprep gradient also selects for myeloid 
(CD11c+) DC, so the blood and later gut DC can be taken to be myeloid DC. 
Hence, blood and gut DC used for the later allogeneic MLR are also of 
myeloid origin. 
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LDC extracted in the above manner were cultured for another 24 hours in 1ml 
complete medium containing GLP-2 in concentrations of 1pM, 1nM and 1µM 
overnight.  
 
Once the cell culture period was complete, cells were washed twice with cold 
PBS and centrifuged (1700rpm, 4oC, 5 mins). The cells were re-suspended in 
1x binding buffer. One hundred microliters (100µl) of each cell suspension 
was transferred into each 4 fresh FACS tubes (5ml). Annexin V-FITC (5µl) 
and/or PI (10µl) were added per tube in the combination listed below, gently 
mixed and incubated for 15 minutes at room temperature in the dark. Upon 
completion of incubation, cell suspensions were washed twice, and then 
1xbinding buffer (400µl) was added to each tube. The cell suspension was 
analysed by flow cytometry within 1 hour. This sequence was repeated for 
each experimental concentration overnight (Figure 3.2). 
1. FITC-Annexin V  
2. PI  
3. FITC-Annexin V and PI  
4. Unlabelled (negative control)  
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3.4 Results 
 
3.4.1 PBMC cell recovery and viability based on Tryphan Blue exclusion  
 
Viability cell recovery demonstrated a decreasing trend after 48 hours in 
culture. This was found both in control and GLP-2 conditions of which there 
was no statistical significance when compared. There was also no significant 
effect of GLP-2 on cell viability and recovery as determined by Trypan blue 
exclusion across the GLP-2 concentrations when compared to controls at all 
time points (Figure 3.3).  
 
 
 
Figure 3.3. Tryphan blue exclusion test.  
Histogram showing viable cell recovery +/- standard error following culture of 
paired PBMC in complete medium containing GLP-2 (1pM, 1nM and 1µM) 
from 4,24 and 48 hours. Plots represent the mean viable cell counts (n=4).  
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3.4.2 LDC Cell Recovery and Viability in the Annexin V- Propidium Iodide 
assay 
 
Using the Annexin V- PI assay, comparison of the viable (R2), all apoptotic 
cells (R3 and R4), late apoptotic cells (R4) and necrotic (R5) cells between 
control and GLP-2 at doses of 1pM, 1nM, 1µM were established (Figure 3.4).  
 
Figure 3.4. Identifying specific regions for DC. 
a) R2 is specific for viable cells, b) R3 represents cells undergoing early 
apoptosis stained with Annexin V and c) R4 represents late apoptotic cells. d) 
R5 represents cells that are necrotic and have taken up propidium Iodide. 
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Figure 3.5. Results of the percentage of cells stained in each region (R2-
R5).  
Basal (a) and GLP-2 dose increments at 1pM (b), 1nM (c) and 1µM (d). 
Representative of several independent experiments performed with similar 
results.  
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The expected increase in necrotic and apoptotic cell populations was not seen 
in the culture when compared to the 0 hour sample. The culture of LDC at 
various concentrations of GLP-2 (1pM, 1nM, 1µM) did not result in a 
statistically significant difference in cell recovery across the viable, apoptotic 
or necrotic populations (Figure 3.5, Figure 3.6, Figure 3.7 and Figure 3.8). 
 
 
Figure 3.6. Effects of GLP-2 on LDC viability.  
Results show no statistical difference in the viability of cells (R2) in the 1pM, 
1nM and 1µM doses of GLP-2. (ANOVA p score not significant); n=6. 
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Figure 3.7. Effects of GLP-2 on LDC apoptosis.  
Statistical analysis of six independent experiments. Results show no 
difference in the apoptosis of cells (R4+R5) up-taking Annexin V in the 1pM, 
1nM and 1µM doses of GLP-2. (ANOVA p score not significant; n=6. 
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Figure 3.8. Effects of GLP-2 on LDC late apoptosis.  
Results show no statistical difference in the late apoptotic cells (R4) in the 
1pM, 1nM and 1µM doses of GLP-2. (ANOVA p score not significant); n=6. 
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Figure 3.9. Effects of GLP-2 on LDC necrosis.  
Results show no statistical difference in the necrosis of LDC (R5) when 
incubated with 1pM, 1nM and 1µM doses of GLP-2. (ANOVA p score not 
significant); n=6. 
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3.5 Discussion 
 
We have demonstrated that PBMC and LDC did not demonstrate significantly 
different rates of apoptosis or necrosis in response to culture with GLP-2 at 
doses of 1pM, 1nM and 1µM when compared to control conditions in vitro. 
The Trypan blue exclusion test and Annexin V-PI fluorocytometric assay of 
cell viability are recognised and commonly used methods of determining cell 
viability; however we recognise that both systems have inherent flaws which 
could reduce data accuracy. 
 
The Trypan blue exclusion test may be prone to inclusion of ‘viable’ cells, 
which are capable of excluding Trypan blue from their cytoplasm due to the 
functionally intact cell membranes, but which already have compromised 
integrity being engaged in the early stages of apoptosis. 
 
The Annexin V-PI cell viability assay may also be impaired by variable 
constitutive expression of PS by several other immune cells that may have not 
been depleted even from cultures of LDC. This assay simply determines the 
proportion of cells within a population positive for external PS expression 
based on Annexin V binding.  
 
In our apoptosis experiments, cultured DC are only a small component of 
PBMC; however DC may have been subject to regulation by GLP-2. These 
DC have not been activated by the presence of allogeneic cells, and hence 
would not necessarily be expected to either induce significant proliferation or 
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apoptosis in the autologous T-cells present in the PBMC. This is supported by 
a lack of significant differences in apoptosis or necrosis when compared to 
control PBMC cultures.  
 
Nevertheless, our investigations using both the Trypan Blue exclusion test 
and Annexin-PI assay, taken together, have simultaneously demonstrated no 
significant or dose-dependent effects of GLP-2 on PBMC or LDC apoptosis or 
necrosis in vitro over a wide range of GLP-2 doses. This data gives 
confidence that observations of the effects of GLP-2 in our subsequent 
chapters, is unlikely to be influenced by significant disproportionate cell 
apoptosis or necrosis when compared to controls for the doses used.  
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Chapter 4 
The Effects of GLP-2 on Human Dendritic Cell Maturation and 
Phenotype. 
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Abstract 
 
Background  
 
Dendritic Cells (DC) are uniquely capable of primary presentation of antigens 
to naïve T cells, determining either an active immune response or tolerance. 
GLP-2 has been shown in animal studies to reduce mucosal inflammation; it 
decreases proinflammatory cytokines and ameliorates chronic colitis (Ivory et 
al., 2007). We do not yet know whether this anti-inflammatory effect occurs in 
humans and the mechanism by which it does this. We hypothesise that GLP-2 
reduces mucosal inflammation via DC.  
 
Low-density cells (LDC) enriched for DC can be isolated from human 
peripheral blood and gut tissue. These ex-vivo DC are not subject to the 
supraphysiological concentrations of cytokines necessary to drive monocyte 
differentiation into DC. Hence, the LDC population provides a source of 
endogenous DC to test our hypothesis.  
 
Aims  
 
To determine the immunomodulatory effects of GLP-2 on the maturational 
and allostimulatory phenotype of LDC enriched for DC obtained from 
peripheral blood. 
 
 
168 
 
Methods  
Peripheral blood LDC enriched for DC were isolated on a NycoPrep gradient 
from non-adherent cells after overnight PBMC culture. LDC were cultured for 
another 24 hours in complete medium with and without GLP-2 at several 
concentrations. The maturation and co-stimulatory phenotype of LDC was 
determined by flow cytometry utilising monoclonal antibodies to CD86, CD40, 
ILT3, CD14 and HLA-DR.  
 
Results  
 
GLP- 2 conditioned LDC demonstrated an immature phenotype compared to 
controls with significant increased expression of monocyte marker CD14 
(p=0.006) and a significantly decreased in HLA-DR (p=0.007), compared with 
basal control culture. However, GLP 2 did not suppress DC differentiation 
marker CD 86 or CD 40 and actually conversely caused a significantly 
elevation in CD86 expression (p=0.0047). ILT3 which is a general feature of 
tolerogenic DC was not affected.  
 
Discussion  
 
In peripheral blood LDC enriched for DC, culture with the active form of GLP-2 
promotes an immature monocyte-like phenotype in peripheral blood LDC in 
vitro suggesting reversion to a monocyte-like state and implying a tolerogenic 
functional phenotype. However, the expected suppression of CD40 and CD86 
stimulation marker was not seen. Also, the ILT3 expression was not increased.  
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4. Introduction 
 
4.1 Effects of GLP-2 on Dendritic Cell Maturity and Allostimulatory 
Potential 
 
Dendritic cells (DCs) are important in the induction of primary immune 
responses, induction of immunological tolerance and regulation of T cell-
mediated immune responses. Part of the crucial life cycle of DCs involves 
differentiation and maturation from precursor monocytes into mature dendritic 
cells. Immature DCs and other antigen presentation cells, such as monocytes 
and B cells, possess poor allostimulatory potential. However, upon maturation, 
mature DCs acquire the ability to strongly stimulate naïve T-cells.  The 
maturation process starts when circulating immature precursor DCs encounter 
antigens in the peripheral tissue (eg. lamina propria of the gut) and then 
migrate to the draining secondary lymphoid tissue where in association with 
antigen-presentation molecules (e.g HLA-DR) and co-stimulatory molecules 
(e.g. CD40, CD86), mature to display MHC complexes to naïve T-cells. This 
stimulates T-cell proliferation which will determine the type of subsequent T-
cell response (Banchereau et al.,2000). 
 
Monocytes are the immediate precursors of DCs and express high surface 
levels of CD14 but low levels of molecules associated with antigen-
presentation, such as MHC Class II molecule HLA-DR. As part of the 
differentiation and maturation process, DC will lose surface CD14 expression 
and HLA-DR expression will be up-regulated. To effectively stimulate naïve T-
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cells, maturing DCs also acquire surface expression of co-stimulatory markers 
(e.g CD40, CD86 and CD80) to facilitate interaction with the T cell receptor 
(TcR). Immature DCs express low levels of these co-stimulatory molecules. 
Immunoglobulin-like Transcript 3 (ILT3) is also found highly expressed in 
tolerogenic immature DCs.  
 
We therefore aimed to establish whether GLP-2 had an effect on DCs 
differentiation, either by inhibition or stimulation and the subsequent 
allostimulatory potential.  
 
Human monocyte-derived myeloid DCs (MoDC) are generated in vitro by 
culture of purified CD14+ peripheral blood monocytes, for several days, in a 
cocktail of cytokines (GM-CSF and IL-4) at supra-physiological concentrations, 
which drive differentiation into a DC phenotype expressing HLA-DR with loss 
of CD14. Hence, we opted using LDC as a source of endogenous DC. This 
allowed us to establish GLP-2’s effects on maturation as these cells are likely 
to reflect more closely blood and gut DC in vivo.  
 
We described in the previous chapter (Chapter 3) the theory and methods 
behind LDC enriched for human blood DC. 
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4.2 Methods 
 
4.2.1 Low Density Cells enriched for Dendritic Cells from Peripheral 
Blood  
 
Peripheral blood LDC enriched for DC were isolated on a NycoPrep gradient 
from non-adherent cells after overnight PBMC culture as per previous chapter 
(Chapter 3). 
 
LDC extracted in the above manner were cultured for another 24 hours in 1ml 
of complete medium containing GLP-2 in concentrations of 1pM, 1nM and 
1µM (these concentrations and length of culture time were chosen as 
described later in this chapter).  
 
4.2.2 Flow Cytometry 
 
Following Nycoprep enrichment, DC within the isolated LDC population were 
identified according to viable cell characteristics on light scatter (FSC:SCC) 
profiles and HLA-DR+ Lineage- phenotype at flow cytometry (Chapter 2). 
However, initial unresolved difficulties experienced during identification of DC 
within the LDC populations from the blood and intestine using the HLA-DR+ 
Lineage- system resulted in the decision to analyse maturation marker 
expression within the LDC population as a whole based on FSC:SCC 
characteristics alone (discussed below). 
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LDC maturation status and co-stimulatory potential was determined by flow 
cytometry using monoclonal antibodies to maturation markers including CD14 
and HLA-DR. The number of LDC available for antibody labelling restricted 
analysis of other markers. 
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4.3 Results  
 
4.3.1 Identification of Low-Density Cells Enriched for DC from Peripheral 
Blood  
 
Low-density mononuclear cells enriched for DC were identified using multi-
colour flow cytometry using FSC:SCC characteristics (Figure 4.2). Previous 
unpublished work in our laboratory (has demonstrated DC-enrichment of this 
low-density cell population of up to 80% using cell suspensions over a 
NycoPrep gradient (Chapter 2). EM analysis confirmed enrichment of LDC 
with majority of cells having DC morphology (Figure 4.1). 
 
 
Figure 4.1. LDC show a predominately dendritic cell morphology.  
By Electron Microscopy, LDC show a predominately dendritic cell morphology. 
In this representative example, cell types present include a very small DC, 
DC/Mo and DC Type 3. Courtesy of NR English, APRG. Total magnification 
x6900. 
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a)       b) 
Figure 4.2. NycoPrep increases proportion of cells in the antigen 
presenting cell (APC) region within PBMC. 
a) Pre-NycoPrep: APC population (R2) and lymphocyte region (R1) 
constituted 9.11% and 57.7% of total events within PBMC respectively; b) 
Post- NycoPrep the lymphocyte region was reduced to 3.6%. Hence, the cell 
suspension has been depleted of lymphocytes and refined to include low 
density cells (enriched for DC). When gated on the viable cell region (large 
box) of the scatter plot, the proportion of events within the APC population 
was greater than 75%. 
 
Although our laboratory has previously demonstrated enrichment of cells with 
DC morphology up to 80%, many cells maintained some CD14 on their cell 
surface. We sought to enhance the specificity of the DC population within 
LDC analysed for surface marker expression using HLA-DR+ Lineage- 
phenotyping (Figure 4.3), which would exclude cells still bearing CD14. 
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a)        b) 
Figure 4.3. Identification of DC within low density mononuclear cells. 
The APC population following cell suspension separation over a Nycoprep 
density gradient are shown on a FSS vs. SCC plot. Although already enriched 
for DC, the specific DC population within the mononuclear cell region could be 
further identified as HLA-DR+ and Lineage- (CD3-, CD14-, CD16-, CD19-, 
CD34- and CD56-). 
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Figure 4.4. Loss of CD11c- DC population within LDC.  
Histogram shows CD11c fluorescence gated on the DC region indication in 
Figure 4.5.  
 
We gated our phenotypic analysis on the known antigen-presenting cell (APC) 
region defined by the scatter characteristics (Figure 4.4). Although cells 
maintaining some monocyte features (e.g. CD14+) are likely to be present in 
this population, they were largely of low density and with veiled morphology. 
The population was therefore considered adequately enriched for DC. These 
HLA-DR+ cells were gated with reference to the isotype control antibody 
labelling. Similarly, when looking at co-stimulatory markers the cells were also 
gated with reference to the isotype control antibody labelling (Figure 4.5). 
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Figure 4.5. Subtraction method using WinList.  
The number of cells positive for CD86 was subtracted from the isotype control 
IgG mouse to give the total percentage of cells expressing CD86.  
 
4.3.2 Dose-dependent effect of GLP-2 conditioning on DC leading to a 
modulated homeostatic state. 
 
Initial dose ranging experiments were conducted on LDC to identify an optimal 
culture concentration in the pilot studies. Expression of the co-stimulatory 
markers CD14, CD40 and CD86 by peripheral blood LDC were determined in 
response to co-culture of 30 mins and 24 hours (overnight) with GLP-2 at 
concentrations (1pM, 1nM and 1µM). For those markers which are 
constitutively expressed by DC (e.g. HLA-DR), in which the percentage of 
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cells positive (PP) is by definition over 90% (i.e. all DC are HLA-DRHi), the 
data shown are mean intensity ratio of fluorescence (MFI). 
 
The results of 3 independent experiments showed that the incubation of LDC 
in GLP-2 at different concentrations (1pM, 1nM and 1µM) for 30 mins did not 
yield any significant changes of CD40 or CD86 expression. However there 
was a trend towards higher expression of CD86. There was also no change in 
the HLA-DR intensity or CD14 expression with GLP culture of only 30mins 
(Figure 4.6).  
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Figure 4.6. GLP-2 effects on CD86, CD40, CD14 and HLADR expression. 
No significant change was detected in expression of CD86, CD40 and CD14 
as well as HLA DR intensity ratio (2 way ANOVA), n=3.  
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A further three experiments were carried out, this time with a 24-hour 
(overnight) incubation period of GLP-2 at different concentrations (1pM, 1nM 
and 1µM). Again there were no significant changes in the expression of co-
stimulatory markers CD40 but there was a significant higher expression of 
CD86 co-stimulatory marker (p=0.0047) (Figure 4.7).  
 
 
Figure 4.7. GLP-2 effects on CD86 expression. 
CD86 from 3 independent pooled experiments showing an increase in 
percentage of expressing cells (ANOVA; *p=0.0047). 
 
The results of the 24-hour (overnight) incubation period of GLP-2 on CD14 
and CD86 was interesting as the three independent experiments showed a 
significant higher expression of CD14 (*p=0.0237) and a significant reduction 
in HLA DR intensity ratio (*p=0.0243) in a dose dependent way (Figure 4.8).  
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Figure 4.8. GLP-2 effects on CD14 and HLA DR.  
HLA DR intensity ratio from 3 pooled experiments showing a significant 
decrease in IR (*p=0.0243) and CD14 expression showing a significant 
increase in the percentage expression (p=*0.0237) using ANOVA.  
 
Following the above-mentioned experiment, it was noted that the optimal 
effects on LDC phenotype were demonstrated at the highest dose of GLP-2 of  
1µM. This dose was therefore selected for a further 6 experiments to confirm 
the findings of GLP-2’s effect on human blood LDC co-stimulatory phenotype.  
 
The results from this 6 pooled independent experiments showed that GLP-2 
conditioning at a concentration of 1µM over 24-hour (overnight) changed the 
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phenotype of DC with a statistical significance decrease in HLA DR intensity 
ratio (*p=0.007) and an increase in CD14 expression (*p=0.006), compared 
with basal control culture (Figure 4.9). 
 
 
Figure 4.9. GLP-2 at 1µM concentration on LDC maturation.  
Statistically significant changes in phenotype of LDC with a decrease in HLA 
DR intensity ratio (*p=0.007; paired T test) and upregulation of CD14 
expression (*p=0.006; paired T test) after 24 hour incubation with GLP-2 at 
1µM concentration, n=6. 
 
The findings suggest that GLP-2 at the optimal dose of 1µM has an 
immunomodulatory effect on DC after incubation of 24 hours. The effect 
suggests induction of a ‘homeostatic’ or ‘immunotolerant’ state as shown by 
reducing HLA DR intensity ratio and increasing CD14 expression. This seen 
effect however, may be secondary to reduction of number of cells and hence 
total number of cells from the experiments above were analysed. 
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4.3.3 GLP-2 conditioning did not reduce DC total numbers. 
 
The changes seen with a reduction in HLA DR intensity ratio and an increase 
in CD14 expression may be secondary to the decline in cell numbers during 
the long 24 hour incubation period influenced by the differing doses of GLP-2. 
The concern of toxicity would certainly be a valid one especially in the higher 
doses of GLP-2; despite findings of our apoptosis experiments in the previous 
chapter (Chapter 3). Hence, the findings of GLP-2, in particular the higher 
dose of 1µM influencing an immature phenotype in DC may not be a true 
result. In order to clarify this issue, we looked at the total numbers of cells 
using counting beads during incubation of GLP-2 up to 48 hours at the three 
different concentrations (1pM, 1nM and 1µM) in 3 pooled experiments. This 
data was collected from the number of cells established by the flow cytometer 
in each tube.  
 
As expected, there was a gradual decline in the number of cells over time. 
There was however no statistically significant decline in the number of cells 
when comparing the different concentrations of GLP-2 with the basal control 
culture (Figure 4.10). Interestingly, there was a trend to the contrary; there 
were higher numbers of cells left at 48 hours compared to basal in the higher 
doses of GLP-2 (1nM and 1µM). The findings also confirmed that using 24 hr 
incubation period in our earlier set of experiments was optimal to establish the 
effects of GLP-2.  
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Figure 4.10. Total number of cells. 
Total number of cells during incubation with GLP-2 at varying concentrations 
over 48 hours with no significant decline in number of cells when comparing 
the doses (ANOVA; bonferroni’s multiple comparison test); n=3. 
 
Hence, our findings of GLP-2 influencing an immature phenotype in incubated 
DC is not due to GLP-2 cytotoxic effect.  
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4.3.4 GLP-2 did not influence the Immunoglobulin-like transcript 3 (ILT-
3) expression on DC. 
 
LDC conditioned for 24 hours in complete media containing GLP-2 at a 
concentration of 1pM, 1nM and 1µM compared with controls demonstrated no 
increase in expression (% and IR) of ILT-3 in three separate independent 
experiments  (Figure 4.11). 
 
 
Figure 4.11. GLP-2 effects on ILT3 expression.  
In various concentrations did not affect the ILT3 expression in blood LDC 
compared to control, n=3.  
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4.4 Discussion 
 
In peripheral blood LDC enriched for DC, culture with GLP-2 promoted an 
immature monocyte-like phenotype, increasing CD14 expression and 
reducing HLA DR intensity ratio, suggesting reversion to a monocyte-like state 
and implying a tolerogenic functional phenotype. However, the co-stimulatory 
molecule expression of CD86 was not in keeping with this finding. Also the 
expected high expression of ILT3 normally seen expressed on immature 
dendritic cells was not seen. This may suggest that the effect of GLP-2 on the 
phenotype is only a partial one and may require other upstream mediators 
(proteins, cytokines, growth factors) to complete its immunomodulatory 
function.  
 
The aforementioned changes noted may certainly be due to a total decline in 
cell numbers especially in light of the long 24 hr incubation period with 
different doses of GLP-2. The expected gradual decline in the number of cells 
over the incubation period was seen however GLP-2 incubation especially at 
the highest dose of 1µM was not different from the basal culture. This 
confirmed that the homeostatic immunomodulatory effects seen were not due 
to differing cell numbers.  
 
Experiments on intestinal lamina propria LDC enriched for DC were not 
carried out due to time limits required for experiments during the funded 
research period. We however expect that findings of gut LDC would most 
likely mirror that of blood LDC especially when the functional effects on T cell 
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proliferation and cytokine profile were similar in later experiments (discussed 
in Chapter 6 and 7).  However we admit that these experiments were 
essential and would have cement our results. Also, it may have clarified the 
unexpected increased allostimulatory potential (CD 86) and lack of expression 
of ILT3.  
 
In conclusion, ex-vivo LDC responded to the active GLP-2 in culture, 
demonstrating an immunotolerant functional phenotype with an increase in 
allostimulatory potential. However this is only seen in peripheral blood LDC 
enriched for DC and will need to be clarified by T cell functional experiments 
that we will discuss in the later chapters. This early findings of DC phenotype 
effects of GLP-2 supports the hypothesis that GLP-2 may be useful in 
inflammatory conditions, in particular IBD.  
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Chapter 5 
The Effects of GLP-2 on Human Dendritic Cells Endocytosis 
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Abstract 
 
Background  
 
GLP-2 has an influence in maintaining an immature phenotype in DC as seen 
in our previous chapter results. Immature DC are efficient in endocytosis, a 
process by which the plasma membrane invaginates, engulfs a sample of the 
external environmental milieu thereby enabling cells to internalize external 
proteins and substrates. DC then present antigen-derived peptides to T cells. 
Therefore an increase in endocytosis of GLP-2 conditioned immature DC 
would be expected.  
 
Aims  
 
To determine the immunomodulatory effects of GLP-2 on LDC enriched for 
DC endocytosis to confirm the tolerogenic or homeostatic properties seen with 
an immature phenotype 
 
Methods 
 
Peripheral blood LDC enriched for DC were again isolated on a NycoPrep 
gradient from non-adherent cells after overnight PBMC culture. LDC were 
cultured for another 24 hours in complete medium with and without GLP-2 at 
several concentrations. FITC-dextran is commonly used for testing the 
receptor-mediated endocytosis function of immature DC. FITC-Dextran 
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(1mg/ml) was added to each tube for the last 2 hours of the final 24 hour 
incubation period at 37°C. An internal control (‘pseudo-isotype’) was 
performed in parallel, incubating cells at 4°C upon addition of FITC-Dextran 
resulting in arrest of further cell metabolism and function, preventing FITC-
Dextran uptake. By subtracting the number of cells expressing FITC at 37°C 
from the control, the level of phagocytosis was established (Figure 5.2).  
 
Results  
 
GLP- 2 conditioned LDC did not show any significant FITC-Dextran uptake or 
ability to decrease FITC-Dextran uptake in 6 independent experiments.  
 
Discussion  
 
GLP-2 conditioned LDC with an immature phenotype did not have the 
expected enhanced endocytosis capacity. Hence, the immature LDC may be 
kept dormant by GLP-2 in a tolerogenic manner.  
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5. Introduction 
 
5.1 Dendritic Cell Endocytosis 
 
Antigen presentation of exogenous antigens in the context of class II major 
histocompatibility complex (MHC) molecules is preceded by antigen 
processing, in which the first step is endocytosis. Endocytosis is the process 
by which the plasma membrane invaginates, engulfing a sample of the 
external environmental milieu thereby enabling cells to internalize external 
proteins and substrates. 
 
Dendritic cells (DC) are potent specialized antigen-presenting cells with the 
ability to internalize antigen, and present antigen-derived peptides to T cells. 
The functions of DC depend on the subset, as well as their location and 
activation state. Immature DC act as sentinels by continuously sampling the 
antigenic environment through various endocytosing mechanism.  
 
In response to inflammatory stimuli, DC trigger maturation, a terminal 
differentiation program required to initiate T cell response. A hallmark of 
maturation is downregulation of endocytosis, widely assumed to restrict the 
ability of mature DC to capture and present antigens encountered after the 
initial stimulus. Whereas increased endocytosis is expected in immature DC 
that are constantly sampling the antigenic environment. 
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5.2 GLP-2 effects on human Dendritic Cell Endocytosis. 
 
Based on our findings from the previous chapter, there is a suggestion that 
GLP-2 has an influence in keeping DC in an immature state preventing 
differentiation with subsequent downstream T cell activation. Immature DC 
are efficient in endocytosis and therefore by looking at the endocytosis of 
GLP-2 conditioned DC (in the immature state after modulation by GLP-2), we 
could assess whether these affected cells are in fact still in their immature 
form and continues to sample the antigenic environment without differentiating.  
 
5.3 Methods 
 
5.3.1 Low Density Cells enriched for Dendritic Cells from Peripheral 
Blood  
 
Peripheral blood LDC enriched for DC were isolated on a NycoPrep gradient 
from non-adherent cells after overnight PBMC as per the previous chapter.  
 
5.3.2 Flow Cytometry 
 
Following Nycoprep enrichment, DC within the isolated LDC population were 
identified according to viable cell characteristics on light scatter (FSC: SCC) 
profiles and HLA-DR+ Lineage- phenotype at flow cytometry described more 
in depth in the previous chapter (Figure 5.1).  
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Figure 5.1. NycoPrep increases proportion of cells in the antigen 
presenting cell (APC) region within LDC.  
APC population gated on (R3) as shown.  
 
5.3.3 FITC Dextran 
 
Because FITC-dextran is mainly taken up through the mannose receptor, the 
up-taking rate of FITC-dextran is commonly used for testing the receptor-
mediated endocytosis function of immature DC. FITC-Dextran (1mg/ml) was 
added to each tube for the last 2 hours of the final 24 hour incubation period 
at 37°C. An internal control (‘pseudo-isotype’) was performed in parallel, 
incubating cells at 4°C upon addition of FITC-Dextran resulting in arrest of 
194 
 
further cell metabolism and function, preventing FITC-Dextran uptake. By 
subtracting the number of cells expressing FITC at 37°C from the control, the 
level of phagocytosis was established (Figure 5.2).  
 
 
 
Figure 5.2. Subtraction method using WinList.  
By subtracting the number of cells expressing FITC dextran from the control 
at 4°C the percentage of phagocytosis that a DC undergoes is established. 
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5.4 Results  
 
5.4.1 GLP-2 conditioned LDC did not exhibit an increase in endocytosis 
for the expected immature phenotype form. 
 
Comparisons of the intensity ratio were made with control (basal) and the 
different GLP-2 concentrations (1pM, 1nM and 1µM) (Figure 5.3). 
 
 
Figure 5.3. FITC intensity ratio.  
Intensity ratio of cells expressing FITC after substraction in basal and 
concentration of GLP-2 at 1pM, 1nM and 1µM. 
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The results from 6 independent experiments comparing the control and the 3 
different GLP-2 concentrations did not show any significant FITC-Dextran 
uptake or ability to decrease FITC-Dextran uptake (Figure 5.4).  
 
 
 
 
Figure 5.4. FITC-Dextran - comparison of 6 independent experiments.  
Paired T-Test statistical analysis showing p values for each concentration 
against basal. ANOVA p score was not significant. 
 
 
 
 
197 
 
5.5 Discussion 
 
In our set of endocytosis experiments, the expected capacity of GLP-2 to 
enhance endocytosis, which would correlate with the increase expression of 
CD14 and reduction of HLA-DR was not seen. However, this may be a 
consequence of delayed recovery of the monocyte-like surface phenotype in 
LDC of which longer exposure to GLP-2 may eventually induce functional 
modification. 
 
Alternatively, we may be seeing the consequence of DC maturing during the 
long incubation period with GLP-2 and subsequently reverting back to an 
immature phenotype due to the GLP-2’s modulation. In this form, the DC may 
have internalized antigens and expressed surface markers but kept in a 
tolerogenic state by GLP-2. Hence, endocytosis would not be seen.  
 
The data presented in the last chapter certainly confirms immaturity of the DC 
modulated by GLP-2. In peripheral blood LDC enriched for DC, culture with 
GLP-2 promotes an immature monocyte-like phenotype, increasing CD14 
expression and decreasing HLA DR intensity ratio, suggesting reversion to a 
monocyte-like state and implying a tolerogenic functional phenotype. We do 
not know however, whether this is prior to DC maturing or GLP-2 having 
subsequently modulated DC into an immature form from a mature state.  
 
The co-stimulatory molecule expression of CD86 was upregulated, again 
suggesting that the DC within the experiment may have matured and have 
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maintained the high expression values of CD86. This gives further weight to 
the likelihood that the DC have underwent maturation and the final modulation 
effects of GLP-2 is one of sending the DC back to immaturity, hence keeping 
it tolerogenic or in homeostasis. 
 
In the subsequent chapters, we will explore whether the GLP-2 influence DC 
have the capacity to prevent differentiation with subsequent downstream T 
cell activation as well as effects on the cytokine profile.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
199 
 
Chapter 6 
The Effects of GLP-2 on Human Blood and Intestinal Dendritic 
Cell Function: DC Cytokine profile. 
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Abstract 
 
Background  
 
GLP-2 in murine studies have shown a reduction in cytokine production in 
three models of intestinal inflammation in the ileum and colon. Modulation of 
cytokine production by DC will subsequently alter the T cell function and 
cascade of inflammation. GLP-2 may therefore modulate DC cytokine 
production and ultimately affect intestinal inflammation.  
 
Aims  
 
To determine effects of GLP-2 on LDC enriched for DC cytokine production 
both in human blood and intestinal small bowel and colonic DC. 
 
Methods 
 
LDC enriched for DC from peripheral blood and tissue biopsies from small 
bowel and colon were again isolated on a NycoPrep gradient from non-
adherent cells after overnight PBMC culture. LDC were cultured for another 
24 hours in complete medium with and without GLP-2 at several 
concentrations. Quantification of the ongoing production of cytokines in LDC 
via a sensitive subtraction method using monensin was applied.  
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Results  
 
GLP-2 reduced both IFN-γ and IL-12 p40/p70 ongoing cytokine production in 
human blood dendritic cells. In both colonic and small bowel dendritic cells, 
GLP-2 only reduced IFN-γ ongoing cytokine production. 
 
Discussion  
 
GLP-2 induced a homeostatic Th1 bias profile in GLP-2 conditioned human 
peripheral blood DC by reducing the ongoing cytokine production of both IFN-
γ and IL-12 (p40/p70) and in intestinal DC (from large and small bowel), 
reduced the ongoing cytokine production of only IFN-γ. This is in keeping with 
the murine studies showing reduction of cytokine production in inflammatory 
conditions.  
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6. Introduction 
 
DC in the disease state are associated with increased release of pro-
inflammatory cytokines likely to contribute to the initiation or perpetuation of 
inflammation, either as a local effector cell population active in innate 
immunity or by modifying responses of lymphocytes activated in an adaptive 
immune response.  
 
GLP-2 in murine studies have shown a reduction in cytokine production in 
three models of intestinal inflammation in the ileum and colon (Sigalet et al., 
2007) and from our experiments in Chapter 3 and 4, has the potential to exert 
an immunotolerant state on DC. Therefore, if the modulation of cytokine 
production by DC can be influenced by GLP-2, subsequent alteration in the T-
cell function and the cascade of inflammation may be altered by GLP-2.  
 
One of the driving factors in the pathogenesis of IBD is thought to be a 
dysregulated immune response to the gut microflora. DC as sentinels of the 
GI tracts population of antigens and pathogens play a significant role in the 
regulation of the gut immune system. In murine models of colitis, DC 
accumulate throughout the entire lamina propria and MLN. Blockade of the 
DC- T-cell interaction prevents experimental T cell-mediated colitis and DC 
ablation will ameliorate dextran-sulphate induced colitis in mice (Berndt et al., 
2007). Additionally, lamina propria DC from inflamed tissue produce higher 
levels of IL12p40, IL-23p19 and IL-10 (Becker et al., 2003).  
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As mentioned in Chapter 1, cytokines such as IL-12, IL-18 and IFN-γ 
produced by DC can bias CD4+ T- cell priming towards a Th1 phenotype. The 
cytokines act directly on the T-cells and production is amplified by positive 
feedback signals from the activated T- cells also (Schulz et al., 2000; Sporri 
and Reis e Sousa, 2003). The combination of IL-12 and IFN-γ also act to 
prevent the Th2 cell differentiation, inhibiting IL-4, IL-5 and IL-13 production. 
The fact that IL-12 can be produced by both APC and T-cells suggests that it 
represents an important link between innate and adaptive immune systems. 
IL-12 acts via the STAT-4 transcription factor, which is essential for its actions. 
IL-12 signalling is initiated by the tyrosine phosphorylation and activation of 
the Januse kinase, Jak-2 and Tyk-2. IFN-γ is the main effector cytokine of the 
Th1 subclass but also acts to stabilise Th1 cells, acting to prevent them from 
being able to switch to secreting Th2 subclass associated cytokines. This has 
been shown in IFN-γ deficient mouse models where Th1 cells are able to 
produce the Th2 associate cytokine IL-4 when stimulated under Th2 
conditions (Zhang et al., 2001). IFN-γ exerts its effect through the induction of 
T-bet; this then leads to IL12β2 receptor production, a marker for Th1 cell 
differentiation, as well as further production from T-cells thereby promoting a 
positive feedback loop.  
 
Although there are clear roles for APCs in Th1 polarisation, the APC initiators 
of Th2 polarisation are less clear. Other innate immune cells, including 
basophils, eosinophils, NKT cells and mast cells may complement DC 
activation by providing early sources of IL-4 to promote Th2 cell development 
in vivo (Min et al., 2006), IL-4 being the signatory cytokine of the Th2 
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response. The production of IL-4 after stimulation by antigens influences 
naïve T cells to differentiate through the Th2 pathway. IL-10 priming of DC 
has been shown to be a requirement to induce DC to secrete IL-4. 
Furthermore, the addition of IL-10 in vitro, during DC cell maturation 
suppresses their ability to produce IL-12 and activate Th1 cells (De Smedt et 
al., 1997). 
 
Th17 cell lineage discovered recently develops from naïve T-cells in the 
presence of TGF- β and IL-6 and has contrastingly been described as both an 
immunoregulatory and pro-inflammatory cytokine respectively. The effects of 
Th17 response have been viewed as pro-inflammatory given the secretion of 
cytokines including IL-17a, IL-17f, IL-21, IL-22, IL-6 and TNF-α and its 
regulation by IL-10 (Yosef et al., 2013). There is also data supportive of anti-
IL17a antibody therapies in psoriasis, rheumatoid arthritis and uveitis (Hueber 
et al., 2010).  There is however a suggestion that Th17 have some plasticity 
to their function, with an ability to stop production of IL-17a as well as express 
T-bet, which is a regulator in the Th1 cell differentiation and IFN-γ (Symons et 
al., 2012). Not only do Th17 cells have plasticity to their primary cytokine 
profiles, there also appears to be a variation in the function of their signatory 
cytokine IL-17a. A mouse transfer model of colitis has shown that IL17a -/- T-
cells induce a more aggressive disease phenotype compared to the wild type 
cell populations, implying a protective effect for IL-17a in this model 
(O’Connor et al., 2009).  
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Therefore, much of the data indicates that the immune system sustains 
chronic inflammation and understanding the interplay of cytokines is important 
to understanding chronic inflammatory conditions like IBD. We hypothesised 
that GLP-2 has an immunomodulatory function and can influence the 
production of cytokines in both blood DC as well as lamina propria DC. We 
examined the production of cytokines by human blood DC in the first part of 
the experiments and lamina propria DC in the latter. We concentrated on the 
ongoing cytokine production of IL-12, IFN-γ, IL-10 and IL-17a in GLP-2 
conditioned human blood dendritic cells and lamina propria DC compared to 
control.  
 
6.1 Methods 
 
6.1.1 Low Density Cells enriched for dendritic cells from peripheral 
blood  
 
Peripheral blood LDC enriched for DC were isolated on a NycoPrep gradient 
from non-adherent cells after overnight PBMC as per the previous chapter.  
 
6.1.2 Low Density Cells enriched for dendritic cells from tissue colonic 
and distal ileum biopsies. 
 
Biologically active GLP-21-33 is secreted by enteroendocrine L cells, most of 
which are located in the distal ileum and colon. Hence, DC compartmentalised 
in the gut epithelial microenvironment and regional lymphatics may be 
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physiologically exposed to doses of GLP-2 normally. We therefore also 
elected to investigate LDC (enriched for lamina propria DC) extracted from the 
colon and ileum of healthy controls separately. 
 
In earlier work from our laboratory, protocols for identification and re-
enrichment of lamina propria DC from human intestinal biopsy tissue have 
been developed. This process involves isolation of intestinal lamina propria 
mononuclear cell preparations, using either a collagenase digestion or ‘walk-
out ‘technique' (Chapter 2), followed by extraction of low-density mononuclear 
cells enriched for DC by the Nycoprep density gradient method. The walk-out 
method allowed DC to be walked out of either colon or ileal biopsies overnight, 
in culture medium with and without GLP-2, whilst remaining exposed to some 
elements in the gut microenvironment which may be lost in the digestion 
process. This perhaps is a more realistic representation of the gut 
microenvironment in vivo, admittedly at supraphysiological concentrations of 
GLP-2.  
 
The ‘walk-out’ technique offered the ability to extract adequate cell numbers 
for phenotyping and was favoured over tissue digestion for several reasons: 
 
1. There were concerns over the adverse effects of collagenase on cells 
during prolonged tissue biopsy digestion (Personal communication Dr 
Hafid Omar, APRG). 
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2. LDC could be pre-conditioned in complete media containing GLP-2 whilst 
in situ within colonic biopsy tissue during the walk-out process, likely with a 
limited degree of continued exposure to the gut tissue microenvironment. 
 
6.1.3 Flow Cytometry 
 
Following Nycoprep enrichment, DC within the isolated LDC population were 
identified according to viable cell characteristics on light scatter (FSC:SCC) 
profiles and HLA-DR+ Lineage- phenotype at flow cytometry (Figure 6.1).  
 
6.1.4 Ongoing cytokine Production 
 
We quantified the ongoing production of cytokines in LDC via a sensitive 
subtraction method using monensin that acts by blocking the transport of 
newly synthesised cytokines through the Golgi apparatus (Figure 6.1). 
Intracellular staining for specific cytokines was then carried out after 4 hr 
incubation in monensin and superenhanced Dmax (SED) normalised 
subtraction from monensin- carried out. The experiments compared basal and 
GLP-2 at a concentration of 1µM alone. 
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Blood dendritic cell   Lamina propria dendritic cells 
 
 
Figure 6.1 Subtraction method (SED) using WinList.  
FACS histograms of ongoing cytokine IFN-γ production by LDC following 4 
hour monensin incubation at 37°C, 5% CO2  after 24 hour culture with and 
without GLP-2. No monensin incubated cells acted as a reference sample and 
these values were subtracted from the monensin control to quantify the level 
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of ongoing cytokine production (SED subtraction). The cells showing higher 
cytokine levels in the presence of monensin are shown in the shaded area of 
the histogram and small differences in ongoing cytokine production can be 
detected. This set of histograms is representative of several independent 
experiments with similar results.  
 
6.2 Results 
 
6.2.1 GLP-2 reduced both IFN-γ and IL-12 p40/p70 ongoing cytokine 
production in human blood dendritic cells. 
 
Five separate independent experiments were carried out with the method 
mentioned above to establish whether GLP-2 had any potential to modulate 
cytokine production of IFN-γ and IL-12 p40/p70 in dendritic cells. GLP-2 
inhibited both the production of inflammatory cytokine IFN-γ and IL-12 
p40/p70 by DC consistently in all experiments (n=5; Figure 6.2). Conversely, 
the level of cytokine production did not defer for IL-10 and IL-17a between 
control DC and GLP-2 conditioned DC (Figure 6.3 and Figure 6.4).  
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Figure 6.2. GLP-2 induced a homeostatic cytokine profile in blood DC.  
Following conditioning of GLP-2, the mean ± SEM proportion of LDC 
producing IFN γ and IL-12 was reduced (n=5). The statistical analysis of these 
experiments showed that GLP-2 reduced both IFN γ and IL-12 (p40/p70) 
ongoing cytokine production in dendritic cells (*p= 0.028 and *p=0.0426) (P-
value below 0.05 was considered statistically significant).  
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Figure 6.3. GLP-2 modulation of DC was independent of IL-10.  
Following conditioning of GLP-2, the mean ± SEM proportion of LDC 
producing IL-10 was unchanged (n=5). There was no statistical significance 
found for IL-10 ongoing cytokine production in dendritic cells (p=0.4832). 
 
Figure 6.4. IL-17a cytokine production unaffected by GLP-2 
Following conditioning of GLP-2, the mean ± SEM proportion of LDC 
producing IL-17a was unchanged (n=5). There was no statistical significance 
found for IL-10 ongoing cytokine production in dendritic cells (p=0.6930). 
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This suggests that GLP-2 may exert its immunomodulatory function by 
suppression of the Th1 pathway, affecting mainly cytokine IFN-γ and IL-12 
p40/p70 and is independent of IL-10 and IL-17a.  
 
6.2.2 GLP-2 only reduced IFN-γ ongoing cytokine production in both 
colonic and small bowel dendritic cells. 
 
We proceeded to then investigate whether colonic and small bowel GLP-2 
conditioned DC would produce the same cytokine profile as GLP-2 
conditioned blood DC.  
 
Similarly, IFN-γ ongoing cytokine production was significantly reduced by 
GLP-2 in colonic lamina propria DC compared to control. However, IL-12 
(p40/p70), IL10 and IL-17a were unaffected (Figure 6.5) 
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Figure 6.5. GLP-2 conditioned colonic lamina propria DC induce a 
homeostatic IFN-γ cytokine profile. 
Following conditioning of GLP-2, the mean ± SEM proportion of colonic 
lamina priopria LDC producing IFN-γ was reduced (n=8) compared to control 
(*p=0.0044) (P-value below 0.05 was considered statistically significant).  
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When comparing GLP-2 conditioned small bowel lamina propria DC to 
controls, findings from 6 experiments again showed a reduction in ongoing 
cytokine production of IFN-γ alone with no changes in the production of IL-12 
(p40/p70), IL-10 or IL-17a cytokines (Figure 6.6). This is in keeping with a 
general homeostatic cytokine profile within the Th1 pathway, independent of 
IL-10 and IL-17a. 
 
 
 
  
215 
 
 
 
 
Figure 6.6. GLP-2 induced small bowel lamina propria DC induce a 
homeostatic IFN-γ cytokine profile. 
Following conditioning of GLP-2, the mean± SEM proportion of small bowel 
lamina priopria LDC producing IFN-γ was reduced (n=6) compared to control 
(*p=0.0119) (P-value below 0.05 was considered statistically significant).  
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6.3 Discussion 
 
We demonstrated that GLP-2 induced a homeostatic Th1 bias profile in GLP-
2 conditioned human peripheral blood DC by reducing the ongoing cytokine 
production of both IFN-γ and IL-12 (p40/p70). This was independent of IL-10 
and IL-17a. Similarly, ongoing cytokine production of IFN-γ was reduced in 
GLP-2 treated colonic and small bowel lamina propria DC. Our data supports 
the findings in murine studies suggesting that GLP-2 plays an important role 
in the homeostasis of the gut by reducing inflammatory cytokines; in particular 
the Th1 pathway and independent of IL-10.  
 
Intracellular staining was used to measure spontaneous or ongoing 
production of cytokines by DC without exogenous stimulation. Monensin is an 
ionophore originating from Streptomyces cinnamonensis that disrupts protein 
transportation from the Golgi apparatus leading to the trapping of newly 
synthesized protein within the cytoplasm of cells (Mollenhauer et al., 1990). 
To minimize the effects of non-specific binding, we used control cells treated 
in the absence of monensin. These cells were fixed, permeabilised and 
labelled with identical antibody as the test sample staining, hence we felt that 
the inclusion of an isotype control was not necessary. To discriminate positive 
from negative events in the test histograms, we used WinlistTM software and 
Enhanced Normalised Subtraction technique which can sensitively detect 
intracellular cytokine in non stimulated DC. When there is an obvious 
separation between the test and control histogram, flow cytometry analysis 
software can generate cut off markers to accurately define the positive events. 
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However, when the fluorescence associated with antibody binding in the test 
histogram overlaps with the peak of the control histogram, the number of 
positive events may be higher in the control sample than the test sample in 
some cases. This may occur when secreted protein binds back to the surface 
of the cell in the no monensin sample together with the loss of pre-exiting 
cytokine from cells in the monensin sample, adding to the overall loss of 
cytokine. In such situation, the subtraction process can be reversed to 
generate negative results. In this system, the control sample does not 
represent zero but represents a reference point on which to quantify the build 
up of cytokine in our test sample. The no monensin sample may contain 
cytokine positive cells. It is therefore important to quantify the reduction of 
cytokine production compared with background control as labelling these 
negative results as zero would be inaccurate. The optimization of this 
technique to detect ongoing cytokine production in un-stimulated DC has 
been describe, and this modified technique may complement both secretion 
and gene expression techniques (Holden et al., 2008).  
 
IFN-γ as the main effector cytokine of the Th1 subclass with the ability to 
stabilise Th1 cells is crucial in the initiation or perpetuation of inflammation. 
Modulating this cytokine has the potential of altering T-cell function and the 
cascade of inflammation. We have shown in our set of experiments that DC 
from healthy whole human blood, colonic and small bowel lamina propria can 
be modulated by GLP-2 into a homeostatic profile, reducing the ongoing 
production of IFN-γ significantly. 
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Murine studies in rat models of ileitis and colitis showed that GLP-2 treatment 
resulted in significant reduction in inflammatory cytokines such as IL-1ß, INFγ 
and TNFα along with reduction in neutrophil activity (Sigalet et al., 2007). Also 
Ivory et al confirmed the anti-inflammatory actions of GLP-2 via use of IL-10 
knockout (IL-10-/-) mouse model and established that this immunomodulatory 
effect was IL-10 independent (Ivory CPA et al., 2008). This is consistent with 
our cytokine profile findings of the reduction in IFN-γ cytokine and no change 
in IL-10.  
 
Cytokine production by human colonic DC is altered in IBD. An increase in 
production of pro-inflammatory cytokine has been demonstrated in patients 
with CD (Fichtner-Feigl et al., 2007; Fuss et al., 1996). Our current work 
confirms that GLP-2 reduces production of IFN-γ cytokine. Hence theoretically, 
if we extrapolated our results using whole blood and lamina propria DC from 
patients with IBD, GLP-2 could potentially play an important therapeutic role in 
reducing the inflammatory process. This, in tandem with the intestinotrophic 
properties of GLP-2 (diarrheal symptoms; via reabsorption of fluid), may 
potentially be a treatment option in patients with IBD (Buchman AL et al., 
2010).  
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Chapter 7 
The Effects of GLP-2 on Human Blood and Intestinal Dendritic 
Cell Function; allo-stimulatory potential and cytokine 
production in T cells.  
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Abstract 
 
Background  
 
DC are stimulatory for naïve T cells and dictate the type of T cell immune 
response (e.g. pro-inflammatory or regulatory). DC can determine whether a 
type 1, type 2 or regulatory response predominates. Hence, effects of GLP-2 
influence on subsequent alteration in the T cell function and cytokine profile 
will confirm the findings in our previous experiments suggesting that GLP-2 
has an immunotolerogenic effect.  
 
Aims  
 
To determine the allostimulatory effects of GLP-2 conditioned LDC (enriched 
for DC) on T cells and the type of T cell immune response by looking at the 
cytokine profile. 
 
Methods 
 
LDC enriched for DC from peripheral blood and tissue biopsies colon were 
isolated on a NycoPrep gradient from non-adherent cells after overnight 
PBMC culture. LDC were cultured for another 24 hours in complete medium 
with and without GLP-2 at several concentrations.  Modulated DC were then 
applied to proliferation assays using CFSE to determine the subsequent 
proliferation of allogeneic T cells. Dividing responders were stained with 
221 
 
specific cytokines; again via a sensitive subtraction method using monensin to 
establish the ongoing cytokine production in T cells.  
 
Results  
 
The T cell proliferation induced by GLP-2 conditioned DC from human blood 
at varying doses was unchanged with the T cell clones producing less 
ongoing cytokine IFN-γ. T cell proliferation stimulated by GLP-2 conditioned 
colonic lamina propria DC however was increased. These stimulated T cell 
clones had a decreased level of cytokine IFN-γ and IL12 production.  
 
Discussion  
 
GLP-2 conditioned human lamina propria DC had an increased capacity in 
stimulation of T cell proliferation but the T cell clones stimulated by lamina 
propria DC had a decreased ongoing production of both IFN-γ and IL12. 
Therefore it is likely that the modulating effects of GLP-2 on DC appear to be 
an increase in allostimulatory potential probably of regulatory T cells with 
subsequent inhibition of Th1 differentiation. 
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7. Introduction 
 
Studying alteration in the T cell function and the cytokine profile that ultimately 
leads to the cascade of inflammation is essential to establish the role of GLP-
2 in inflammatory conditions. Previous chapters have explored the role of 
GLP-2 on DC phenotype and cytokine profile. These findings point to a 
homeostatic or immunotolerogenic property.  
 
DC are stimulatory for naïve T cells and dictate the type of T cell immune 
response (e.g. pro-inflammatory or regulatory). The proliferation of T cell 
clones takes about 4-5 days, producing a hoard of effector cells which 
express surface proteins distinguishing them from naïve cells, and which upon 
reactivation can synthesize all the molecules required to fulfill their specialist 
role as either cytotoxic or helper cells (regulatory). Once these clones 
encounter their specific antigen, they can ‘attack’ with no need for co-
stimulation. Clones also change their expression of adhesion markers and 
end up regulating various specific integrins and chemokine receptors. This 
enables them to leave lymphoid tissues, enter the blood stream, and then 
cross into target tissues at sites of infection (Janeway et al., 2005).  
 
Naïve CD8+ T cells are predestined to become cytotoxic cells upon activation; 
however, CD4+T cells can differentiate into Th1, Th2, Th17 or T regulatory (T 
reg) cells, which all differ in the cytokines that they produce, and thus in 
function. DCs are integral in driving the differentiation of T cells to induce 
responses appropriate to the pathogen they have encountered. Different 
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subsets of DC, which express varying PRRs, will be activated to produce 
different combinations of cytokines, which then control T cell differentiation. 
Th1 cells produce mainly IFN-γ; these activates macrophages, NK cells, and 
CD8+ cytotoxic T cells and stimulate complement which aids phagocytosis 
(Rautajoki et al., 2008). Th1 cells are associated with autoimmune disease, 
such as type 1 DM, multiple sclerosis and have been implicated as the main 
mediators of the pathogenesis of Crohn’s disease (Brand S, 2009) (Figure 
7.1).  Th2 cells produce IL-4, IL-13, IL-9 and IL-5; activating granulocytes and 
inducing B cells to release neutralizing antibodies. Th2 cells are linked to 
atopic disease and allergy. Th17 cells are pro-inflammatory, producing IL-17 
and IL-22 and also have a role in autoimmunity. T reg are a group of 
suppressor cells that produce large amounts of the regulatory cytokine IL-10.  
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Figure 7.1. The imbalances of pro- and anti- inflammatory cytokines in 
Crohn’s disease.  
In patients with Crohn’s disease, proinflammatory T helper (Th)17 and Th1 
cytokines outweigh the effect of anti-inflammatory cytokines secreted by 
regulatory T cells (T reg). Cytokines released by antigen presenting cells (DC) 
following contact with microbial products, trigger the differentiation of Th1 and 
Th17 cells or have a direct pro-inflammatory effect.  
 
IL-12 produced largely by DC and macrophages, is considered to be the main 
cytokine that drives Th1 differentiation. Naïve CD4+ T cells are unresponsive 
to IL-12 due to lack of IL-12 receptor that is upregulated upon T cell 
stimulation. IFN-γ, IL-27, IL-18 and TNF-α also play an important role in Th1 
differentiation.  
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The effective proliferation of cytotoxic CD8+ T cells requires a third signal after 
antigen presentation and co-stimulation, in the form of IL-12 or type 1 INFs 
signalling (Mescher et al., 2006). The CD8+ clones can then carry out their 
killing function by binding to infected cells presenting their cognate antigenic 
peptides bound to MHC I, and releasing soluble factors to induce cell death.  
 
The effects of DC on T cell populations have an ultimate influence on the gut 
immune homeostasis (Coombes and Maloy, 2008; Strober, 2006). Altered DC 
phenotype and function in inflammatory conditions like IBD, suggests that 
they contribute to the inflammatory process (Bell et al., 2001; Hart et al., 
2005). DC are therefore likely to be the key initiators and perpetuators of 
inflammatory responses in IBD.  
 
We have in the previous chapter (Chapter 4) shown that GLP-2 has a partial 
effect on DC maturity; modulating an immature state as well as reducing DC 
cytokine production of IFN-γ in both human and intestinal DC. This 
immunotolerogenicity of GLP-2 should therefore functionally correlate with a 
poor stimulatory potential of T cells and consequent decrease in the 
corresponding cytokines. This chapter will therefore focus on the allo-
stimulatory capacity of GLP-2 on conditioned human and intestinal LDC in the 
mixed leucocyte reaction as well as the subsequent T cell cytokine production.  
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7.1 Methods 
 
7.1.1 Low Density Cells enriched for dendritic cells from peripheral 
blood  
 
Peripheral blood LDC enriched for DC were again isolated on a NycoPrep 
gradient from non-adherent cells after overnight PBMC as per the previous 
chapter.  
 
7.1.2 Low Density Cells enriched for dendritic cells from tissue colonic  
 
LDC (enriched for lamina propria DC) extracted via the ‘walk-out’ process 
from the colon were pre-conditioned with GLP-2 (as per previous chapter 
methods). 
 
7.1.3 Stimulation of Allogeneic T cells by GLP-2 conditioned DC in the 
Mixed Leukocyte Reaction (MLR). 
 
We chose to perform proliferation assays using CFSE to track responder 
division. CFSE is a cell permeable dye which is cleaved by intracellular 
esterases into an amine-reactive fluorescent product which can be analysed 
by flow cytometry, and is now a common tool for lymphocyte research 
(Callard R et al., 2007). The dye is well tolerated by cells within a working 
concentration range, and after 24-48 hr, fluorescence levels are fairly stable in 
non – dividing cells. Stained proliferating cells divide fluorescence equally 
227 
 
between daughter cells, allowing each round of division (up to approximately 
8) to be seen on flow cytometry plots.  
 
LDC were conditioned with and without GLP-2 in culture for 24 hours before 
the MLR. Allogeneic T cells were stimulated with control DC and GLP-2 
conditioned DC (human blood and intestinal lamina propria DC respectively). 
The subsequent proliferation of allogeneic T cells were determined using 
CFSE to identify dividing T-cells (Figure 7.2).  The dose response proliferation 
of T cells following 5-day stimulation with different doses of DC cultures with 
basal medium and GLP-2 was established.  
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Figure 7.2. Identifying dividing allogeneic T-cells in the MLR.  
Identification of T-cell populations in the MLR at flow cytometry based on dot 
plots of forward and side scatters. Subsequent T-cell histograms were used to 
identify the dividing CD3 +ve T cells from their reduced expression of CFSE. 
 
7.1.3 T cells cytokine production 
 
Dividing responders can also be stained for specific intracellular cytokines, 
again via a sensitive subtraction method using monensin similar to the 
experiments carried out in the previous chapter. Intracellular staining for 
specific cytokines was carried out after 4 hr incubation with and without 
monensin and superenhanced Dmax (SED) normalised subtraction of 
monensin- from monensin+ was carried out. 
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7.2 Results 
 
7.2.1. The T cell stimulatory capacity of GLP-2 conditioned DC from 
human blood at varying doses was unchanged.  
 
GLP-2 conditioned DC at varying doses (1pM, 1nM and 1µM) had no effect 
on the results of 5-day stimulation of T-cells in all DC dose-dependent 
proliferation experiments. Three independent experiments were carried out 
(Figure 7.3) and compared with basal medium (unconditioned DC). 
 
 
Figure 7.3. T cell stimulatory capacity unchanged. 
Dose response proliferation of T-cells following a 5-day stimulation with GLP-
2 conditioned DC when compared to control (n=3). Basal proliferation is 
shown as the proportion of proliferating T-cells with unconditioned DC. After 
two-way ANOVA analysis (corrected with Bonferroni correction for multiple 
comparisons), both the DC dose and GLP-2 conditioning doses (1pM, 1nM 
and 1µM) were revealed as not statistically different. 
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7.2.2. GLP-2 induced a homeostatic cytokine profile in dividing T cells 
when stimulated by GLP-2 conditioned blood DC. 
 
T cells stimulated by GLP-2 (1µM) conditioned blood DC produced a lower 
ongoing cytokine production of IFN-γ in 5 independent experiments (Figure 
7.4). This homeostatic cytokine profile suggests inhibition of the Th1 
differentiation pathway. The other cytokines, IL12, IL17a and IL-10 production 
were not significantly changed (Figure 7.5).  
 
 
Figure 7.4. GLP-2 conditioned human blood DC induced a homeostatic 
IFN-γ cytokine profile. 
Following conditioning of GLP-2, the mean± SEM proportion of human blood 
LDC producing IFN-γ was reduced (n=5) compared to control (*p=0.046) (P-
value below 0.05 was considered statistically significant).  
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Figure 7.5. GLP-2 conditioned human blood DC did not modulate the 
IL12, IL17a and IL10 cytokine production.  
Following conditioning of GLP-2, the mean± SEM proportion of human blood 
LDC producing IL12, IL17a and IL10 remained unchanged (n=5) compared to 
control. (P-value below 0.05 was considered statistically significant). 
232 
 
7.2.3. GLP-2 conditioned lamina propria DC increased the 5-day dose 
response proliferation of T-cell. 
 
Unlike GLP-2 conditioned blood DC, GLP-2 conditioned lamina propria DC 
(from colonic biopsies) had an increased T cell stimulatory capacity compared 
to control DC (Figure 7.6 & Figure 7.7). This effect was most significant in the 
higher dose % of DC.  
 
 
Figure 7.6. GLP-2 conditioned lamina propria DC T cell stimulatory 
capacity. 
FACS histograms demonstrating the effects of GLP-2 lamina propria DC on 
dividing T cells following 5-day stimulation with basal, 1%, 2% and 3% 
allogeneic DC. Histograms are representative of several independent 
experiments performed with similar results.  
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Figure 7.7. GLP-2 conditioned lamina propria DC have an increased 
stimulation capacity.  
Proliferation of T cells following 5-day stimulation with allogeneic GLP-2 
conditioned lamina propria DC (1µM) compared to control (basal proliferation 
shown as the proportion of proliferating T cells with unconditioned DC). Two-
way ANOVA analysis (corrected by Bonferroni correction for multiple 
comparisons), confirmed statistically significant increase in proliferation by the 
GLP-2 conditioned DC at 2% and 3% dose (*p<0.05, ***p<0.001); n=6. 
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7.2.4. GLP-2 induced a homeostatic cytokine profile in dividing T cells 
when stimulated by GLP-2 conditioned lamina propria DC. 
 
GLP-2 (1µM) conditioned lamina propria DC in 7 independent experiments 
induced a homeostatic cytokine profile with the reduction of IFN-γ and IL12 
ongoing cytokine production in dividing T cells (Figure 7.8 & Figure 7.9). This 
is in keeping with the cytokine profile findings in blood conditioned DC again 
suggesting an inhibition of the Th1 differentiation pathway. This was 
independent of IL10 and Th17 regulation which was not affected (Figure 7.10).  
 
 
 
Figure 7.8. GLP-2 induces a homeostatic cytokine profile in dividing T 
cells.  
FACS histogram demonstrating the effects of GLP-2 lamina propria DC on 
IFN-γ and IL-12 production of T cells following 4 hour monensin incubation 
(Histograms are representative of several independent experiments 
performed with similar results.) 
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Figure 7.9 GLP-2 conditioned lamina propria DC induced a homeostatic 
IFN-γ and IL12 cytokine T cell profile. 
Following conditioning of GLP-2, the mean± SEM proportion of T cells 
stimulated by lamina propria LDC producing IFN- and IL12 was reduced (n=7) 
compared to control (*p=0.0028 and *p=0.0278 respectively) (P-value below 
0.05 was considered statistically significant).  
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Figure 7.10. Unaffected IL17 and IL10 ongoing cytokine production by T 
cells when stimulated by GLP-2 conditioned lamina propria DC.  
Following conditioning of GLP-2, the mean± SEM proportion of T cells 
stimulated by lamina propria LDC producing IL17 and IL10 was unchanged 
(n=7) compared to control (p=0.4250 and p=0.0784 respectively) (P-value 
below 0.05 was considered statistically significant).  
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7.3. Discussion 
 
We demonstrated within this chapter that GLP-2 is capable of modulating 
human lamina propria DC leading to increased stimulation of T cell 
proliferation. This effects however, was not seen using human blood DC 
despite results from chapter 4 showing an increase in CD86 co stimulatory 
cytokine. Again, it is unfortunate that we did not study the modulating effects 
of GLP-2 on human lamina propria DC phenotype.   
 
The increased T cell clones stimulated by lamina propria DC had a decreased 
ongoing cytokine production of both IFN-γ and IL12. Both these cytokine are 
important in the Th1 differentiation pathway and as mentioned previously, 
considered to be crucial in IBD in particular in Crohn’s disease. GLP-2 
appears to modulate DC to inhibit the Th1 pathway and hence, strengthens 
our resolve in regards to the possible anti-inflammatory property of this growth 
hormone.  
 
T cell clones from stimulated human blood DC also had a decreased ongoing 
cytokine production of IFN-γ. IL17 and IL10 cytokines were unchanged in 
dividing T cells stimulated by either blood or lamina propria DC. This result 
confirms that the effects of GLP-2 in humans are likely independent of IL10 as 
seen in murine studies.  
 
Therefore it is likely that the modulating effects of GLP-2 on DC appear to be 
an increase in stimulatory potential for T cells (which are probably regulatory 
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T cells) with subsequent inhibition of Th1 differentiation. Though, further 
experiments will be necessary to determine whether there is an increase in 
regulatory T cell differentiation with unchanged IL17 and IL10 levels.  
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Chapter 8 
General Discussion and Future Research 
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8.1 General discussion 
 
GLP-2 is a potent intestinotrophic peptide that is secreted by enteroendocrine 
L-cells, in response to nutrient ingestion (Dube PE et al., 2007). GLP-2 has 
several beneficial actions in the gut including increased mucosal growth, 
blood flow and digestive and absorptive function (Brubaker PL et al., 1997; 
Drucker DJ et al., 1996; Brenholm L et al., 2011). Although there have been 
numerous reports showing that GLP-2 exerts an anti-inflammatory action 
(mainly in murine studies), the underlying molecular mechanism have not 
been resolved. Therefore, more detailed mechanisms may be elucidated via 
immunological studies. 
 
Teduglutide, an analogue of GLP-2, has a prolonged half-life and provides 
intestinotrophic effects with once-daily subcutaneous injection in patients with 
SBS. It increases intestinal absorption and diminishes the need for parenteral 
support in patients with SBS. Teduglutide (Gattex) is now approved for use in 
treatment of patients with short bowel syndrome-associated intestinal failure 
by the US Food and Drug Administration (FDA) and the European Medicines 
Agency (EMA). The recent use of Teduglutide in the clinical arena led to an 
early phase II clinical trial of teduglutide in Crohn’s disease. This trial 
observed remission rates of 55.6% in patients compared to placebo and 
therefore raises the question of whether teduglutide could be used in 
combination with established therapies to improve clinical outcomes of 
patients with IBD (Buchman AL et al., 2010).  
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This thesis was therefore aimed at understanding GLP-2 modulation of the 
inflammatory pathway via known immunological pathways involving DC. In the 
first part of this thesis (chapter 1), we discussed the understanding of current 
immunological pathways involving DC and the role of DC in inflammatory 
conditions like IBD. We also discussed the current understanding of the GLP-
2 peptide synthesis, secretion and degradation as well as the physiological 
functions, role in mucosal immunity and safety.  
 
Methods established in our laboratory have allowed us to identify and 
phenotype freshly isolated human circulating DC from blood PBMC 
populations and isolated human small bowel and colonic DC samples from 
small bowel and colonic biopsies, respectively (Bell et al., 2001). Monoclonal 
antibody labelling and flow cytometry were used in all cases allowing us to 
investigate the modulatory effects of GLP-2 on DC and T cells. 
 
The presented data showed that GLP-2 peptide at a dose of 1pM, 1nM and 
1µM had no significant or dose-dependent effects on PBMC or LDC viability, 
apoptosis or necrosis in vitro. These experiments were carried out using 
trypan blue exclusion tests and Annexin V-PI fluorocytometric assay of cell 
viability. Results showing no difference between GLP-2 treated DC and 
controls provided confidence that the observed effects of GLP-2 seen in all 
the results within this thesis are not due to changes in the proportion of cell 
populations due to cell death but due to modulation in DC properties.  
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This study also focused on the GLP-2 conditioned DC maturation, phenotype 
and co-stimulatory molecule expression. We looked at the expression of 
CD14 on GLP-2 conditioned DC compared to control. The results showed an 
increase in CD14 expression suggesting that GLP-2 has the capability of 
modulating DC into a more immature phenotype. This homeostatic or 
tolerogenic state of induction by GLP-2 was confirmed with a significant 
increase in HLA-DR expression. The effect on GLP-2 causing an immature 
DC state interestingly however also caused a high expression of CD86 
suggesting a high co-stimulatory function. Of note, higher expression of ILT3, 
a general feature of tolerogenic DC was not seen.  
 
We have to however keep in mind that the amount of time required for GLP-2 
incubation with DC in our experimental model was relatively long (overnight; 
24 hours). Immature DC within the culture medium may have matured and 
expressed high levels of co-stimulatory molecules in preparation for T cell 
stimulation but modulated mid process by GLP-2 back into an immature 
phenotype. Results from chapter 5 showed that GLP-2 conditioned DC (in 
their immature status) have low endocytosis. This strengthens the theory of a 
mature DC having sampled the environment and differentiated, being 
modulated back into expressing an immature phenotype by GLP-2. The 
endocytosis experiments were carried out using FITC Dextran uptake. 
 
So far the experiments carried out in the early part of the chapters involved 
only human blood DC from PBMC. Due to time constraints with funding for the 
research project, GLP-2 effects on lamina propria DC maturation, phenotype 
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and co-stimulatory molecule expression as well as endocytosis were not 
established. Hence, GLP-2 may have modulatory differences in different types 
of human DC in steady state. However, in the later chapters, we describe the 
modulation of GLP-2 on cytokine profiles of both human blood and intestinal 
DC. We also look at stimulation capacity of T cell and cytokine profile in T cell 
differentiation in both human blood and intestinal DC conditioned with GLP-2. 
Similar results between blood and intestinal conditioned DC suggests that 
there are likely little modulatory differences.  
 
We also studied the ongoing cytokine production of GLP-2 conditioned DC 
from human blood, small bowel and colonic biopsies. Comparison of 
monensin-incubated cells against non-monensin control allowed quantification 
of the level of ongoing cytokine production via superenhanced Dmax (SED) 
normalised subtraction. We established that GLP-2 induced human blood DC 
to produce less IFN-γ and IL-12 (p40/p70) cytokine. This was independent of 
IL-10 and IL-17a. Similarly, ongoing cytokine production of IFN-γ was reduced 
in GLP-2 influence colonic and small bowel lamina propria DC. The data 
therefore supports previous murine study findings suggesting that GLP-2 
plays an important role in the homeostasis of the gut by reducing 
inflammatory cytokines; in particular the Th1 pathway and the process is 
independent of IL-10.  
 
Finally we determined the functional effects of GLP-2 on DC using T cell 
proliferation experiments. The results demonstrated an increased stimulation 
of T cell proliferation by human lamina propria DC. However this was not seen 
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in GLP-2 conditioned human blood DC despite an increase in CD86 co-
stimulatory molecule expression in the earlier chapters. Hence, looking at the 
modulating effects of GLP-2 on human lamina propria phenotype as part of 
the foundation to our experiments would have been useful in explaining the 
discrepancies. Ultimately however, both GLP-2 conditioned blood DC and 
lamina propria DC were shown to inhibit T cell clone production of IFN-γ. 
GLP-2 conditioned lamina propria DC also inhibited the ongoing production of 
IL-12 cytokine. Taken together, the results strongly suggest that GLP-2 is 
capable of modulating DC to stimulate and differentiate naïve T cells away 
from the Th1 pathway. This pathway is important in IBD, in particular Crohn’s 
disease where a dysregulation of Th1 pathway directly contributes to the 
disease process. Therefore the results seen in this thesis strengthens the 
hypothesis that GLP-2 exerts its immunomodulatory actions via DC. 
Modulation of DC phenotype and function in patients with inflammatory bowel 
conditions may be a target of future therapy. This in tandem with GLP-2’s 
intestinotrophic function may improve the long-term prognosis and morbidity 
of patients with symptomatic inflammatory bowel disease. 
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8.2 Future work 
 
The results seen in this thesis is encouraging and helps us further understand 
the possible role of GLP-2 in intestinal disorders. Having a clinical drug 
(Teduglutide) licensed for use in patients with SBS opens the possibility of 
studying the modulatory functions of GLP-2 on DC within in-vivo experiments. 
The findings of such experiments may cement the results seen within this 
thesis. We initially ventured out to accomplish a small pilot in-vivo study 
whereby samples of blood and intestinal biopsies from patient on Teduglutide 
for SBS would be collected for in-vitro experiments. However due to ethical 
issues and the reluctance of the large pharmaceutical company, our 
experiments were limited to influencing DC via the in-vitro method. Hopefully 
once the use of Teduglutide is more established especially in the intestinal 
unit at St. Mark’s hospital, such studies may be performed. 
 
If time and funding had been permitting, we would have performed a number 
of independent experiments looking at lamina propria DC phenotype 
modulation by GLP-2. This would have assisted in much of our interpretation 
of results throughout the thesis. Also, to further establish the possible 
immunomodulatory functions on DC, experiments looking at changes in the 
homing profile of DC (eg. CCR9 and α4B7) would have contributed to 
establishing its role in the homeostatic function of intestinal DC.  
 
Current therapies of IBD aim to control the immune response using potent 
immunomodulators eg. corticosteroids, thiopurines, antimetabolites or 
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antibodies targeting pro-inflammatory cytokines or their receptors, such as 
anti-TNF-α (infliximab). Although treatment with such agents may be effective, 
their use is associated with potentially severe and intolerable adverse side 
effects. The previously mentioned Buchman et al study confirmed the clinical 
safety of teduglutide in a cohort of IBD patients with remission rates of 55.6%. 
Therefore, GLP-2 use in tandem with established treatment regimes in IBD 
may help improve overall remission rates and outcomes for patients. Hence, 
obtaining blood and intestinal samples from patients with active IBD (Crohn’s 
and UC) rather than from just healthy individuals for the in-vitro experiments 
would have confirmed and strengthen the possible use of GLP-2 in not only 
inflammatory intestinal conditions but Crohn’s disease in particular. 
Confirmation of the ability of GLP-2 to specifically manipulate the tolerogenic 
phenotype and function of DC in the clinical setting offers an attractive 
therapeutic target.  
 
To conclude, GLP-2 has an anti-inflammatory function of which one of the 
possible mechanisms of action involves DC. It modulates DC into a 
tolerogenic phenotype with subsequent Th1 inhibitory function of T cells. This 
provides an insight into possible therapeutic targets for treatment of intestinal 
inflammatory conditions like Crohn’s disease and ulcerative colitis.  
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